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Abstract 
While the eye presents numerous opportunities for drug delivery (DD); there are many 
challenges met by conventional methods. Despite the exponential growth in research to 
overcome these downfalls and achieve sustained and controlled DD, the anatomical 
characteristics of the eye still pose formulation challenges.   
The research presented in this thesis utilises Electrohydrodynamic Atomization (EHDA) to 
engineer novel coatings for ocular contact lenses. EDHA was selected to develop coatings for 
the delivery of timolol maleate (TM); with the intention of achieving sustained drug release for 
treatment of glaucoma. The work presented here is a proof-of-concept; showing the versatility 
of a promising technique by applying it to a DD remit within which EHDA has not yet been fully 
exploited: Ocular Drug Delivery (ODD).   
The first step was to identify a suitable polymeric matrix to act as the vehicle/carrier and see the 
effects of different polymers on the in vitro release of TM and ex vivo TM permeation. Hereafter, 
based on the results of this work, 4 different PEs were incorporated to attempt to enhance TM 
release and permeation through the cornea. Further modification of the formulations saw the 
effect of integrating chitosan on the release of TM from the electrically atomised coatings.  
Characterisation of the atomised coatings at each stage demonstrated highly stable matrices, 
which possessed extremely advantageous morphologies and sizes (within the nanometre 
range). All coatings also demonstrated adequate to high encapsulation efficiencies (EEs) (>64%) 
with the highest EE being 99.7%. In vitro release (i.e. cumulative percentage release) steadily 
increased upon introduction of additives to the base polymeric formulations yielding different 
release profiles; ranging from biphasic profiles to triphasic profiles. Ex vivo analysis and 
biological compatibility testing also presented promising results.  
The use of EHDA has not yet been explored in depth within the ocular research remit. It has 
shown great potential in the work presented here; engineering on demand lens coatings capable 
of sustaining both TM release and TM permeation.   
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Chapter 1 Introduction 
1.1 Fundamentals 
The generation of complex nanostructures with multifaceted release kinetics and 
multifunctional characteristics has resulted from critical developments within the 
pharmaceutical and drug delivery (DD) remit. Advances in conventional DD methods, although 
met with reservation and hesitancy, have the ability to overcome flaws in simpler concepts, 
hence allowing relevant research to have high impact on key areas of research and 
development.  
There are currently several methods which have been developed to yield such structures but 
each have drawbacks. Solvent evaporation, precipitation, emulsification and spray drying are a 
few paradigmatic methodologies used to produce NPs with explicit morphologies (Huanbutta et 
al, 2016; Khajavi and Abbaspour, 2012; Rasekh et al, 2008; Liao, Chew and Leong, 2006). Whilst 
these methods can successfully produce structurally stable particles of various morphologies 
there is the drawback of potentially inducing product degradation as a consequence of some of 
the processing conditions required/necessary for successful particle production (e.g. elevated 
temperatures and shear stresses). For example, the nature and functionality of biomaterials (e.g. 
proteins) or active pharmaceutical ingredients (APIs) can be compromised due to high 
temperatures required for spray drying, inducing protein denaturation. Other drawbacks include 
non-uniformity in particle size and size distribution, particularly in emulsification where large 
particles are often yielded. 
Electrohydrodynamic atomization (EHDA) is a promising technique and of great interest in the 
field of pharmaceutics and nanotechnology. It is a versatile method that atomises liquids to 
produce uniform (with respect to size and morphology) micro- and nano-structures. The process 
of EHDA is based on an electrically imposed liquid jet exiting a nozzle in the form of particles or 
fibers. Process parameters and physical liquid properties can be altered, resulting in various EHD 
modes, (e.g. cone-jetting, spindle, dripping).  
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EHDA is a cost effective, simple, one step process and easily amendable to achieve optimum 
conditions for the production of nanostructures at ambient temperatures. The resulting 
products can subsequently be utilised for numerous pharmaceutical applications with the 
advantage of producing structures with controlled size and shape, as the following literature 
review will criticize in Section 2.4.  
Glaucoma is the term used to refer to a group of optic conditions which result in progressive loss 
of retinal ganglion cells and their corresponding axons ultimately leading to loss of vision. There 
is currently no cure for glaucoma and being the second leading cause of blindness in the world, 
it is clear why addressing such a global issue is important (Tham et al, 2014). The main dosage 
form used in the treatment of glaucoma is eye drops; however, poor compliance with 
medication alongside anatomical and physiological barriers present demanding challenges for 
topical/local eye DD.  
The focus on ODD has expedited in recent years in a bid to address limitations associated with 
conventional dosage forms. The exponential growth in related publications along with material 
development has led to research being directed at the potential of various ocular DD devices, 
the most common being contact lenses (CLs).  The concept was first introduced in the 1960’s; 
however initial research demonstrated complications with both drug loading and drug release 
(lack of sustained, controlled release). Research to improve drug release from CLs with various 
coating methods and drug loading techniques has been presented, many with promising results.  
1.2 Aims and Objectives 
The ultimate aim of this research was to show the capabilities of EHDA as a potential method 
for the coating of CLs.  It was vital to show how EHDA works, current applications of this 
promising technique (with respect to drug loading and delivery) as well as how this can be 
utilised or applied to my field of research. 
The research to be presented here aims to acknowledge the fundamental principles of EHDA 
and its utilisation to achieve TM encapsulation within a polymeric carrier. The work also intends 
to modify formulations to optimise the EHDA process and help increase TM permeation, both in 
vitro and ex vivo.   
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In order to accomplish this, a series of studies were conducted:  
 Establishing and optimisation of the important parameters of single needle EHDA 
 Synthesis of TM-loaded polymeric nanostructures using single needle EHDA 
 Establishing the most suitable polymeric matrix 
 Modification of formulation to increase TM permeation 
 Further formulation optimisation to sustain TM release 
1.3 Structure of thesis 
Chapter 1 is an introduction to the thesis; providing a brief insight into the ocular condition 
glaucoma, as well as contact lenses and the EHDA process. This chapter briefly touches upon the 
disadvantages of current ocular drug delivery methods and devices along with a succinct outline 
of EHDA principles, criteria and application.  Chapter 2 will delve deeper into the matters 
touched upon in chapter 1. An extensive literature review will show conventional and current 
approaches in glaucoma treatment, the fundamental principles and application of EHDA and 
utilisation of ocular lenses as DD devices. Chapter 3 outlines the materials and methods used in 
this study and chapters 4 to 6 comprise the experimental studies carried out for the chosen 
thesis subject. Chapter 4 consist of characterising and optimising the fabrication of atomised 
TM-loaded samples containing PVP, PNIPAM or a composite of both. The in vitro drug release 
studies as well as ex vivo corneal permeation studies showed the structures that had the 
greatest potential to release TM were TM-loaded composite beaded fibers. This formulation was 
taken through to Chapter 5, which looks at improving the corneal permeation of TM. Here 4 
different permeation enhancers (PEs) were incorporated into the initial solutions with 2 
different drug loadings (5% and 15%w/w of the polymer) to assess the ability of the PEs to 
increase TM penetration through the cornea. Biological evaluation of all the formulations also 
aided the efforts to distinguish the most promising formulation for further modification for 
sustained release of TM. Chapter 6 demonstrates the effect of incorporating chitosan at 
different concentrations (1%, 2%, and 5%) with PE borneol on TM release from the electrospun 
structures. Chapter 7 concludes the thesis with a summary of findings and touching upon future 
work in this innovative arena of pharmaceutics. Appendix A presents supplementary data to 
compliment some of the work presented in this thesis.   
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Chapter 2 Literature Review 
2.1 The Eye 
2.1.1 Introduction 
The eye is one of the most easily accessible organs of the human body. Despite this, the 
physiology and anatomy of the eye poses challenges with respect to ODD (Rathod, Kapadia and 
Sawant, 2017; Forrester et al., 2015; Mitra, Anand and Duvvuri, 2005). As a result of these 
hurdles, effective ocular formulations and devices must be developed in order to target specific 
ophthalmic tissue and to help control ophthalmic disease progression. To be able to overcome 
these barriers in ODD and to develop efficient devices for DD, it is important to fully understand 
and appreciate the eye; especially the relevant anatomical and physiological characteristics that 
may alter drug pharmacokinetics.  
2.1.2 Anatomy of the Eye 
The eye can be seen as a spherical entity made up of 2 spheres: the anterior chamber (front 1/3 
of the eye) and the posterior chamber (back 2/3 of the eye). It is made up of several structures, 











Figure 2.1 Structure of the Eye 
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2.1.2.1 The Cornea 
The cornea is a transparent structure which makes up 7-10% of the eye. Its role is predominantly 
to protect the front of the eye and provide a majority of the optical focusing power, focusing 
the light that enters the eye (Forrester et al., 2015). The cornea is approximately 500 µm thick 
and 11 mm in diameter with no blood vessels. Due to this avascular nature and lack of blood 
supply, the cornea receives its nutrition from tears and the aqueous humour (AH), the gel-like 
substance that occupies the space behind the cornea.  
The cornea is a multi-layered tissue, consisting of 5 layers. The outer most layer is made up of 
non-keratinised cells which are flattened and nucleated and connected via desmosomes. This 
layer, known as the corneal epithelium, is six cells (50-60 µm) thick. It is impenetrable to 
hydrophilic or polar molecules with molecular weight greater than 60 Da (for example glucose 
and ions), while lipophilic molecules such as oxygen or steroids can pass through via 
solubilisation in the lipid cell membrane. Below this comes the Bowman’s Layer (also known as 
the Anterior Limiting Laminar); a posterior boundary that is separated from the epithelium by a 
thin basal lamina. It is 8-12 µm thick and made up of collagen fibrils (type I, III, IV, VI) 20-30 nm 
in diameter. The Bowman’s layer merges with the corneal stroma, dense connective tissue (85% 
of the cornea) consisting of 200 to 250 layers of keratinocyte-containing collagenous lamellae 
of predominately type I collagen, each layer 1-2.5 µm thick.   
Following the stroma is Descemet’s membrane. A unique characteristic of this layer is its ability 
to repair itself following injury, which justifies its primary function to protect against infections 
and injuries. This layer consists of 2 sections; an anterior banded section which makes up 1/3 of 
the layer and the homogenous posterior section which makes up the final 2/3. Rich in basement 
membrane glycoproteins and type IV collagen, this is a layer approximately 5-20 µm thick which 
is connected to the final inner layer of the cornea, the endothelium, a very porous monolayer 
membrane. This one-cell thick layer contributes to the transparency of the cornea and also 
maintains corneal hydration through the presence of a water pump (maintaining corneal 
hydration in turn controls corneal thickness).  
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2.1.2.2 Additional Structures that make up the Eye.  
The iris is the pigmented structure of the eye, located between the cornea and lens. Whilst the 
cornea focuses the light coming into the eye, the iris controls the amount of light entering the 
eye. The process by which it achieves this is similar to that of a diaphragm. The iris can dilate or 
contract the pupil, hence allowing more or less light in, respectively. The lens is a transparent 
structure which changes in shape to increase or decrease the amount of refracting power 
applied to the light coming into the eye. It is located behind the iris and focuses the light allowed 
through the iris onto the retina.  
The ciliary body is an important part of the eye between the iris and choroid as it holds the lens 
in place and produces the AH.  The AH is a transparent liquid gel which occupies the space 
between the lens and the cornea.  It provides nutrients such as amino acids and glucose to the 
cornea and the lens. Its production exerts pressure in the space between the cornea and the 
lens, this pressure is known as the intraocular pressure (IOP) (Acott and Kelley, 2008). A complex 
structure called trabecular meshwork maintains the IOP at adequate levels (12-22mmHg) by 
controlling production and drainage (Martin, 1992). If this pressure is compromised, then the 
consequence can be severe, as with glaucoma where an increase of IOP causes blindness. The 
trabecular meshwork is located where the cornea meets the iris and allows the AH to drain into 
a set of tubes called the Canal of Schlemm to systemic blood flow. The AH is also believed to 
have an immunological function in that it defends against pathogens due to the presence of 
immunoglobulins in the gelatinous fluid. 
The sclera is the white of the eye; it is an opaque white tissue 5-30 µm thick predominately made 
up of Type I collagen. It serves as anchor tissue for extraocular muscles. The retina can be seen 
as an extension of the brain as it is a layer of nerve tissue which is stimulated by light. This 
induces an electrochemical reaction in which electrical impulses are transmitted to the brain, 
resulting in vision. The conjunctiva is a vascularised membrane that lines the inside of the eyelid 
and covers the sclera. It facilitates lubrication of the eye via the production of mucus and tears. 
There is also a microbiological aspect to the conjunctiva; it prevents microbes entering the eye. 
The choroid consists of layers of blood vessels between the sclera and the retina and provides 
nourishment to the back of the eye. The optic nerve carries the electrical impulses from the 
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photoreceptor cells (rods and cones) in the retina to the visual cortex in the brain. In glaucoma, 
this can become damaged due to increase in IOP.  
2.1.3 Drug Transport through the Cornea 
The main route for drug transport to the anterior chamber is via the cornea. There are two 
recognised pathways for drug transport: paracellular movement and transcellular movement. 
Paracellular movement involves the transport of molecules between cells whilst transcellular 
movement involves the molecules travelling through the cells, in this case passing through all 5 








2.1.3.1 Paracellular Transport 
This mechanism of drug transport comprises the drug molecules moving through the spaces 
between cells (Forrester, 2008). This mode of transport is often unlikely in corneal drug delivery 
due to the cellular arrangement of the outer corneal epithelium. A majority of ocular drugs are 
too large (<100Da) to pass through and across the Bowman’s Layer. Paracellular movement is 
possible through the stroma but as a result of its hydrophilic nature, transport is limited to only 
polar molecules. Hydrophilic molecules can also pass through pores in the epithelial layer but 
larger molecules are often limited by tight junctions.  
Figure 2.2 Schematic diagram illustrating the transcellular and paracellular movement of drug 
molecules through corneal tissue  
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2.1.3.2 Transcellular Transport  
Transcellular movement through a membrane is based on diffusive methods or partitioning into 
and within cell membranes (Forrester, 2008).  There are two main pathways for drug molecules 
to reach the anterior chamber behind the cornea. The first pathway, known as the lateral route, 
involves the drug molecule partitioning from the hydrophilic stroma into the lipophilic 
endothelium followed by diffusion within the lipid rich endothelium and partitioning into the 
AH. The alternate route, the transverse route, entails partitioning of drug molecules out of the 
anterior cell membrane into the posterior cell membrane and diffusing out.  
2.1.4 Barriers in Ocular Drug Delivery 
It is clear to see why the structure of the cornea poses such a challenge to achieve high drug 
bioavailability (BA) in the eye. As a result of years of research, the factors that affect drug 
permeation have been established and categorised into 3 groups: physiochemical factors, 
physiological factors and formulation factors. Physiochemical aspects are associated with the 
drug properties that affect drug diffusion whilst physiological barriers refer to precorneal 
factors.  A summary can be found in Table 2.1 (Forrester, 2008; Forrester et al, 2015; Agrahari 
et al., 2016; Djebli et al, 2017).   
Table 2.1 Summary of the factors that affect ocular drug permeation 
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2.1.5 Routes of Administration in Ocular Delivery 
There are three main administration routes for the treatment of ocular conditions: topical, local 
ocular and the systemic approach. The selected approach is often determined by the targeted 
tissue and ocular condition. The topical line of therapy is preferred predominantly due to cost 
and patient compliance. Ease of administration for a patient is also a major advantage with 
topical delivery of ocular drugs (Wilson, 2004). However, despite being a non-invasive method, 
only 5% of the drug reaches the targeted tissue. High tear turnover rate (16% per minute) and 
dilution (as a result of tear production) can also have a significant effect on drug delivery causing 
the drug to be pumped into the drainage canals and taken away in systemic circulation (Wilson 
et al., 2011).   
For treatment of posterior segment conditions, systemic approaches are taken through the use 
of tablets. Like topical delivery, only 1-5% of the drug reaches the targeted region due to the 
nature of the eye tissue. Systemic administration of drugs for ocular conditions are often 
rejected due to the very small ratio of eye to the body (Agrahari et al., 2016). Many ocular drugs 
also have multiple effects on different systems of the body. For example, anti-glaucoma drug 
timolol also acts as a non-selective β-adrenergic blocking agent acting on the sympathetic 
nervous system, which can cause a decrease in blood pressure and can slow cardiac activity and 
lung function (Pratt et al., 2015).  
Anatomical barriers (due to the various structures that make up the eye) make precise drug 
delivery challenging.  For example, the blood aqueous barrier (BAB) and the blood retinal barrier 
(BRB) limit the BA of the drug and are the major barrier for drug delivery to the anterior segment 
and posterior segment, respectively. The BAB is a bilayer membrane consisting of an 
endothelium of ciliary blood vessels and the non-pigmented ciliary epithelium. The nature of the 
two distinct layers and the presence of the tight junctions limit the entry and/or permeation of 
drugs into the intraocular region. The BRB is a physiological barrier made up of two segments. 
The inner BRB consists of tight junctions between retinal capillary endothelial cells whilst the 
outer BRB is made up of retinal pigment epithelial cells held together by tight junctions. While 
systemic administration is favourable for drug delivery to the retina, the BRB mediates the 
penetration of drugs. Due to the selective permeability of this membrane, frequent dosing is 
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essential to ensure therapeutic effect (Thrimawithana et al., 2011). However, frequent 
administration can result in systemic toxicity and adverse side effects.  
As a result of low BA and potential side effects, more novel approaches have been developed to 
improved ODD to the posterior segment. One such approach is intravitreal injections. Despite 
low patient compliance, these injections are capable of delivering therapeutic agents directly to 
the target tissue, bypassing the anatomical barriers of the eye. Using a very fine needle (30-G 
diameter), the drug solution is injected directly to the vitreous and retina. Regardless of the 
delivery of the drug at high concentrations directly to the targeted region, drug distribution is 
not homogenous. Another challenge with intravitreal injections concerns the clearance of the 
drug. Direct delivery to the vitreous means drug clearance occurs either via the anterior pathway 
or posterior pathway. The aqueous clearance pathway consists of the drug diffusing through the 
AH and is subsequently drained whilst the posterior pathway involves drug management across 
the BRB, requiring active transport (Mitra et al., 2005). Due to this, hydrophilic solutes with high 
molecular weight remain in the vitreous humour for extended period of time. This, alongside 
repetitive perforation of the eye tissue can lead to the development of conditions such as 
endophthalmitis and cataracts.   
Research in this field is constantly evolving, resulting in developments of more innovative 
methods to overcome limitations of conventional methods of ODD. Periocular administration 
can effectively deliver drugs to the posterior chamber. DD using this method can advance to the 
posterior segment in one of three ways: transceral, systemic circulation (through the choroid) 
and the anterior pathway through the tear film and cornea, the AH and the vitreous humour 
(Moisseiev and Loewenstein, 2017). Whilst boasting high drug levels, the risks of subconjunctival 
and retrobulbar haemorrhage is high alongside increased probability of fast drug elimination via 
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2.2 Conventional Topical Ocular Drug Delivery Dosage Forms 
The choice of dosage form or device for ocular drug delivery is dependent on an array of aspects, 
predominately the ocular condition in question and the severity of the condition. The following 
section will discuss conventional topical approaches for therapeutic ODD.  
2.2.1 Eye Drops 
Eye drops make up approximately 90% of all topical ocular formulations, in the form of solutions, 
suspensions and emulsions (Conway, 2008). As a result of the nature of the targeting tissue and 
the mode of application, extreme care is needed for such formulations to be isotonic, non-
invasive and sterile. Despite ease of formulation and patient compliance, making eye drops 
favourable to both manufacturers and patients alike, there are some drawbacks. Less than 5% 
of the drug from a typical eye drop (50 µL) actually permeates the cornea (Schopf et al., 2015). 
Precorneal volume is around 7 µL; hence most of the administered eye drop overflows and leaks 
from the eye.  In addition to this, anatomical, physiological, metabolic and biochemical 
properties and barriers of the eye can result in drug loss via nasolacrimal drainage (Schopf et al., 
2015). Here, the diluted formulation (due to instigation of tear production upon introduction of 
eye drop) can be carried away to the blood stream or nasal cavity reducing the amount of 
drug/active reaching targeted site. Consequently, frequent administration of drug is needed in 
order to achieve the therapeutic drug levels in the eye.  
In a bid to improve the residence time of the drug in the eye, additives such as viscosity 
enhancers, permeability enhancers and cyclodextrins have been incorporated into formulations. 
Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), is commonly used to treat anterior 
chamber inflammation alongside pain and inflammation associated with post-operative 
treatment. Dave and Paliwal used preservatives such as methyl paraben, propyl paraben, 
benzalkonium chloride (BAC) and viscosity enhancer hydropropyl methylcellulose (HPMC) to 
decrease the permeability coefficient of the NSAID (Dave and Paliwal, 2014). Moreover, the 
apparent permeability coefficient was also reduced by increasing the solution pH value from 6.0 
to 8.0. The combination of MP, PP and BAC enabled an increase in the transcorneal permeation 
of this active drug whilst pharmacodynamics in vivo studies showed this novel formulation was 
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more effective than commercially available Voltaren® ophthalmic drops 0.1% (diclofenac 
sodium).   
Some ocular drugs (e.g. dexamethasone (Shulman et al., 2015)) and metabolites (e.g. 
prednisolone (Couto et al., 2014)) are poorly-soluble or insoluble in aqueous media. These 
materials can be complexed with cyclodextrins (CDs) to form water soluble inclusion complexes, 
increasing their solubility. CDs are amphiphilic (they have both hydrophobic and hydrophilic 
regions) cyclic oligosaccharides which have been extensively used to improve the solubility and 
stability of some ocular drugs such as dexamethasone (Shulman et al., 2015), dorzolamide 
(Gudmundsdottir et al., 2014; Johannesson et al., 2014), ciprofloxacin (Nijhawan and Agarwal, 
2003) and cyclosporine A (Kapoor and Chauhan, 2008). Nijhawan and Agarwal developed a 
ciprofloxacin-loaded ophthalmic preparation by inclusion complexes of ciprofloxacin 
hydrochloride with hydroxypropyl-β-CDs. The complexes (produced using freeze drying) 
exhibited increased water solubility of the drug, stability, biological activity and ocular tolerance 
when compared to a commercially available ocular formulation (Nijhawan and Agarwal, 2003). 
Couto et al exploited the amphiphilic nature of dimethyl-β-CDs to form complex with 
prednisolone and HPMC. Prednisolone (a water insoluble corticosteroid) manipulates the body’s 
immune system response conditions such as arthritis, cancers and eye conditions (e.g. keratitis). 
Dimethyl-β-CDs increased drug water solubility and maintained pseudoplastic behaviour in the 
suspension that presented a d90 lower than 90 µm (particle size) (Couto et al., 2014). 
2.2.2 Emulsions 
Incorporating additives is one approach to improve liquid formulations for topical drug delivery 
to the eye. Modifying the physical properties of the ocular cells (e.g. membrane permeability, 
cellular uptake), attempts to increase drug penetration and drug presence at the site of action 
is another common approach.  
Emulsions are often used to improve the solubility of poorly soluble drugs. They are 
heterogeneous dispersions of oil in water (o/w) or water in oil (w/o), usually with the addition 
of surfactants or co-surfactants (Khadka et al., 2014). Emulsions are considered to be 
advantageous to topical ODD due to their ability to increase membrane permeability and cellular 
uptake (due to the presence of surfactants) (Gasco et al., 1989). The underlying theory for this 
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revolves around the fact that surfactants interact with the lipid bilayer around ocular cells 
modifying their physiochemical properties. Surfactant saturation in the lipid bilayer 
consequently leads to the formation of micelles which act to remove lipids from the cell 
membrane by solubilisation, in turn increasing the membrane permeability. This fundamental 
principle has led to numerous studies finding increased drug concentration in vital structures of 
the eye (Bar-Ilan et al., 1994; Acheampong et al., 1996).  There are various ways of categorising 
emulsions, the most common is via droplet size. Nano-(submicron) emulsions usually contain 
droplets 100-1000nm in diameter whilst droplets in micro-emulsions range from 10nm to 
100nm and in macroemulsions 0.5 µm to 100 µm. 
The use of emulsions in topical ODD was first investigated in 1989, for the treatment of 
glaucoma. Incorporation of surfactant lecithin to an o/w microemulsion increased the BA of 
timolol in the AH when administered to the conjunctival sac of rabbits. When compared to a 
lecithin-free formulation there was 3.5 times as much drug present in the AH (Gasco et al., 1989). 
Lidocaine, (a hydrophobic drug), has been entrapped in various oil-in-water microemulsions 
(~10-20 nm particle size) before dispersion through poly (hydroxyethyl methacrylate) (pHEMA) 
lenses (Gulsen and Chauhan, 2005). Gulsen et al found that these particles gave a burst release 
at first (35% of drug) followed by 80% and 95% of the drug being released within 4 days and 9 
days, respectively. 
More recently, topical ODD with respect to emulsions have turned to nanoemulsions; o/w or 
w/o. The dispersed phase is in the form of nanodroplets 50-200 nm in diameter heterogeneously 
dispersed within the external immiscible phase. These formulations are useful for the delivery 
of both hydrophilic and lipophilic drugs (Tamilvanan and Benita, 2004), however they are still 
subject to emulsion instabilities: coalescence (droplets coming together to make larger 
droplets), flocculation (aggregation of droplets to give 3D clusters without coalescence) and 
Otswald ripening (growth of emulsion droplet due to changes in chemical potential). 
Nanoemulsions have been investigated for the delivery of a wide range of bioactive molecules 
like antibacterial agents (e.g. cetalkonium chloride (Daull, Lallemand and Garrigue, 2014)) and 
anti-glaucoma drugs (e.g. dorzolamide hydrochloride (Ammar et al., 2010)). The anti-glaucoma 
drug delta-8-tetrahydrocannabinol was one of first drugs to be encapsulated successfully into a 
nanoemulsion for topical ODD. The lipophilic drug was incorporated into the oil phase of a 
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submicron emulsion (mean droplet size: 130±41 nm) and showed an intense and long lasting 
reduction effect for the IOP. This formulation remained stable after steam autoclaving and after 
storage for 9 months (Muchtar et al., 1992). These promising results sparked a search for more 
biocompatible actives for extended action in the eye.   
Incorporation of surfactants ultimately affects the charge of formulation and due to this cationic 
surfactants have been found to increase BA of drugs due to electrostatic interactions between 
the cornea and membrane protein (mucin); hence, increasing drug residence time in the cornea 
(Daull et al., 2012; Wei et al., 2011). However, their toxicity is a disadvantage that needs to be 
overcome and because of this very few have been approved for ocular use.   
Novagali, a French pharmaceutical company, developed a cationic nanoemulsion that improved 
drug delivery by exploiting the negative charge of ophthalmic cells at physiological pH. The use 
of positively charged formulations can increase the electrostatic interactions between the 
formulation and biological tissue, consequently increasing the residence time. This innovative 
technology has already been used to deliver cyclosporin A (Cyclokat® and Vekacia®) (Lallemand 
et al., 2012) with several more applications in the pipeline including latanoprost delivery for 
glaucoma treatment (Ismail et al., 2011).  
More recently, emulsion cross-linking and formulation optimisation via factorial design was 
utilised to improve precorneal residence time and drug penetration of the hydrophilic antibiotic 
doxycycline hydrochloride. The particles (331-850 nm size range) encapsulated around 45-80% 
of the drug. This formulation showed sustained drug release with significant antibacterial effect 
on strains of Staphylococcus aureus and Escherichia coli (p<0.011) as compared to doxycycline 
hydrochloride aqueous solution (Pokharkar, Patil and Mandpe, 2015).  
2.2.3 Hydrogels 
Hydrogels (HGs) are hydrophilic polymeric matrices capable of swelling after water uptake, 
allowing drug diffusion in and out of the system. Once swollen, the HG matrix is approximately 
60-90% water (Kang-Mieler and Mieler, 2016). These gels can form before administration or in 
situ; however, more emphasis has been placed on the latter due to ease of administration and 
precision of solution compared to gels (Anumolu et al., 2009). Phase transition on the ocular 
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surface increases formulation residence time and hence increases drug exposure. Both natural 
polymers (e.g. gelatin (Prabhu et al., 2015), dextran (Chau-Minh Phan et al., 2014), alginate (Liu, 
Griffith and Li, 2008), chitosan (Cheng et al., 2014; Prabhu et al., 2015), polysaccharides (Xu et 
al., 2013)) and synthetic polymers (e.g. HEMA) (Hu and Li, 2013; Rapado and Peniche, 2015), 
glycolic acid (Gasmi et al., 2015; Do et al., 2015)  have been used as swellable matrices. It is 
important to note that the selection of polymer is crucial due to the effect on the final HG 
properties. Due to different polymers having different advantageous characteristics, it is 
common to blend two or more polymers to obtain optimised HG systems. For example, chitosan 
has been blended with gelatin and glycerol phosphate to develop a thermoresponsive HG which 
enhanced in vitro and in vivo compatibility for the delivery of latanoprost (Cheng et al., 2014). 
In vivo release studies in rabbit models demonstrated steady drug concentration in the aqueous 
humour without burst release. This sustained release system continued for 8 days with IOP being 
restored within this time period and maintained for a further 31 days (Cheng et al., 2014).  
Chitosan has also been combined with PNIPAM to exploit the thermosensitive nature of PNIPAM 
to develop an in situ thermoresponsive HG for the delivery of antiglaucoma drug TM (Cao et al., 
2007). In vivo studies showed increased drug permeation in rabbit cornea in the absence of any 
cytotoxicity. Compared to conventional TM eye drops, despite the onset of action being 
observed at t=0.5 hours, the HG demonstrated stronger IOP reduction, highlighting the potential 
of chitosan-PNIPAM blend for improving efficacy of TM (Cao et al., 2007).   
Temperature is not the only stimulus that has been employed to trigger the swelling of HG 
matrices; pH triggered systems (e.g. Poly acrylic acid (PAA) (Dubey and Prabhu, 2014; Patel et 
al., 2012)), ionic strength (e.g. sodium alginate (Khan et al., 2015; Nanjwade et al., 2012; Shastri, 
Patel and Parikh, 2010)) and enzyme substrate systems have also been evaluated.  PAA is a 
polymer which has a large array of applications, including as a thickening agent, a suspending 
agent and emulsifying agent. In physiological conditions and aqueous environment, PAA is an 
anionic polymer and is commonly combined with HPMC to increase the viscosity of the 
formulation, ultimately increasing drug residence time (Dubey and Prabhu, 2014).  
Dubey et al studied the in vivo IOP lowering activity of PAA (carbopol C 934p)-HPMC stimuli 
sensitive HG (Dubey and Prabhu, 2014). Once administered to the eye, the pH changed 
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accordingly causing the HG to increase in viscosity, providing sustained release of the drug. In 
vitro release studies demonstrated zero order release with 90% of the drug (TM, brimonidine 
tartrate) being released within 8 hours; exhibiting sustained release. The ability of the novel 
stimuli-sensitive TM and brimonidine tartrate loaded HG to lower IOP was compared to a 
marketed formulation. Whilst the marketed formulation was able to lower the IOP, it failed to 
maintain this reduction. The newly formulated HG with a combination of both drugs achieved 
greater IOP reduction, which was maintained for a longer time than the marketed formulation 
(Dubey and Prabhu, 2014).  
Sodium alginate is a viscosity enhancer often used in drug delivery due to its ability to undergo 
gelation as a result of changes in ionic strength (Mandal et al., 2012). Sodium alginate is 
susceptible to phase change when exposed to divalent ions such as magnesium and calcium; an 
ion which is abundant in tear fluid (Mandal et al., 2012; Liu et al., 2010). This property of sodium 
alginate has been exploited to increase drug residence time. For instance, along with methyl 
cellulose it was successfully used to formulate a novel in situ gelling matrix for therapeutically 
efficacious sustained release and stable ophthalmic drug delivery of moxifloxacin hydrochloride 
(Nanjwade et al., 2012).  There are also some marketed formulations already available for topical 
ocular delivery of TM. Timoptic-XE® is based on anionic heteropolysaccharide derived from 
gellan gum. In this product, an aqueous solution of gellan gum, in the presence of a cation (in 
precorneal tear fluid), has the ability to gel, allowing prolonged exposure to the product, 
increasing drug release.  
2.2.4 Contact Lenses 
Whilst there have been attempts to improve conventional methods to accomplish extended 
drug exposure time to ophthalmic tissue, these methods are no longer adequate for treating 
ocular conditions. Despite good patient compliance and simple administration, there are some 
fundamental drawbacks with respect to the formulation itself (e.g. eye-drops, hydrogels). The 
extended residence time, blurred vision (as a result of increased formulation viscosity) (Gupta 
et al., 2007) and poor availability (due to nasolacrimal drainage) can limit the 
application/administration of such formulations to specific times (e.g. night) (McGhee, Dean and 
Danesh-Meyer, 2002). 
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As a result the need to overcome these challenges, research has shifted focus onto developing 
various ocular devices for successful, controllable drug delivery. The most common device to 
emerge from this research are contact lenses (CLs). CLs are polymeric discs which are inserted 
into the eye and come into contact with the cornea; held to the corneal tear film by surface 
tension (Lin and Svitova, 2010; Vidal-Rohr., 2018). The primary function of contact lenses is to 
correct vision imperfections (e.g. conditions such as astigmatism and myopia) (ElShaer et al., 
2014), but their uses have also been exploited in cosmetics/aesthetics as well as therapeutics 
and theranostics (Peng, Kim and Chauhan, 2010; Thomas, Lähdesmäki and Parviz, 2012; 
Kaczmarek et al., 2014; Tashakori-Sabzevar and Mohajeri, 2015a).  
The idea of CLs was first conceptualised by Sir John Herschel in 1832; with the first glass CL being 
developed in 1887. In the 1960’s, there was a major breakthrough for CLs where Wichterle and 
Lim experimented with soft, water-absorbent materials for biological use (Wheeler et al., 1996) 
whilst advances in material development led to a breakthrough in the topical ocular drug 
delivery arena. The crosslinking of monomer 2-hydroxyethyl methacrylate with ethylene glycol 
dimethylacrylate yielded pHEMA.  This polymer is capable of forming flexible hydrophilic 
hydrogels (ElShaer et al., 2014). The characteristic capacity for pHEMA to retain up to 38% water 
forming flexible systems was able to overcome the disadvantages met with earlier proposed 
rigid materials (e.g. glass).  
Due to advances in material development, monomers (e.g. tris(trimethylsiloxy) silane) were the 
choice to fabricate silicone hydrogels (Vanderlaan et al., 1999). These lenses possessed 
increased oxygen permeability, unlike conventional pHEMA lenses and therefore could be worn 
for prolonged periods of time. Silicone lenses have a more rigid structure, accordingly 
development and manufacture was much easier. It is only in the last two decades that CLs have 
been considered as useful devices suitable for drug delivery for such drugs as antibiotics, NSAIDs 
and anti-glaucoma drugs. As a result, many concepts (conventional and novel) to alter HG lenses 
have been introduced to achieve sustained/extended ocular drug delivery. For example, timolol 
has been incorporated into contact lenses which exhibited 12 hours of sustained release 
(Alvarez-Lorenzo et al., 2002) while lidocaine-loaded contact lenses demonstrated a sustained 
release over 8 days (Gulsen, Li and Chauhan, 2005).  
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2.2.4.1 Mechanisms of Drug Loading 
It has only been in the last two decades that ocular lenses have been considered as an 
advantageous device suitable for drug delivery. Various methods have since been developed to 
produce drug eluting contact lenses. 
2.2.4.1.1 Soak and Release 
One of the first attempts to develop drug loaded CLs involved soaking pre-prepared or 
commercial lenses in a saturated aqueous drug solution, allowing the drug to be taken into the 
hydrophilic matrix of the lens (via diffusion). This conventional method was first proposed over 
40 years ago (Waltman and Kaufman, 1970) and is now commonly used for  the delivery of anti-
glaucoma drugs (Hillman, 1974; Kim, Conway and Chauhan, 2008; Peng, Burke et al., 2012; Peng, 
Ben-Shlomo et al., 2012), antihistamines (Soluri, Hui and Jones, 2012; Karlgard et al., 2003) and 
antibiotics (Peng et al., 2010). Upon insertion in the eye, initial burst release of drug is achieved 
followed by sustained release via diffusion. The drug solution can alternatively be topically 
applied to the eye with the lens in situ.  
Hillman et al were one of the first to utilise this method using the cholinergic anti-glaucoma drug 
pilocarpine hydrochloride. A blend of vinyl pyrrolidone/acrylic monomers were used as CL 
material. The resulting hydrophilic lenses was soaked in a 1% drug solution and inserted into the 
eyes of patients with acute closed angle glaucoma. An average of 54.8% IOP reduction was 
observed within 2 hours, notably comparable to the 49.7% IOP reduction seen with intensive 
pilocarpine treatment (1-2 drops every minute for 5 min, every 5 min for 30 min) (Hillman, 1974).  
More recently, the potential delivery of hyaluronic acid from CLs was assessed for the treatment 
of dry eye syndrome. The HG CLs loaded with hyaluronic acid exhibited release for up to 48 
hours; whilst maintaining the physical properties of the lens. In vivo release pharmacokinetics in 
rabbit tear fluid demonstrated an effective increase in residence time in comparison to eye 
drops (Maulvi, Soni and Shah, 2015).  
In an attempt to retard the diffusion of hydrophilic drugs from CLs for sustained release, vitamin 
E (VE) has been incorporated into lens matrices to provide a hydrophobic barrier (Peng et al., 
2010; Peng et al., 2012; Peng, Burke and Chauhan, 2012; Hsu, Fentzke and Chauhan, 2013; Hsu 
Chapter 2 Literature Review 
19 | P a g e  
 
et al., 2015; Kim, Peng and Chauhan, 2010). Soaking of lens in VE:ethanol solution prior to drug 
loading poses a barrier to the drug molecules when diffusing out of the matrix, presenting the 
potential for sustained drug delivery which is advantageous for conditions where frequent doses 
are essential.   
Cytinosis is a rare genetic condition which mostly affects children in which the amino acid 
‘cysteine’ accumulates in vital organs (eye, kidney, pancreas and brain). Hsu et al developed 
lenses loaded with cysteamine with incorporation of VE to achieve sustained drug release (K. 
Hsu et al., 2013). Addition of VE increased drug duration from 10 minutes to 3 hours in solution. 
The lenses exhibited therapeutic concentration of the drug within 2 hours of the lenses being 
worn, mimicking the action of hourly eye drops. Hsu et al also demonstrated that 20-30% of VE 
increased the release of moisturising agent dexpanthenol and osmoprotectant betaine 
(compatible solutes that restore cell volume, stabilise proteins and protect cells from 
hyperosmolarity stress (Giannaccare, Fresina and Versura, 2016) from silicone lenses to 10 
hours; 60 times longer than unmodified lenses (Hsu et al., 2015). Topical anaesthetics such as 
lidocaine, bupivacaine and tetracaine (all hydrophilic at physiological pH) were loaded into VE 
soaked lenses (Peng et al., 2012). These lenses continually released drug for 1-7 days, beneficial 
for post-operative pain of corneal surgery.  
Along with impeding drug diffusion, VE aggregates can provide UV protection to the cornea 
without altering lens transparency. Operating at a wavelength smaller than that of visible light 
ensures there is no obstruction with respect to vision (Gonzalez-Chomon, Conchiero and 
Alvarez-Lorenzo, 2013). Although the method of soak and release has been met with various 
successes, the main challenge is to achieve and maintain controlled release kinetics.    
2.2.4.1.2 Molecular Imprinting 
Molecular Imprinting (MI) is a more recent technique in which nano-cavities are created within 
the lens matrix, which are subsequently used in molecular recognition. Incorporation of 
functional monomers (e.g. methacrylic acid (MAA)) on polymer backbone advances drug affinity 
to the lens by providing sufficient binding sites for drugs (Hiratani and Alvarez-Lorenzo, 2004). 
Selection of the functional monomer is crucial; they must be compatible with the lens material 
and also have high affinity to the active. The process of MI is based on arranging the functional 
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monomer around the drug molecules during polymerisation, creating a fixed, rigid structure due 
to the cross-linking stage in polymerisation (Hiratani and Alvarez-Lorenzo, 2004). The drug and 
any unreacted monomers are extracted leaving behind nano-cavities that only have molecular 
recognition for that particular drug. The lens can then be loaded by soaking in drug solution. MI 
is also a sought out technique as it enhances the spatial arrangement of the lens matrices, 
ensuring maximum drug loading.  
Timolol has been used with MAA acting as the functional monomer and ethylene glycol 
dimethacrylate as the cross-linker due to its ionic interaction with timolol (Korogiannaki et al., 
2015; Tashakori-Sabzevar and Mohajeri, 2015b; Alvarez-Lorenzo et al., 2002; Guidi, 
Korogiannaki and Sheardown, 2014). Hiratani et al were among the first to evaluate the in vivo 
potential of MI N-N-diethylacrylamide lenses (Alvarez-Lorenzo et al., 2002; Hiratani and Alvarez-
Lorenzo, 2002). Using different concentrations of the cross linker ethylene glycol 
dimethacrylate, Hiratani et al utilised the MI method to increase timolol loading capacity. 
Imprinted contact lenses increased the hydrogels affinity for timolol, demonstrating prolonged 
drug release in the tear fluid of rabbits. Timolol from MI lenses was detected for 180 minutes; 
two fold longer than that found by non-imprinted lenses and three times longer than the 60 
minutes observed with 0.25% aqueous eye drops (Alvarez-Lorenzo et al., 2002). The same team 
also prepared imprinted HGs that increased the uptake of broad-spectrum antibiotic norfloxacin 
(300 fold) using acrylic acid as the monomer (Alvarez-Lorenzo et al., 2006).  
Other therapeutic agents have also benefitted from MI including NSAIDs (where a tenfold 
increase ibuprofen and diclofenac loading capacity with sustained release for up to a week was 
observed (Andrade-Vivero et al., 2007)) and antibiotics (e.g. polymyxin B and vancomycin 
(Malakooti, Alexander and Alvarez-Lorenzo, 2015), ciprofloxacin (Hui, Sheardown and Jones, 
2012; Hui, Willcox and Jones, 2014)).  
Hui et al developed imprinted lenses with acetic acid and acrylic acid (the functional monomer( 
that extended the release duration of ciprofloxacin to 3-14 days (Hui et al., 2012). Using various 
ratios of acetic acid to ciprofloxacin solution, Hui et al also developed MI silicone lenses (Hui et 
al., 2014). Compared to non-imprinted lenses, the modified lens matrices released ciproflaxcin 
for a considerably longer time (p<0.05). The MI lenses were evaluated for the ability to inhibit 
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gram negative bacterium Pseudomonas aeruginosa. Lenses loaded with 0.3% ciprofloxacin 
demonstrated complete bacteria inhibition for initial two days, showing inhibitory 
concentrations of drug were being reached/released from the lenses. However, after day three, 
an increase in the bacterial concentration was observed; this was thought to be due to the 
reduction of ciprofloxacin concentration after being released from the lenses. Although 
differences in bacteria population was observed when comparing both non-imprinted lenses 
and MI lenses; they were not statistically significant (p>0.05) (Hui et al., 2014).    
2.2.4.1.3 Modifying Lens Composition 
The permeability of ocular therapeutic agents can be affected by their charge in physiological 
conditions. Modifying the lens composition and exploiting the ionic interactions of functional 
monomers can potentially aid in achieving sustained and/or controlled drug release (Hsu, Gause 
and Chauhan, 2014). Variations in these side groups ultimately affect the final properties of the 
HG lenses; subsequently, the monomer used and its ratios can be altered to achieve specific 
criteria. Incorporating cationic or anionic functional monomers (also known as ligands), can 
increase the weak interactions (e.g. hydrogen bonding, electrostatic forces), allowing the HG 
matrices to store charged drugs on the basis of ion exchange reactions. Ergo, the percentage of 
HG matrix that is made up of ligands will be directly proportional to the drug loading efficiency 
(Hsu et al., 2014).  
MAA is the most common ligand used to increase the ionic interactions in lenses, predominantly 
in pHEMA lenses and is highly anionic and hydrophilic. Release kinetics of various ophthalmic 
drugs from MAA-loaded lenses has been studied numerous times, all yielding promising results 
(Uchida et al., 2003; Sato et al., 2005; Garcia-Millan, Koprivnik and Javier Otero-Espinar, 2015). 
Uchida et al have developed contact lenses using hydrogels with cationic functional groups on 
the side chain (using methacrylamidopropyltrimethylammonium chloride and 2-hydroxyethyl 
methacylate to obtain the cationic group) (Uchida et al., 2003). The hydrogels were capable of 
storing azulene (anionic drug), by the effect of ion exchange reaction, and releasing the drug 
under physiological conditions. There was a problem relating to the size change of the hydrogel 
pre- and post- drug release; changes which were prevented by adding anionic monomers MAA 
and 2-methacryloyloxyethyl phosphate to the matrix (Uchida et al., 2003). These monomers 
were also added to pHEMA lenses which resulted in extended release of naphazoline (a cationic 
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vasoconstrictor). About 85% of the drug was released within 14 hours, with the uptake of drug 
increasing in turn with increasing the amount of anionic ligands within the matrix (Sato et al., 
2005).  
Copolymerisation of pHEMA soft lenses with functional monomers (different concentrations of 
MAA or N-vinyl-2-pyrrolidone) was used to assess the in vitro release kinetics of corticosteroid 
triamcinolone acetonide (Garcia-Millan et al., 2015). The modified lenses with MAA exhibited 
similar swelling behaviour in physiological condition. However, MAA-containing lenses 
demonstrated a higher degree of swelling with the change in pH as a result of repulsive forces 
contained by the hydrogel (generated by ionisation of carboxyl groups of MAA residues). 
Moreover, MAA lenses showed the best drug loading and the fastest drug release when 
compared with N-vinyl-2-pyrrolidone hydrogels (Garcia-Millan et al., 2015).  
On basis of the ion-ligand mechanism, the in vitro uptake of antibiotic agents gatifloxacin and 
moxifloxacin was assessed (Kakisu et al., 2013). The drug uptake seemed to increase as 
percentage weight of anionic MAA increased. Initial burst release kinetics were observed from 
the modified lenses where in vivo studies exhibited greater drug concentration in cornea 
(gatifloxacin: 0.89 µg/mL, moxifloxacin: 2.22 µg/mL) and aqueous humour (gatifloxacin: 4.1 
µg/mL, moxifloxacin: 9.35 µg/mL) after 24 hours when compared to antibacterial eye drops with 
the same antibacterial agents, which indicate an improvement in penetration into the eye.  
Whilst previous studies focussed on incorporating ligands via copolymerisation, another novel 
concept was proposed which saw the use of surfactants to improve the release of ionic drugs 
for more than two hours. Generally, this can be done by creating a high surface charged lens by 
adsorbing an ionic surfactant on the hydrogel matrix increasing the sustained release of active 
for an extended time. For instance, pHEMA CLs were developed for the controlled release of 
anionic drug dexamethasone 21-disodium phosphate using the cationic surfactant cetalkonium 
chloride. The drug release time was significantly improved from 2 hours to 50 hours (Bengani 
and Chauhan, 2013).  
Altering the composition of the matrix can also solve the issue of low oxygen permeability. 
Ocular hypotensive active (timolol) and the steroid (dexamethasone) have been released at a 
sustained rate from lenses when silicone polymers have been used to replace conventional lens 
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material (pHEMA) (J. Kim et al., 2008). Silicone polymers are highly advantageous with regards 
to O2 permeability but can encounter problems with lack of patient compliance as a result of 
decreased water content leading to stiffness of the lens (Compan et al., 1999).  
2.2.4.1.4 Colloidal Carriers and Nanocarriers 
The arena of nanotechnology has already been successfully exploited in drug delivery for an 
array of therapeutic applications e.g. transdermal (Khan et al., 2014), nasal (Rassu et al., 2015) 
and ocular (Mehta et al., 2015). The concept has extended to ocular drug delivery via contact 
lenses in the form of nanoparticles (NPs), surfactants, liposomes and CDs. The nature of these 
nano-carriers can protect sensitive materials from harsh external environments and can prevent 
drug degradation; the drug can exist in an environment they would otherwise be unstable in. 
The sizes of these colloidal carriers also prove advantageous and patients’ vision is not 
compromised upon administration whilst increasing drug loading. The most common types of 
NPs are either lipid-based or polymeric-based.  
2.2.4.1.4.1 Liposomes 
Liposomes are amphiphilic, closed bilayer phospholipid vesicles. They consist of a hydrophilic 
core and surface with an internal hydrophobic ring. Their amphiphilic nature enables them to 
encapsulate both hydrophilic and lipophilic drugs whilst their high thermodynamic stability can 
achieve high drug loading capacity providing subsequent extended drug release (Johannesson, 
Stefansson and Loftsson, 2016). Liposomes also have the ability to change their size (20nm to 
few µm), zeta potential and their surface charge, allowing these carriers to be customised for 
specific applications. They are usually incorporated into the pre lens or post lens region of the 
eye, retarding diffusion in both directions providing extended/sustained release (ElShaer et al., 
2014). The interaction between liposomes and the cornea was first investigated by Schaeffer 
and Krohn in 1982. They found that corneal liposome uptake was greatest with positively 
charged liposomes, suggesting preliminary interaction is electrostatic adsorption; the uptake of 
water soluble penicillin G also increased four-fold when using positively charged unilamellar 
liposomes (Schaeffer and Krohn, 1982).  One of the first attempts to use liposomes for ocular 
topical drug delivery was for the treatment of acute and chronic herpetic keratitis, where Smolin 
et al found the delivery of idoxuridine was more effective with liposomes than without (Smolin 
et al., 1981; Smolin et al., 1980).  
Chapter 2 Literature Review 
24 | P a g e  
 
Liposomes were first used in conjunction with soft CLs by Gulsen et al (Gulsen et al., 2005). 
Lidocaine was entrapped in the lipid bilayer of dimyristoyl-phosphatidylcholine liposomes, 
which were loaded into pHEMA lenses. The lenses remained transparent and exhibited initial 
burst release (due to free drug), followed by sustained release from entrapped drug for up to 8 
days (Gulsen et al., 2005).  
A group in Canada demonstrated sustained release of levofloxacin (6 days) by incorporating the 
drug into liposomes which were immobilized onto the surfaces of soft CLs (Danion et al., 2007). 
The same research team immobilized intact liposomes onto multi-layered CLs (Danion, 
Arsenault and Vermette, 2007). Polyethylenimine was first covalently bound to Hioxifilcon B 
lenses (via hydroxyl groups). NHS-PEG-biotin molecules were attached to the amide surface 
groups onto which protein Neutr-Avidin was bound. The intact liposomes (loaded with PEG-
biothylated lipids were docked onto surface immobilized Neutr-Avidin; further exposure to 
Neutr-Avidin and liposomes yielded multi-layered soft CLs (Danion et al., 2007).   
2.2.4.1.4.2 Polymeric Micelles 
Surfactants are amphiphilic entities which have the ability to solubilise aqueous and lipophilic 
drugs/material. During polymerisation of polymeric matrix for CLs, the incorporated surfactants 
come together forming spherical micelles with a hydrophobic core and a hydrophilic shell. 
Hydrophobic molecules can occupy the space in the core of these structures during 
polymerisation, enabling the drug to remain in an environment in which it would otherwise be 
unstable. Entrapment of drug using this method retards drug diffusion; providing sustained 
release (Tran et al., 2012). Surfactant molecules consist of a hydrophilic head connected to a 
hydrophobic tail; which interacts with the CL matrix, creating lenses with charged surfaces. This 
can help enhance drug loading; charged drugs can adsorb onto these charged surfaces hence 
achieve extended drug release (Sahoo, Biswas and Guha, 2014).  
A HG containing silica shell cross-linked methoxy micelles was developed in which 
polycaprolactone (PCL) formed the core and silica formed the shell of the micelles (Lu et al., 
2013). The micelles were loaded with dexamethasone acetate (hydrophobic nature) before they 
were incorporated into HGs. The release rate of the drug from the HGs was observed for up to 
30 days. About 97% of the drug was released within 10 hours with 60% being released within 8 
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hours. The same research group used Cyclosporine A to study the potential development of 
pHEMA lenses for the controlled release using various Brij® surfactants (Kapoor and Chauhan, 
2008; Kapoor et al., 2009). Focussing on how chain length of surfactant affects the HG, Brij® 78 
exhibited the longest release rate (70% after 50 days) compared to pure pHEMA (90% in less 
than 10 days) (Kapoor et al., 2009). Cyclosporine A was also used as a model ophthalmic drug to 
develop surfactant-laden lenses where the effect of thickness of the lens on drug release was 
also assessed (Kapoor and Chauhan, 2008). 100 µm thick lenses indicated extended release of 
7-8 days (2% Brij® 78) and 16 days (8% Brij® 78) whilst with 200 µm thick lenses, the release rate 
was extended to 16-17 days and 40 days for 2% and 8% surfactant, respectively (Kapoor and 
Chauhan, 2008). 
2.2.4.1.4.3 Nanoparticles 
Nanoparticles are colloidal carriers on the nanoscale. Trapping API’s within NPs before 
dispersion through the hydrogel matrix provides a degree of protection to the drug from 
interaction with the hydrogel itself during polymerisation. Gulsen et al developed lidocaine-
loaded NPs using hexadecane microemulsions (stabilised with silica shell). These NPs enabled 
the initial burst release of lidocaine where 50% of drug was released within the first few hours. 
This was followed by 80% drug being released after 5 days (Gulsen and Chauhan, 2004).  
More recently, silicone hydrogels have been loaded with propoxylated glyceryl triacrylate NPs 
containing timolol. It was observed that a HG with 5% drug loading was able to delivery timolol 
at the therapeutic concentration for 1 month at room temperature, preliminarily (Jung et al., 
2013). In vivo testing in glaucomatous beagle dogs demonstrate a reduction in IOP but release 
was much faster at higher temperatures (>40°C), releasing almost 100% within 3-4 days. This is 
thought to be due to the ester links between the timolol and propoxylated glyceryl triacrylate 
(Jung et al., 2013).   
Nanocrystals (100nm) of bovine serum albumin coated meloxicam (NSAID) were prepared and 
dispersed in pHEMA HG for the treatment of post cataract endophthalmitis. The gel released 
the meloxicam-nanoaggregates for approximately 5 days in which the thickness of the lens and 
degree of cross-linking were the dependent variables of drug release and by altering these, the 
drug release rate could be optimised (Zhang et al., 2014). 
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Silver NPs have also been embedded into lenses to enhance their antimicrobial properties. In 
vitro testing using P. aeruginosa and S. aureus demonstrated great antimicrobial effects against 
P. aeruginosa but only lenses with increased concentration of silver NPs were effective against 
S. aureus at 48 and 72 hours (Bazzaz et al., 2014).  
More recently, anti-fungal agent voriconazole was loaded into lipid-based NPs (Füredi et al., 
2017). The resulting NPs were 182±4.1 nm in size. The poorly water soluble drug was readily 
released from the nanocarrier and inhibited the reproduction of fungus.  
Lipid NPs were also utilised to encapsulate indomethacin for delivery to anterior and posterior 
segment ocular tissues (Balguri, Adelli and Majumdar, 2016). The resulting particles (266±5nm) 
achieved encapsulation efficiency of 81±0.9%. Modifying the lipid NPs with chitosan chloride 
increased the ocular penetration of indomethacin, showing these nanocarriers as potential 
vehicles in ocular drug delivery.  
2.2.4.1.4.4 Cyclodextrins 
Cyclodextrins (CDs) are oligosaccharides made up of glucose units linked via α 1,4 –glycosidic 
bonds. These cyclic structures are categorised based on the number of glucopyranose units they 
possess: α-CDs, β-CDs or γ-CDs. Their cyclic structure enables the entrapment of hydrophobic 
drugs (e.g. puerarin (Xu, Li and Sun, 2010) and ethoxzolamide (Garcia-Fernandez et al., 2013; 
Ribeiro et al., 2012)) resulting in increased drug BA, stability as well as reducing the potential of 
undesirable side effects.  
Ribeiro et al exploited the ability for natural β-CDs and γ-CDs to form inclusion complexes with 
carbonic anhydrase inhibitors acetazolamide and ethoxzolamide in aqueous solution and 
developed N-N-dimethylacrylate-co-N-vinylpyrrolidone lenses with these pendant CDs (Ribeiro 
et al., 2012). The incorporation of CDs had no lasting effect on optical transparency of the lenses 
or on the cytocompatiblity of the lenses. Acetazolamide-loaded HG sustained release for 3-6 
hours whilst ethoxzolamide HGs sustained release for over a week. Ethoxzolamide was also 
loaded into poly-CDs which notably enhanced drug solubility and provided a much more delayed 
drug release rate compared to free CDs (Garcia-Fernandez et al., 2013). The poly-CDs also 
enhanced drug loading which resulted in sustained release for several weeks.  
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Puerarin β-CD complexes were successfully loaded into pHEMA lenses where in vitro and in vivo 
studies showed drug- β-CD complexes were 7.2 times and 4 times as effective as eye drops and 
isolated lenses, respectively (Xu et al., 2010). Drug loading was found to be dependent on the β-
CD content; as was the in vitro release of puerarin. In vivo analysis showed that drug retention 
in the precorneal region was enhanced with greater BA using β-CD loaded pHEMA lenses (Xu et 
al., 2010).  Puerarin was also used to synthesise cyclodextrin-containing hydrogels for 
ophthalmic drug delivery. The amount of puerarin loaded into HG matrix using a crosslinkable 
chitosan derivative containing β-CD was greatly increased and the release was much more 
controlled with the addition of the CD (Hu et al., 2013).  
More recently, conventional and silicone lenses (synthesized with methacrylated β-CD and 
methacrylated 2-hydroxypropyl-β CD) were loaded with natamycin and its release was assessed. 
These lenses improved drug release up to a threshold despite not extending the drug release 
duration (Chau-Minh Phan, Subbaraman and Jones, 2014).  
2.2.4.2 Advantages and Limitations of Contact Lens Drug Loading Mechanisms  
Whilst these methods of loading drug into or onto contact lenses have shown potential, there 
are some limitations relating to the feasibility and the use of the developed devices and the 
ability to control drug loading and release. Table 2.2 summarises the advantages and limitations 







Table 2.2 Summary of the advantages and limitations of current drug loading 
mechanisms for contact lenses 
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The ability to control drug loading and drug release from contact lenses stands to be the most 
important drawback when using contact lenses as drug delivery devices. Addressing this and the 
other limitations stated in Table 2.2 to be able to develop a method which ca increase drug 
loading capacity and extend drug release without affect stability in a one-step, on demand 
process would be extremely advantageous. Here, I propose using a novel engineering process 
to develop medicated contact lenses which will ultimately act as a safe and efficacious drug 
delivery device.  
2.2.4.3 Engineering Methods to Coat Contact Lenses 
Rather than incorporation of drug into the lens matrix, there have been attempts to coat the 
surface of lenses in a bid to revolutionise ocular topical drug delivery. This approach has been 
met with promising results (Liu et al., 2009; Garty et al., 2011; Anderson et al., 2009; Manju and 
Kunnatheeri, 2010; Mehta et al., 2015). For instance, rapamycin is an immunosuppressant agent 
used for prevention of organ transplant rejection. It was incorporated into a poly (lactic-glycolic 
acid) (PLGA)-chloroform solution, which was subsequently sprayed on the edge of poly-(methyl 
methacrylate) (PMMA) lens in an attempt to prevent formation and development of posterior 
capsular opacification (PCO). Unmodified lenses (group A) and PLGA lenses (group B) served as 
controls and group C was the rapamycin-sprayed lenses.  After 7 days, the mean concentration 
of rapamycin in aqueous humour reached 1.10±0.3 µg/ml after peaking to 14.57±0.99 µg/ml 
after 24 hours after administration to albino rabbits. In vivo analysis showed that the initial 
detection of PCO in rabbits in group C was much later than in groups A and demonstrating 
effective prevention of PCO formation and development (Liu et al., 2009).  
Anderson et al have exposed HEMA lenses to an octadecyl isocyanate solution where it was 
established that the polyurethane bonds between the hydroxyl groups on the HEMA lenses and 
the isocyanate groups retarded norfloxacin release. Immersion of lenses in octadecyl isocyanate 
solution for 60 minutes led to more than 90% of the drug being released within 2 hours; although 
this is rapid, it is slower than non-coated lenses (Anderson et al., 2009). Coating of PMMA lenses 
(with amino groups) with poly (sodium 4-styrene sulfonate) and ampicillin enhanced drug 
release with a 6-layer coating provided sustained release for 7 days (105µg of ampicillin) (Manju 
and Kunnatheeri, 2010).  
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EHDA is a novel technique that has been utilised to develop multi-functional ocular lenses. It 
was used to produce PVP NPs (50-130 nm) and PVP fibres (130-250 nm) to coat both sides of 
the contact lens (Mehta et al., 2015). As PVP is a rapidly dissolving polymer, the release was over 
80% within 2 minutes with fibres demonstrating slightly longer sustained release due to lower 
surface area EHDA is a one step, on demand process which can bypass many of the limitations 
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2.3 Glaucoma 
Glaucoma is the term given to a group of complex ocular disorders associated with ocular 
hypertension.  
2.3.1 Pathophysiology and Epidemiology 
Glaucoma is the second leading cause of blindness in the world, affecting 60 million people 
worldwide. It is a multi-factorial progressive optic neuropathy that often results in visual loss 
due to fluid imbalance in the eye. This imbalance leads to the characteristic degeneration of the 
optic nerve, the structure responsible for relaying information from the retina and eye to the 
brain (Morrison and Pollack, 2002; Healey and Thomas, 2010). The progressive damage initiates 
with peripheral vision loss, leading to subsequent central vison loss and ultimately full blindness 
in severe cases.  
Glaucoma affects 2% of the worlds’ population over the age of 40 (Figure 2.3); with an estimated 
8.4 million cases resulting in irreversible damage and permanent blindness (Tham et al., 2014). 
Figure 2.3 Prevalence of glaucoma in people over 40 years of age by geographic region. Figure and caption extracted 
from (Healey and Thomas, 2010) 
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In 2010, the World Health Organisation (WHO) estimated glaucoma was liable for 15% of vision 
loss cases globally. Approximately, 60 million people currently suffer from glaucoma 
(Kapetanakis et al., 2016) with this figure estimated to increase to 79.6 million by 2020 (Quigley 
and Broman, 2006) and 111.8 million by 2040 (Tham et al., 2014). 
2.3.2 Aetiology   
As glaucoma is a multi-factorial condition, there is no definitive cause for it, although a majority 
of cases do involve elevation of IOP. This increase in IOP is a result of insufficient drainage of AH 
via the trabecular meshwork. The AH is usually drained from the eye to the bloodstream via 
these tubes at the same rate as it is produced hence maintaining the correct IOP; 12-22 mmHg 
(Barranco Esporcatte and Tavares, 2016). If the meshwork becomes damaged or is blocked, the 
AH cannot drain efficiently and remains in the synapse between the cornea and iris. An 
accumulation of fluid causes the IOP to increase damaging retinal nerves and optic nerves. It has 
not yet been fully established why morphological changes occur in the trabecular meshwork but 
it has been the focus of glaucoma-related research in recent years.  
2.3.3 Types of Glaucoma 
Glaucoma can be subcategorised into 5 main classes all of which are still classed as optic 
neuropathies.  
2.3.3.1 Primary Open Angle Glaucoma 
Primary Open Angle Glaucoma (POAG) is the most common type of glaucoma where the slow 
blockage of the trabecular meshwork causes a slow increase in IOP (Allingham, Liu and Rhee, 
2009). This chronic condition develops very slowly and is painless which makes detecting and 
diagnosing the disease very difficult. The patient can lose up to 40% of their vision before 
noticing any changes, as the peripheral vision is the first to be affected. It is thought the 
obstruction in the tubes within the trabecular meshwork causes an increase in outflow 
resistance consequently requiring an elevated IOP to maintain AH flow through the anterior 
chamber. This increase in IOP is thought to lead to the apoptosis of retinal ganglion cells. The 
rate at which this degeneration occurs is dependent on the hydrostatic pressure on the optic 
nerve and the compromisation of local ocular microvascularity.  
Chapter 2 Literature Review 
32 | P a g e  
 
POAG is more prevalent in adults over the age of 65 years. It is 3 more times likely to occur in 
African–Americans (Abdu, 2013) (Figure 2.2); for whom glaucoma is the leading cause of 
blindness. Research has also concluded that those with a family history of POAG are more 
susceptible to developing glaucoma due to the fact that characteristics such as eye size, IOP and 
AH outflow competency are inherited (Wiggs and Pasquale, 2017; Swierkowska and Gajecka, 
2017). Patients who suffer from diabetes and ocular refractive error conditions such as myopia 
are also at increased risk of developing this type of glaucoma.  
2.3.3.2 Angle-Closure Glaucoma 
Angle Closure Glaucoma (ACG) occurs due to rapid blockage of the draining canals, causing a 
sudden increase in IOP (Lai, Choy and Shum, 2016). This elevation in pressure reduces the 
synapse between the iris and cornea, hindering the drainage of the AH through the trabecular 
meshwork. This space in a healthy working eye usually houses the trabecular meshwork. The 
junction at the edge of the anterior chamber is known as the anterior chamber angle. The name 
ACG comes from the reduction of this angle because of the reduced distance between the iris 
and cornea.  ACG is a chronic condition where the patient experiences great amount of pain and 
requires immediate medical attention and treatment to prevent blindness.  
Whilst age and family history can increase the risk of ACG, ethnicity also plays a big role. ACG is 
very common in South East Asians, especially the Chinese population. Females are also more 
susceptible to developing ACG than men, at a 4 to 1 ratio (International Glaucoma Association 
2017).  
2.3.3.3 Normal Tension Glaucoma 
Normal Tension Glaucoma, also known as low-tension glaucoma, differs from other types of 
glaucoma because neurodegeneration occurs at normal IOP conditions (Barranco Esporcatte 
and Tavares, 2016). The aetiology of normal tension glaucoma is still unknown; research is still 
prominent in ascertaining why the optic nerves are damaged regardless of regular IOP. 
People who have a family history of normal tension glaucoma are more at risk. Those of 
Japanese ancestry are also more prone to developing this type of glaucoma (Anderson, 2017). 
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Although a significant connection has not been identified, patients with history of systemic heart 
diseases such as arrhythmia are also at risk of getting normal tension glaucoma.  
2.3.3.4 Secondary Glaucoma 
Glaucoma can also occur due to pre-existing ocular disorders. Certain conditions can cause an 
increase in IOP, compromising the optic nerve structure and function. Reduction in AH outflow 
can also occur due to inflammatory residue and growth of new blood vessels in the anterior 
chamber as a result of vascular ocular diseases.  
2.3.3.5 Congenital Glaucoma 
Incomplete development of the trabecular meshwork (and in turn increase in outflow 
resistance) in babies during the prenatal period can result in congenital glaucoma (Samant, 
Medsinge and Nischal, 2016). Although this class of glaucoma is very rare (1 in 10,000 births), it 
is very severe. It has also been linked with gene abnormalities concerning the CYPIBI gene; the 
gene that is responsible for the production of the enzyme P450IBI. The CYPIBI gene is present in 
many structures in the eye, however, its function in eye development is yet to be established. 
One hypothesis is that it may aid the formation of the anterior segment of the eye and may be 
involved in the regulation of fluid secretion inside the eye.   
2.3.4 Treatment 
 A majority of treatments developed for glaucoma appertain to lowering IOP in the eye. Therapy 
can be classed into 3 main approaches: topical medical treatment, laser therapy and surgical 
treatment. 
2.3.4.1 Topical Therapeutics 
The most common approach to treating glaucoma is topical drug administration in the form of 
eye drops. There are five main classes of drugs used to lower IOP (Arthur and Cantor, 2011; 
Cheema et al., 2016).  These drugs work in one of two ways: improving the outflow of AH from 
the eye or reducing AH production. Table 2.3 summarizes examples of each category and the 
mode of action.  
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2.3.4.1.1 Beta Blockers 
Beta blockers work by decreasing AH production from the trabecular meshwork. Systemic side 
effects can be avoided by closing the eye after administration to prevent drug drainage into 
systemic circulation. Systemic absorption can cause a decrease in cardiac output and bronchial 
constriction. These actives can also lower blood pressure and rare effects such as reduced libido 
and depression can also occur.  
2.3.4.1.2 Prostaglandin Analogues  
Prostaglandin Analogues are a class of drugs that work by improving the outflow of AH from the 
eye. They are usually prescribed to patients suffering from Primary Open Angle Glaucoma. Side 
effects include change in iris colour, growth of eye lashes, itching, redness and blurred vision. 
No or few systemic effects are seen with prostaglandin analogues.  
2.3.4.1.3 Alpha Agonists 
Like beta blockers, alpha agonists (also known as sympathomimetics) work by reducing AH 
production. Side effects include burning upon administration, headaches, fatigue, drowsiness 
and minimal cardiovascular effect.  
2.3.4.1.4 Cholinergics 
Cholinergics (miotics) work by improving the outflow of AH from the eye. The mode of action 
involves the contraction of the cillary muscle in the eye (shrinking of pupil), constricting the 
trabecular meshwork, increasing outflow of fluid. Cholinergics can be used alone or in 
conjunction with beta-blockers or carbonic anhydrase inhibitors.  
2.3.4.1.5 Carbonic Anhydrase Inhibitors 
Carbonic Anhydrase Inhibitors reduce AH production via inhibition of carbonic anhydrase in the 
ciliary body. These actives are usually administered topically in patients with POAG but systemic 
administration (tablets) is preferred with ACG. Those administered topically have been found to 
be less effective and not have a therapeutic effect for a long period of time. Topically applied 
drugs have found to cause stinging and burning in the eye whilst tablets haven been reported 
to cause tingling in hands and feet with the possibility of developing kidney stones or depression.  
Chapter 2 Literature Review 




While most cases of glaucoma can be treated using topical medication, more severe cases may 
require surgery in order to alleviate the increased IOP to a safe platform/threshold (Ansari, 
2017).  
Trabeculectomy involves a surgical incision and partial removal of the trabecular meshwork; 
creating new drainage tubes to improve fluid outflow (Ansari, 2017; Januleviciene et al., 2015; 
Saheb and Ahmed, 2012; Matlach and Klink, 2015). This is the most common procedure when 
the use of topical medication is rendered inadequate. The incision in the trabecular meshwork 
creates a permanent canal between the cornea and sclera; allowing the controlled 
release/removal of fluid from the eye; the fluid that had built up around the scleral flap is 
absorbed by blood vessels and drained away into the bloodstream. Another similar procedure, 
called a trabeculotomy, can also be carried out which involves surgical incisions without the 
Table 2.3 Examples of the different drug classes used in treatment of glaucoma and the mechanism of action of the active 
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removal of trabecular tissue. This is not as effective as trabeculectomy but minimises infection 
risk and post-operative complications. 
Laser surgery can help to improve outflow of AH by focussing a light beam onto eye tissue; 
creating a hole or burn in the tissue, depending on the strength of the beam (Ianchulev et al., 
2017). There are two types of laser surgeries. Selective Laser Trabeculoplasty is a simple 
technique which is often used in the treatment of POAG (Zhou and Aref, 2017). This process 
utilises a low strength, wide beam to “selectively” treat trabecular meshwork cells; leaving most 
of the drainage tubes intact. This procedure is often for the treatment of POAG (Richter and 
Coleman, 2016).  
Argon Laser Trabeculoplasty works by activating the trabecular meshwork cells by focussing a 
beam onto the canals using a lens (Samples et al., 2011). The laser beam creates an opening in 
drainage canals; helping fluid outflow. 
Those that suffer from ACG can benefit from laser peripheral iridotomy. As the anterior chamber 
angle between the iris and the cornea is significantly reduced, a laser is used to create a new 
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2.4 Electrohydrodynamic Atomization 
2.4.1 Introduction 
EHDA, in recent years, has shown to be a versatile technique with great potential in the 
pharmaceutical industry. The fundamental principle involves using electrical forces for liquid 
atomization to produce micrometre and nanometre structures suitable for DD. The maturing 
area of nanotechnology (in regenerative medicine, tissue engineering and DD) has great 
potential to benefit from such enabling platform technologies. The generation of nano-sized 
entities, in particular those with complex release kinetics and multi-functional capabilities, is 
currently of great interest for pharmaceutical application with respect to DD.  
EHDA is a one-step process which can be employed at ambient temperatures and is easily 
amended to achieve optimum conditions for the production of nanoparticles applicable to 
numerous pharmaceutical applications (Mehta et al., 2017).   
2.4.2 The EHDA Process 
2.4.2.1 Defining the Principle Process 
EHDA utilises electrical forces to atomise liquids. An electrically imposed (electro) liquid (hydro) 
jet (dynamic) exits a nozzle in the form of particles or fibers (Grace and Marijnissen, 1994). These 
structures are then collected on a ground electrode positioned under the tip of the nozzle, 
usually 10-12 cm below the tip (Figure 2.4). Several factors influence the resultant structures: 
process parameters (flow rate (FR), applied voltage (AV) working distance (WD)) and liquid 
properties (surface tension (ST), electro-conductivity (EC) and viscosity) (Kim and Kim, 2011). As 
a consequence, there are two main recognised forms of EHD processing; electrospraying (Esy) 
(particle production) and electrospinning (ES) (fiber production).   
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Esy is a cost-effective, one-step process used for the fabrication of micro and nano particles. In 
the late 16th century, William Gilbert demonstrated the very first concept of electrostatic 
phenomena (Gilbert, 1628). By exposing a droplet of water to charged amber, it was observed 
that the droplet deformed into a cone. More than 200 years later, physicist Lord Rayleigh 
proposed using electrostatic forces to atomise liquids. He hypothetically predicted that a liquid 
droplet would become unstable when a threshold charge is reached. He correctly predicted the 
maximum charge a droplet could “hold” before forming an unstable jet of liquid (Rayleigh, 
1878).  This threshold was confirmed a century later and is now known as Rayleigh’s Limit 
(Taylor, 1964a; Tang and Gomez, 1995). Rayleigh found that a droplet exposed to an electrical 
charge would deform due to repulsion of like electrostatic charge. Once this repulsion exceeds 
the ST keeping the drop intact, the droplet would breakdown into more stable, finer droplets 
i.e. coulomb fission occurs (Tu and Ray, 2005). John Zeleny, a Czech-American physicist, 
exploited this theory by using a capillary-plate configuration to demonstrate how electrostatics 









Figure 2.4 Schematic diagram of the EHD system 
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present day. His work involved experimental research which provided evidence for several Esy 
modes recognised today including dropping, pulsating and cone jetting (Zeleny, 1914).  
Half a century later, Sir Geoffrey Taylor experimented with the balance between the ST of liquid 
and electrical forces, developing the underlying theory of electrospraying (Taylor, 1964a). Taylor 
found there was a threshold where the electrical field was in equilibrium with the ST of the liquid 
which resulted in a stable jet of liquid (Taylor, 1964b). This characteristic jet is now known as the 
Taylor Cone and is a prerequisite for the production of small, uniform spherical structures.  
Esy is an explicit method used for the production of near monodispersed particles. Its application 
to various research disciplines has been of great interest as of late, especially in the maturing 
area of nanotechnology for the delivery of APIs including anti-cancer therapeutics (Luo et al., 
2012), proteins (Suksamran et al., 2009) and NSAIDs (Bohr et al., 2012).  
2.4.2.1.2 Electrospinning 
The first concept of utilising electrostatic forces established by Gilbert along with Rayleigh’s 
work on droplet destabilisation influenced Morton’s theory of developing one dimensional 
structures using ES in the early 20th century. Extensive research was carried out by a number of 
scientists and many patents filed; the first by John Francis Cooley (Cooley, 1900).  Cooley, an 
inventor and electrician from New York, filed a patent that described various charged spinning 
heads including a coaxial head, an air assisted model and a rotating spinneret (Cooley, 1902). 
Another crucial patent issued was filed by Anton Formhals who demonstrated the use of 
electrodes to focus the cone jet to a rotating cylinder. For more than a decade, Formhals 
dedicated his research to the concept of ES; evolving the configuration of the system, resulting 
in a number of patents being issued (Formhal 1934, Formhals 1938). The interest in the ES 
process began to increase dramatically in the 1980’s in sync with the growing significance of 
nanotechnology research. This is reflected in the number of publications that were produced 
which more than tripled in the period of 2005-2010.  
ES uses comparable set-ups to Esy to produce continuous fibers. However, rather than the jet 
breaking up, the electrical field stretches the visco-elastic (polymeric) solutions at the capillary 
exit to form fine strands of nanometre width (Zhang, Jayasinghe and Edirisinghe, 2006). The 
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novel physiochemical and biological characteristics of the electrospun structures is a credit to 
the unique morphology of the structures which can be utilised in a wide range of applications, 
including bioengineering (tissue engineering) (Frohbergh et al., 2013), ophthalmics 
(Tonsomboon and Oyen, 2013) and DD (Jiang et al., 2005). Various controllable morphologies 
have been produced using ES (fibers, filled, hollow tubes) and this, combined with the fact that 
it is an easy to operate, cheap, on-demand process renders ES a common method for the 
production of nanofibers (NFs). 
2.4.2.2 Characterising the Electrohydrodynamic jet  
During the EHD spraying process, the solution is imposed through a conductive needle that leads 
to jet formation at the needle exit. Subsequently, the atomised structures can be collected. The 
process can be altered to produce structures with the desired particle morphology, surface 
charge, porosity and size (with narrow size distribution). This is achieved by varying the process 
parameters and liquid properties. EHD spraying jets are established and characterised by 
evaluating two parameters: intensity and droplet diameter, both of which are affected by the 
physical properties of the liquid being sprayed and the process parameters FR, AV and WD.     
2.4.2.2.1 Modes of EHDA 
Different spraying modes of EHDA have been established based on two principles: i) how the 
liquid exits the needle and ii) how the liquid jet breaks up into droplets (Jaworek and Krupa, 
1999); and these have been classified into two different modes; dripping mode and jetting 
mode.  Dripping mode occurs when only fragments of liquid exit from the nozzle. The atomised 
structures tend to be larger due to gravitational and electrical forces on the liquid attempting to 
overcome liquid ST (Figure 2.5).  Jetting mode occurs when the liquid breaks up into fine droplets 
some distance from the end of the nozzle, causing a continuous jet at the nozzle tip.  
Subdivisions in each category of spraying modes have also been observed upon altering the WD 
between the capillary and the collecting platform and the applied voltage. Both process 
parameters (AV and FR) and physical properties of liquids need to be optimised for mono-
dispersed droplets and a stable jet (Yao et al., 2008).  The cone jet mode is the most prominent, 
stable jet, where the liquid forms an axisymmetric cone at the capillary tip. Taylors’ work to 
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establish this cone; aptly named “Taylor Cone” is the most stable of EHD modes and is a 









With respect to ES, a Taylor cone jet is established but the jet experiences some instability 
causing the jet to solidify much faster than it normally would (i.e. during electrospraying), thus 
stretching the solution; producing fibrous structures (H. B. Zhang et al., 2006). In this regards, 
there are three types of instabilities which have been distinguished; Rayleigh instability, 
axisymmetric instability and non-axisymmetric instability (Wu and Clark, 2008).  The latter was 
found to be the most crucial as it is the main cause of fibrous structure generation (Hohman et 
al., 2001). With non-axisymmetric instability, rather than the jet splitting into multiple jets, an 
inverse cone can be seen consisting of a single rapidly bending strand. These fibers have been 
found to reach several metres in length whilst maintaining their nano-scale widths 
(Laudenslager and Sigmund, 2011).   
2.4.2.2.2 Criteria for EHDA 
Liquid physical properties can significantly affect the EHDA process, hence material selection 
should focus on the viscosity, EC, and ST of the formulation to be processed. The voltage applied 
to the solution as well as the rate at which the liquid is expelled are significantly important to 
Figure 2.5 Schematic Illustration of forces acting in the liquid cone at the needle exit 
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assess and quantify as these also impact on the jetting stability and the outcome of the EHDA 
process (Xie et al., 2008; Ahmad et al., 2008). 
2.4.2.2.2.1 Physical Properties of Liquids 
The physical properties of liquids are critically important in EHDA. These factors help to 
determine the shape, morphology and characteristics of the resulting structures. The EHDA 
process requires the electrical forces to overcome the ST of the liquid in order for the liquid to 
be atomised; ergo the ST needs to be low enough for the AV to overcome it so a stable cone jet 
can be produced. The ST of the liquid cannot exceed 50mNm-1, as liquids with higher ST than 
this cannot be atomised; the electrical field would be exceeded when voltage is applied (Smith, 
1986; Tang and Gomez, 1995).  
Due to the introduction of the electrical field, there is an accumulation of charge at the cone-
jet, resulting in jet break up. Due to this, the EC of the materials and solvent used in the EHDA 
process are critical parameter to consider. Materials with low EC (less than 10-10Sm-1) would not 
be able to produce a stable cone jet. For example, heptane, a straight-chain hydrocarbon, has 
an EC of 0.03pSm-1 at 20°C. In such cases of low EC, additives known as anti-statics can be added 
to increase the EC of the solvent. Liquids with high EC can also experience similar problems due 
to competition between the EC and ST during the spraying process. The ideal range for EC is 
between 10-4 and 10-8 Sm-1.   
The viscosity of the formulations being processed is another vital physical property as this allows 
the differentiation between electrospraying and electrospinning (Bock, Dargaville and 
Woodruff, 2012). Low viscosity liquids are ideal for stable cone jet production, which results in 
small, uniform (with respect to size and morphology) particles when sprayed. With regards to 
electrospinning, polymeric viscosity is directly proportional to the polymer concentration. The 
higher the polymer concentration, the more difficult it may become to control and maintain the 
liquid infusion from the nozzle and fibers can be produced (Bock et al., 2012; Jayasinghe and 
Edirisinghe, 2002).   
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2.4.2.2.2.2 Processing parameters of EHDA 
The FR at which the liquid is expelled from the needle and the AV are crucial during the EHDA 
process as these parameters can control both the jetting mode and the electrical field that exists 
between the tip of the needle and the collecting platform. The AV also has a substantial effect 
on the resulting particle size. Typically, the upper-most limit for AV is 30 kV but this value is 
dependent on the configuration of the device (e.g. single or coaxial arrangement) and the 
formulation. By increasing the AV, the atomization effect on the jet is enhanced resulting in 
smaller particles (below 270 nm) (Moghadam et al., 2009). Altering the voltage results in various 
jetting modes (dropping, Taylor cone, spindle (Wu et al., 2012)), which depend on the electrical 
force applied as well as the flow rate of the liquid. High voltage causes multi-jet spraying 
resulting in poly-disperse particles whereas low voltages result in intermittent jet formation, 
causing dripping mode to occur. Some research has suggested that the higher the voltage, the 
more repulsive forces that are present, resulting in a decrease in particle/fiber diameter. 
However, some have found that a higher voltage encouraged the increase in diameter; hence, 
the voltage needs to be optimised for specific formulations for uniform, stable production of 
particles or fibers (Jayasinghe and Edirisinghe, 2002).  
In order to form a stable Taylor Cone jet, it is imperative to optimise the flow rate of the liquid. 
FR is inversely proportional to the viscosity of the fluid, as flow rate increases, viscosity reduces. 
The rate at which the liquid is expelled through the needle also affects diameter of the resulting 
structures, the slower the rate, the smaller the diameter (Wu et al., 2012). The flow rate needs 
to be slow enough for the solvent to evaporate so spherical particles are generated.  
 It has become increasingly noted that the WD (distance between the needle exit and the 
collection plate) can affect the results of the EHDA process as WD directly affects the electrical 
field strength (Hossain, Gong and Rigout, 2015). It has been reported that the WD can affect the 
morphologies of the resulting structures. If the WD is too short, there is insufficient solvent 
evaporation; leading to “wet” particles (not fully dry) resulting in poly-disperse size distribution. 
If the collection plate is too far from the needle exit, the particles may be lost to the surrounding 
atmosphere. The ideal WD range is between 12 and 15 cm (Moghadam et al., 2009). 
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2.4.2.2.2.3 Scaling Laws 
The minimum FR of the solution can be calculated based on the properties of the liquid. Barreo 
and Loscertales, in 2007, found that for high conductive liquids with low viscosity, the minimum 





             (2.1) 
where 𝑄𝑚𝑖𝑛 is the minimum flow rate, γ is the surface tension, ρ is the density of the liquid, K is 
the concentration of the liquid, εr is the permittivity of the liquid. Due to the concept of EHDA 
evolving and advancing in material development, minimum FR scaling has recently been 
updated to include process parameters as well as physical liquid properties (Scheideler and 
Chen, 2014). As Equation 2.1 does not take into account the nozzle diameter, Scheideler and 




     (2.2) 
where D is the nozzle diameter and µ is liquid viscosity. Several studies concluded that highly 
conductive liquids or highly viscous liquids behaved very differently to low viscosity liquids. 
Solutions that have high viscosities have a relatively low ratio between the change in kinetic 
energy of the liquid jet (in the axial direction) over the change in viscous stress (in the centrifugal 
direction) resulting in fibrous structures (Yurteri, Hartman and Marijnissen, 2010).  
2.4.3 Applications of EHDA 
As mentioned earlier, the technological advancement of EHDA has allowed the process to be 
utilised in an array of applications and yielded numerous experimental systems (coaxial, multi-
needle, needleless, and printing); with the most simple and most common being single needle 
EHDA.  
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2.4.3.1 Single Needle Electrospraying 
The first EHDA configuration consisted of a single stainless steel nozzle through which the 
formulation is infused. The API is usually dissolved into a polymeric-solvent solution, but 
additives have also been incorporated to modify functionality. During the process of single 
needle (SN) Esy, the solvent evaporates at the nozzle exit resulting in the API being uniformly 
distributed through the polymeric matrix. This is turn enhances the amorphous form of 
crystalline drugs, enhancing the solubility of the drug in question. (Jafari-Nodoushan, Barzin and 
Mobedi, 2015). With applications extending to protein delivery, anticancer therapeutics and 
gene therapy, it is clear to see the abundant potential of SN Esy. 
2.4.3.1.1 Protein Delivery 
One of the first biomolecules to be employed by the Esy process was insulin. The hormone-
loaded NPs produced ranged between 98 and 117 nm; with smaller particles being fabricated 
by using a low insulin concentration and by reducing the flow rate (from 0.38 µl/min to 0.17 
µl/min (Gomez et al., 1998).  
The delivery of thermoresponsive materials such as proteins and peptides like insulin has always 
posed challenges due to the physical and chemical lability of these biomacromolecules (Zamani 
et al., 2014). Conventional methods of encapsulating proteins require processing conditions that 
cause the temperature or stress to be increased leading to denaturation altering the 
functionality of the protein (Zamani, Prabhakaran and Ramakrishna, 2013). Esy offers a means 
of successfully encapsulating biomacromolecules without damaging the material in a simple 
one-step process at ambient temperatures.  
Bovine serum albumin (BSA) has served as a model protein to demonstrate protein 
encapsulation using SN Esy, yielding particles 937±158 nm in diameter using high viscosity 
alginate (Suksamran et al., 2009). Poly (lactic-co-glycolic acid) (PLGA) NPs loaded with amino 
acid n-acetylcysteine were fabricated to overcome its poor oral BA of the amino acid (Zarchi et 
al., 2015). The NPs were spherical in shape with some as small as 122 nm and also exhibited 
biphasic release in in vitro release studies.   More recently, peptide angiotensin II was 
encapsulated into N-octyl-o-sulphate chitosan particles which demonstrated triphasic release 
profile with an EE of 92±1.8% and average diameter of 105.7±4 nm (Rasekh et al., 2015b).  
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2.4.3.1.2 Gene Therapy 
DNA-based pharmaceutical preparations have been developed for medical treatment of several 
diseases e.g. asthma, cancer and cystic fibrosis. However, the delivery of genes as a 
pharmaceutical dosage form currently results in instability problems such as losing DNA 
molecular integrity upon processing (Zeles-Hahn et al., 2011). It is vital to conserve either the 
super coiled or the open circle form of plasmid DNA in order to accomplish robust gene 
expression (Kimoto and Taketo, 1996).  
Delivery of DNA based drugs to the desirable organ in the body can be achieved in 3 different 
ways: i) intravenous injection, ii) direct injection and iii) topical application by aerolization. The 
latter is most commonly used due to the advantage of non-invasively targeting the affected cells, 
reducing any toxic effect on other body organs (Bennett et al., 2002; Zeles-Hahn et al., 2011). 
The nature of Esy allows sensitive material to be handled and processed without the integrity of 
the materials being compromised. Zeles-Hahn et al demonstrated that Esy is a reliable method 
for administering DNA-based therapeutics to the epithelium cells in the pulmonary system 
(Zeles-Hahn et al., 2011). Stable plasmid DNA-polyethyleneimine aerosols were sprayed using a 
SN without any signs of structural alteration or loss of integrity of the DNA. The electrical field 
applied was found to cause temporary mild toxicity which reverted to normal conditions within 
a few hours of administration to the tissue. Further in vivo investigation combined with these 
results demonstrates potential for administering DNA-based therapy to the pulmonary 
epithelium and various other tissues using this technology. 
Lee et al successfully improved the transformation efficiency (5-7 fold) of gold NPs (50nm) 
loaded with PET30a-GFP plasmid DNA. The transformation of the plasmid using Esy did not 
require the preparation and time needed for conventional methods, which is often the limiting 
step in such DNA transformation methods (Lee et al., 2011). Similarly, Park et al showed the Esy 
process has the capability to produce adenovirus carriers for effective transduction efficiency in 
cancer cells (Park, Kim et al., 2012). Beads produced using 0.5% alginate concentration 
demonstrated high encapsulation activity and sustained release for 7 days; with high 
transduction efficiency in U343 glioma cells. These cross-linked alginate structures show the 
potential of Esy beads to overcome the limitation of liver accumulation and immune response.   
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2.4.3.1.3 Cancer Treatment 
Due to lack of effectiveness of existing therapeutic approaches, treatment for cancer is still a 
major challenge. Despite various chemotherapy drugs available (both orally and intravenously), 
current treatment still has numerous limitations. Physical properties (e.g. drug solubility) and 
poor pharmacodynamics of the drug and physiological conditions (i.e. pH 7.4) lead to ineffective 
therapeutic concentrations at the target site. Current approaches commonly involve frequent 
radiation application after surgical removal of the tumour.  By producing anti-cancer loaded Esy 
structures, a much more effective dose of drug can be delivered directly to the tumour (i.e. local 
drug delivery), halting the need for repetitive drug and radiation administration.  
Various drugs used for an array of cancers (including breast, ovarian, retinoblastoma) have 
already been incorporated into polymeric particles yielding promising results. Tamoxifen, a 
lipophilic drug used for breast cancer treatment, was loaded into poly (amidoamine)-cholesterol 
carriers, producing particles in powder form with an average diameter of 500 nm (Cavalli et al., 
2011). Wu et al incorporated active doxorubicin (DOX) into elastin-like polypeptides, producing 
biocompatible NPs ranging from 300 nm to 400 nm in diameter (Wu et al., 2009).  
Cancer treatment using cyclophosphamide is advantageous due to the mode of action 
interfering with DNA replication of cancer cells. A study by Gulfam found 7% gliadin polymer 
entrapped 72.02% of cyclophosphamide following Esy deposition (Gulfam et al., 2012). Gradual 
release of the drug from the gliadin NPs was observed for 48 hours and the homogenous NPs 
(218.66±5.1nm) demonstrated down regulation of BCC-2 protein in breast cancer cells following 
exposure for 24 hours. Luo et al also demonstrated high encapsulation using Esy to load 
hydroxycamptothecin into poly (benzyldehyde poly ethylene glycol) poly (D,L-lactide) NPs (Luo 
et al., 2014). These biodegradable, acid-labile NPs showed fewer side effects (e.g. tissue 
necrosis, tumour growth) in in vivo testing with Hepa2 cells and H22 tumour-bearing mice; a 
substantial improvement compared to existing methods (Venditto and Simanek, 2010).  
More recently, Lee et al developed hyaluronic acid derivative nanocomposites to entrap the 
drug reservatol for local tumour treatment (Lee et al., 2016). The amphiphilic nature of 
hyaluronic-ceramide combined with Soluplus (a solubility enhancer) in this study enabled more 
than 80% of drug to be loaded into the nanocomposites. Compared to Soluplus alone, the 
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combination of solubility enhancer and hyaluronic acid derivatives demonstrated higher cellular 
uptake efficiency in CD44 receptor and positive human breast cancer cells. The nanocomposites 
had an average diameter of 230 nm and showed sustained, pH dependant release whilst 
showing decrease in in vivo clearance, highlighting the potential of Esy in theranostic nano-
systems for receptor expressed cancers.  
2.4.3.1.4 Non-Steroidal Anti-Inflammatory Drugs 
NSAIDs are actives known for their role in pain mitigation and reduction of inflammation. The 
mode of action involves interfering with cyclo-oxygenase, an enzyme which controls the 
production of prostaglandins. Esy can bypass the time consuming manufacture of tablets and 
develop NSAID-loaded structures on demand with increased drug loading reducing the need for 
frequent dosage.  
Yu et al prepared naproxen, a non-selective COX inhibitor, and lecithin-loaded PVP 
microparticles (MPs) as templates for molecular self-assembly for in situ liposome synthesis (Yu 
et al., 2012). Using Esy, an EE of 91.2% was achieved and in vitro release analysis from the self-
assembled liposomes from Esy composites exhibited high EE (91.3%) and 80.7% drug release 
over 24 hours via Fickian diffusion.  
Piroxicam is an analgesic NSAID described as a class 2 drug in the Biopharmaceutical 
Classification System, an active displaying low aqueous solubility and high permeability. A 
research group in Finland found that by electrospraying piroxicam, an unknown polymeric form 
of the NSAID could be yielded (Nyström et al., 2015). 3 polymorphs (I, II, III) have been found to 
date; with Esy now presenting yet another polymorph. X-ray Diffraction (XRD) analysis of the 
resulting structures demonstrated an unknown crystal structure of piroxicam. Comparison of 
Fourier Transform Infrared (FTIR) spectra of generated particles to that of form I of piroxicam 
showed evident changes with new functional groups and chemical bonds present in the 
atomised particles (11.4 µm). Various analytical methods (Scanning Electron Microscopy (SEM), 
Differential Scanning Calorimetry (DSC), High Pressure Liquid Chromatography (HPLC)) found the 
particles were spherical in shape and showed no signs of degradation during 127 days of storage.  
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Biodegradable PLGA microspheres loaded with celecoxib were developed to help improve the 
oral solubility of the drug (Bohr et al., 2012). Celecoxib remained in its amorphous state and the 
microspheres (28 µm) remained stable for up to 3 months.  
2.4.3.1.5 Miscellaneous 
PLGA has been utilised to encapsulate antibiotic metronidazole using trifluoroethanol, yielding 
microspheres 1774±167 nm in diameter (Prabhakaran et al., 2015). PLGA has also been used as 
a carrier for statin simvastatin (Imanparast et al., 2016). The biocompatible NPs (160 nm) 
developed here possessed high encapsulation (90.3%) and demonstrated enhanced aqueous 
solubility. 
Hia et al attempted to produce a self-healing composite system incorporating epoxy resin into 
alginate microcapsules (Hia et al., 2016). Although SN Esy was used in this study, the capsules 
that were produced presented core-shell structures commonly seen with a coaxially arranged 
system. The stable particles had an average diameter 320±20 µm and possessed the ability to 
heal up to 3 times more due to multi-core capsule structure, demonstrating the first sustainable, 
eco-friendly self-healing system.  
2.4.3.2 Single Needle Electrospinning 
As mentioned earlier, ES is the production of fibers using an electrical field. SN ES uses a similar 
device set-up to that of Esy i.e. a polymeric solution is fed through a conductive needle via a 
syringe pump. The drug is dissolved or dispersed into the polymer and solvent, achieving a 
homogenous distribution once fibers are formed. When the electrical force is applied and 
reaches the critical threshold at which the ST of the polymeric solution is overcome, rather than 
breaking up into particles (as with Esy), the jet becomes unstable. This results in a whipping 
motion of the liquid jet in the synapse between the needle and collection plate due to the 
applied voltage trying to overcome solution ST. This rapid whipping causes the solvent to 
evaporate, yielding polymeric fibers, which over time form fibrous mats. Over the past 2-3 
decades, the interest in ES has spiked, allowing research to discover new applications for these 
fibrous structures including protein delivery (Li et al. 2005, Xu et al, 2013, Ozcan, Ertul and 
Maltas, 2016), anticancer therapy (Xie and Wang, 2006, Zhang et al, 2015) and bioengineering 
(Zakaria et al 2013, Dash et al 2011, Li et al 2014).  
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2.4.3.2.1 Protein delivery 
Maintaining the bioactivity of sensitive materials like proteins can be challenging during 
processing or encapsulation. By optimising material properties and the EHD process, the 
bioactivity of biomacromolecules can be preserved whilst achieving high encapsulation 
efficiency.  
Electrospun fibrous scaffolds have been developed which successfully incorporate 
biomacromolecules providing structural support as well as to stimulate tissue regeneration. A 
research group from Philadelphia, Pennsylvania fabricated PLGA, gelatin and elastin scaffolds 
with the ability to support dense cell growth (Li et al., 2005). Common limitations often seen 
with engineering of macroscopic tissue, such as necrotic cores, were absent with these fibers 
with the scaffolds showing high porosity, facilitating sufficient nutrient transport to a high 
number of cells as well waste removal.  
BSA is a common protein used to model the potential of ES for protein delivery. Along with 
myoglobin, BSA has been incorporated into PLGA NFs (468±139 nm) forming scaffolds with a 
loading efficiency of around 80%. This dual-protein delivery system can be utilised and has 
potential for controlled tissue engineering application (Xu et al., 2013). Zeng et al demonstrated 
the encapsulation of BSA and enzyme luciferase into poly (vinyl acid) (PVA) fibers with both 
molecules retaining their bioactivity once electrospun (Zeng et al., 2005). BSA has also been used 
to develop fiber scaffolds with the ability to mimic tissue (Ozcan, Ertul and Maltas, 2016). Ozcan 
et al fabricated BSA, globulin, and haemoglobin fiber mats (75 nm, 117 nm and 220 nm in 
diameter, respectively) which had high surface area and were potential substrates for 
regenerative tissue growth.  
Kim et al reported multi-functionalised electrospun scaffolds containing PCL fibers ranging from 
100 nm to 200 nm in diameter (Kim, Choi and Cha, 2012). These fibers were loaded with mussel 
adhesive protein and exhibited apt mechanical strength with the ability to encapsulate protein 
without surface modification. In vivo analysis using a rat model showed the hydrophilicity of 
protein-PCL fibers facilitated keratinocyte growth demonstrating accelerated skin regeneration. 
The blended nanofibrous scaffolds also possessed an entrapment efficiency three times higher 
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than non-blended structures thereby increasing growth factor residence time in the wound. This 
allowed the activation of adjacent cells and hence improved skin regeneration (Kim et al., 2017).  
2.4.3.2.2 Gene Therapy  
Gene therapy has also benefitted from the ES process. The formulation, handling and logistics 
of DNA based formulations require great attention due to the sensitivity of the structure of DNA 
molecules and preservation of the DNA is vital for optimum treatment/delivery of DNA based 
drugs. The process parameters of ES enable such sensitive formulations to be handled without 
the integrity of the material being compromised.   
One of the first studies which used the electrospinning process for DNA based application was 
in the late 1990s where DNA fibers using calf thymus-NA with diameters between 50 nm and 80 
nm were observed (Fang and Reneker, 1997).  Following this, experiments were directed 
towards preparing fibrous matrices incorporating lambda DNA, an Escherichia coli 
bacteriophage. Bellan et al isolated stretched DNA molecules and loaded them into polyethylene 
oxide (PEO) NFs (100-350 nm) (Bellan et al., 2006). Modifying the process parameters yielded 
fibers with smaller diameters, ranging from 50 nm to 250 nm.  
DNA plasmids have also successfully been incorporated into fibrous polymer scaffolds using 
biodegradable co-block polymers (PLGA, Poly (lactic acid) (PLA) - poly (ethylene glycol) (PEG)). 
10% copolymer block formulation gave fibers with diameter average of 250 to 875 nm. In vitro 
assessment of DNA release showed the plasmid was released from the scaffold intact with 
bioactive capabilities, highlighting the possibility of using ES for gene therapy (Luu et al., 2003).  
The potential of DNA-based molecules small interfering RNA (siRNA), up until recently, have not 
been exploited fully with respect to silencing genes. siRNA are molecules comprising of 2 RNA 
strands, which can be integrated into “RNA induced silencing complexes” (Tokatlian and Segura, 
2010) which controls mRNA binding and cleavage. However, delivery of siRNA has its limitations; 
both extracellular (degradation, specific cell targeting) and intracellular (endosomal escape, 
mRNA targeting) (Grabow and Jaeger, 2014). The therapeutic application of siRNA often takes 
the form of nanoparticles, however, for fundamental applications such as tissue regeneration, 
electrospun fiber production offers a cheap and simple alternative. 
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Cao et al encapsulated siRNA in a PCL shell to form polymeric nanofibers (300-400 nm in 
diameter) which achieved controlled release for 28 days under physiological conditions (Cao et 
al., 2010). The siRNA remained bioactive for this duration, showing potential for sustained gene 
delivery. Copolymeric nanofibers (caprolactone and ethyl ethylene phosphate) has also been 
used a platform to alter siRNA kinetics for siRNA delivery and gene silencing (Rujitanaroj et al., 
2011).  
2.4.3.2.3 Anticancer Therapy 
Physiological conditions (pH 7.4, temperature 37°C) pose challenges with respect to 
administering a sustainable amount of drug to achieve a therapeutic effect at the site of action. 
By loading such drugs into electrospun fibrous mats, the amount and release of drug delivered 
to the site of the tumour can be controlled. The fibrous mat can be administered directly to the 
tumour site following surgery or for treating the tumour, ensuring almost all of the drug loaded 
into the matrix will be delivered at the desired site.  
Cisplatin is one of the most potent anticancer drugs in medicine. It has been used extensively to 
treat various cancers including testicular, ovarian and bladder cancer. Although efforts to 
understand the exact mode of action of cisplatin still advance, it is clear that drug - DNA 
interaction is a key component. Mechanisms such as binding to the purine bases in the DNA 
double helix structure and the cisplatin interfering with the DNA repair mechanism (resulting in 
damage to DNA) have been associated with the mode of action.  Xie et al developed optimised 
cisplatin-loaded PLA/PLGA fibers for the in vitro treatment of C6 glioma (Xie, Tan and Wang, 
2008).  SEM analysis showed the fibers (0.5 µm-1.7 µm) were interlocked, increasing the 
strength of the resulting fibrous mat produced in turn improving the efficacy of the scaffold.  
Paclitaxel-loaded fibers have also been produced to analyse its potential in treating C6 glioma 
(Xie and Wang, 2006). These PLGA fibers (30nm) had EE over 90% and provided sustained 
release for more than 60 days.  Cytotoxicity tests were carried out to obtain the half maximal 
inhibitory concentration (IC50) of the drug in this formulation. An IC50 value of 36 mg/mL was 
observed, a value comparable to Taxol®, a commercial paclitaxel formulation (W. Xie, 
Marijnissen and Wang, 2006).    
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DOX hydrochloride (DHCl) (an anticancer, bacterial antibiotic active) was used as a model drug 
to demonstrate the feasibility of drug delivery from electrospun PEG/Poly (L-lactic acid (PLLA) 
(di-block copolymer) fibers; using an emulsion rather than a solution (Xu et al., 2005). The fibers 
ranged from 300 nm to 1 µm in diameter with 1-5% drug content within the fibers. Using MTT 
methods (C6 cell lines) it was established that DHCl could be released without any detriment to 
its cytotoxicity. The encapsulated DHCl also had the same chemical structure and exhibited 
comparable antitumor activity to pure DOX, highlighting the EHDA process does not affect the 
drug in any way. PEG/PLA and PEO/water water-oil-emulsion was electrospun to create core-
shell fibers, with average size of 749 µm (Xu et al., 2006). The resulting composite fibers 
exhibited a water-soluble polymeric core. In an extended study, Xu et al incorporated paclitaxel 
into the oil phase of a w/o emulsion and DHCl into the aqueous phase, creating a multi-drug 
delivery system (Xu et al., 2009). SEM images showed smooth surfaces on the fibers (730 nm) 
with crystal formation, indicating both drugs were finely incorporated within the nanofibers. 
DOX was also loaded into carbon nanotubes which were successfully electrospun into PLLA 
fibers (326±63 nm) (Zhang et al., 2015). Combining ES with photothermal therapy induced 
cancer cell death as well as promoting increased diffusion of DOX to the tumour site, 
consequently demonstrating enhanced inhibitory effect on tumour growth.  
2.4.3.2.4 Antibiotic Delivery 
There are a wide variety of antibiotics available to prevent or treat bacterial infections. However, 
to maintain their antibacterial activity constant administration of the drug is required. Failure to 
do so can result in a concentration lower than the Minimum Inhibition Concentration (MIC), 
leading to antibiotic resistance. Maintaining the drug concentration above MIC can achieve the 
desired therapeutic effect over an extended period of time whilst preventing antibiotic 
resistance.  
Incorporating the antibiotics into NFs has been found to extend the release of drug when ES 
fibrous mats are applied as wound dressings, accelerating the rate of wound healing as well as 
preventing infection. A research group in the USA developed a biodegradable gauze made of 
poly (lactic-co-glycolide) (PLAGA) NFs (Katti et al., 2004). These NFs were loaded with cefazolin, 
a broad spectrum bactericidal antibiotic. This API works by attaching to penicillin binding 
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proteins resulting in inhibition of cell wall synthesis for that bacterium. The electrospun fibers 
ranged from 470 nm to 490 nm. By modifying the process parameters the PLAGA fibers could 
be tailored for personalised for wound healing depending on the type and location of the wound.  
More recently, PLGA fibers containing multiple antibiotics were developed for the prevention of 
orthopaedic implant associated infections (Gilchrist et al., 2013). The NFs (loaded with fusidic 
acid and rifampicin) had an average diameter of 612±32.2 nm with an EE exceeding 75%. Fibers 
loaded with 10% fusidic acid and 5% rifampicin caused a reduction of more than 99% of the 
adherent cells in a rodent model of implant associated infections.  
Fluoroquinolone antibiotics (ciprofloxacin hydrochloride, levofloxacin hemihydrate or 
moxifloxacin hydrochloride) have been entrapped into poly (L-lactic-co-D,L-lactide)/PEG) matrix 
for wound dressings (Toncheva et al., 2012). The electrospun fibers exhibited a biphasic release 
profile with an initial burst release followed by sustained release, a fundamental prerequisite 
for wound treatment.   
Zupancic et al incorporated ciprofloxacin into poly (methyl methacrylate) (PMMA) and PVA 
blended fibers or chitosan fibers which demonstrated drug release over 18 days (Zupancic et al., 
2016). Ciprofloxacin loaded-PEO fibers in the same study showed the highest burst release 
whereas chitosan fibers showed the slowest release. Zupancic also loaded metronidazole into 
chitosan/PEO NFs for treatment for local infections. The biocompatible and biodegradable fibers 
were smaller than 80nm in diameter when using high drug loading (15%). Release kinetics of 
metronidazole varies with the fluid at the therapeutic site; areas with limited volume (e.g. 
chronic wounds) exhibited slower drug release whilst at sites with larger volumes of bodily 
fluids, such as the buccal mucosa, the fibers showed greater drug release.  
A research group from Egypt produce gelatin electrospun fibers loaded with chloramphenicol 
150-450nm in diameter (Nada et al., 2016). The resulting biocompatible, biodegradable fibers 
demonstrated strong inhibitory activity against gram positive S. aureus, gram negative P. 
aeruginosa and fungus Candida albicans whilst presenting sufficient EE of chloramphenicol.  
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2.4.3.2.5 Bioengineering 
Material development and the continuous evolution of the ES process has allowed the process 
to be used in much more critical applications such as biomaterial engineering. Biomaterial 
electrospun systems can be developed to mimic bone extracellular matrix to repair primarily 
degenerated bone functionality (Liu et al., 2013). 
Hydroxyapatite (HA) is a biomaterial largely used for bone replacement and regeneration. HA-
loaded-fibers with diameters ranging from <100 nm to 20 µm have been produced using various 
polymeric matrices such as polyurethane (A. S. Khan et al., 2008), polyvinyl butyal (Zakaria et al., 
2013), chitosan (Frohbergh et al., 2013) and PCL (Zakaria et al., 2013).   For example, HA-loaded 
chitosan fibers were fabricated by Frohbergh et al for bone tissue engineering. The electrospun 
NFs were 227±154 nm in diameter and supported adhesion, proliferation and osteogenic 
differentiation of mouse 7F2 osteoblast-like cells. Crosslinking HA-loaded chitosan fibers with 
genipin yielded scaffolds useful in the repair and regeneration of maxillofacial defects and 
injuries (Frohbergh et al., 2013).  
Chitosan along with collagen has been used extensively in this area due to their biocompatibility 
and resemblance to structures in the body such as skin, bone and muscle. Chitosan is a semi-
synthetic versatile polymer that has a number of biomedical uses (Dash et al., 2011), whilst 
collagen is structural protein found in abundance in animal connective tissue which has been 
utilised in treating various bone and skin impediments (Matthews et al., 2002). Electrospun 
chitosan and collagen nanofibers have been used to produce novel matrices for wound dressings 
to encourage/promote skin regeneration. Type 1 collagen, chitosan and PEO were used to 
fabricate thin membranes of nanofibers (134±42 nm) (Chen, Chang and Chen, 2008). SEM 
images showed that a flow rate of 0.5 ml/h and an AV of 30 kV were the optimised 
electrospinning processing conditions to obtain nanofibers. In vitro studies showed good 
biocompatibility while in vivo animal studies proved the nanofiber membranes were sufficiently 
better than gauze and commercial collagen sponge wound dressings with respect to the rate of 
wound healing (Chen et al., 2008).  
Chitosan has also been used in conjunction with polyurethane to fabricate silver sulfadiazine 
loaded fibers to enhance antibacterial activity and mechanical strength of wound dressings. The 
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fiber sheets exhibited strong antimicrobial activity by inhibition of bacterial growth of both gram 
positive (S. aureus) and gram negative (P. aeruginosa) bacteria whilst preventing infection of the 
wound (Lee et al., 2014).  
Recent studies have also fabricated nanofibers combining chitosan with PEO to encapsulate 
multi-cancer treating drug 5 Fluorouracil, (5FU) to achieve controlled drug release for 
biomedical application (Li et al., 2014). 5FU has also been electrospun into nanofibers for use in 
tissue scaffolds and novel controlled drug delivery systems for multiple drugs using nanomicelles 
(Hu et al., 2014) as well as multifunctional PEO fibers containing amphiphilic vesicles for the 
encapsulation of hydrophobic 5FU and hydrophobic paeonolum (Li et al., 2015). The operating 
parameters of ES can evidently create systems that can efficiently encapsulate and potentially 
deliver “environmentally demanding” materials/actives.   
Collagen micro and nanofibers have successfully been used as artificial skin support and as bone 
scaffolds highlighting the potential of using ES nanofibers as future material for tissue 
engineering (Matthews et al., 2002).  Biodegradable poly(esteramides) (derived from L-alanine) 
scaffolds were fabricated to show potential for biomedical engineering. The nanofibers (average 
of 400 nm) proved to be a strong candidate for vascular tissue engineering (Srinath et al., 2012). 
2.4.3.3 Complex EHDA Systems 
An increase in material knowledge, material development and process understanding has 
enabled the EHDA process to evolve yielding complex and innovative systems for an array of 
applications.  
Coaxial EHDA (Co EHDA) is the term used to describe when two conductive needles are used in 
conjunction in a coaxial arrangement. This configuration can be utilised for one-step 
encapsulation of APIs and therapeutic agents within a polymeric shell. The solutions used with 
this system are immiscible, therefore, the coaxially aligned needles produce particles with a 
defined shell and a defined core. As with single needle, this mode of EHDA can produce 
structures with narrow size distribution in the micro-/nano-meter range. Loscertales et al were 
the first to propose the use of two conjunctive needles. Using a coaxial set-up, capsules (inner 
needle: water, outer needle: olive oil) ranging between 150 nm and 10 µm were produced 
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(Loscertales et al., 2002). Chen et al found that when encapsulating cooking oil in a shell of 
ethanol, glycerol and tween, the outer liquid flow rate determined the properties of the spray 
itself (the viscosity, EC of the liquid) (Chen et al., 2005).  
Co EHDA, like single needle, has been used to produce structures, encapsulating 
biomacromolecules such as peptides and proteins without denaturation and degradation.  
Angiotensin II was successfully encapsulated into N-octyl-O-Sulphate chitosan and tristearin, 
respectively; yielding NPs 100-300 nm in diameter, with peptide EE of 92±1.8%. A triphasic 
release profile is indicative of the emerging potential of Co EHDA (Rasekh et al., 2015b). model 
protein BSA has been encapsulated within a PLGA shell where the core-shell particles had 
diameters between 3 and 5.5 μm. The EE of BSA was 15.7% and 25.1% higher than emulsion Esy 
particles for high and low molecular PLGA, respectively (Zamani et al., 2014).  BSA has also been 
encapsulated into biodegradable PLGA particles (3.4 μm) along with lysozyme which retained 
more than 90% of its bioactivity during release (more than 30 days), highlighting structure and 
function was not compromised by the Esy process (Xie et al., 2008).  
A distinguishing aspect of EHDA is being able to produce structures with a large array of 
structures valuable for poorly soluble materials such as quercetin, a poorly soluble pigment used 
in the treatment of high blood pressure and diabetes. 3 formulations with various drug loadings 
with a PVP:Quercetin core and PVP:sodium shell were atomised at different flow rates. 
Quercetin remained in its amorphous form; unaffected by the EHD process. The interactions 
between the components increase the dissolution and permeability of quercetin, a theory easily 
applicable to other poorly water-soluble drugs for novel drug delivery systems (Li et al., 2014). 
Laelorspoen et al developed zein microparticles consisting of an alginate and Lactobacillus 
acidophilus core to assess the ability to produce EHD delivery vehicles for microorganisms. The 
core-shell structures provided sufficient protection from harsh physiological conditions. The 
capsules (259±62 μm in diameter) improved the survival of the probiotic bacterium five-fold 
(Laelorspoen et al., 2014).  
The evolving development and optimisation of process parameters and liquid properties has 
made the concept of producing nanocapsules a reality (Ghayempour and Mortazavi, 2013; Hao 
et al., 2015; Cao et al., 2014). Alginate nanocapsules as small as 80 nm where generated for the 
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encapsulation of an essential oil (Ghayempour and Mortazavi, 2013), whilst antibiotic agent 
metronidazole was loaded into Eudragit RS/PMMA core-shell particles, 60 nm in diameter. The 
amphiphilic (hydrophobic shell, hydrophilic core) metronidazole nanocapsules exhibited EE of 
100.2±0.92% at 2% PMMA and sufficient controlled release, highlighting potential in an array of 
clinical applications (Hao et al., 2015).    
Microbubbles (MBs) have successfully been developed and utilised in a vast array of application 
in the pharmaceutical industry e.g. ultrasound imaging and biomedical engineering (Li et al., 
2008). Hollow microparticles (filled with air) are produced using a similar set-up to Co EHDA 
except air is passed through the inner needle. Farook et al prepared MB suspensions using a 
glycerol-air system. These MBs were less than 10 μm in diameter with narrow size distribution 
(Farook et al., 2007). By adapting this process it was possible to develop MBs with phospholipid 
coating. These MBs were produced at high yield rate (109 bubbles/min) and were found to 
decrease in size at physiological temperature. The size and shape reduced and maintained shape 
at 1-2 μm after 20 minutes, showing an increase in temperature increased the diffusion of air 
through the phospholipid shell (Farook, Stride and Edirisinghe, 2009).   
Coaxial configuration of EHDA has also been used to develop protein (BSA) MBs and porous films 
(Ekemen, Ahmad et al., 2011; Ekemen, Chang et al., 2011; Ekemen et al., 2013; Mahaingam, 
Meinders and Edirisinghe, 2014) suggesting a novel tool in protein and peptide delivery. A 
combination of high production yield and uniform production with easily amendable size 
modifications show the potential for multiple biomedical applications including tissue 
engineering. For example, Ekemen et al developed silk fibroin bubbles (240-1000 μm) where the 
hollow bubbles also served as porous material when dehydrated; advantageous in bio-coatings 
and tissue engineering (Ekemen et al., 2013).  
Coaxial configuration in ES is particularly useful for materials/solutions that cannot be 
electrically atomised (e.g. non-conductive); they can be passed through the inner nozzle and be 
entrapped in a polymeric shell to produce hollow or “core-sheath” structures 
(Jarusuwannapoom et al., 2005).  For susceptible materials, the shell structure of fibres can 
protect the contents of the core whilst providing sustained release of the encapsulated material. 
The first work in producing unique core-sheath structures was done using w/o emulsion (Xu et 
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al., 2006). Coaxial Es (COES) has been used in developing drug delivery systems and has initiated 
various novel devices in nanotechnology.   
Generation of core-shell fibres encapsulating anticancer drugs have exhibited controlled, 
sustained drug release and have demonstrated prohibition of cancer cells (Huang et al., 2009; 
Yan et al., 2014; Yang et al., 2015). Yang et al developed an implantable device which exploited 
the amphiphilic nature of micelles and broad application of polymeric NFs. Hydrophobic DOX 
was entrapped into micelles which formed the core of gelatin fibres along with PVA. The 
development of this biodegradable device reduced the drug dose required to be administered 
as well as administration frequency whilst still having a sufficient therapeutic effect against 
cancerous tissue (Yang et al., 2015).  
PCL, like PVA, is a biodegradable polymer and has been commonly used for shell material for 
biodegradable NF scaffolds. It has been found to provide sustained release of various antibiotics 
(Huang et al., 2006; Park, Yoo et al., 2012). Chitosan-PCL core-shell fibres exhibited sustained 
release of levofloxacin; beneficial for prevention of bacterial infections stemming from post-
operative surgery (Park et al., 2012). Antibiotic gentamycin sulphate and antioxidant resveratrol 
were encapsulated into PCL fibres to form double-layered ultrafine fibres (208-1585 nm for 
gentamycin-loaded fibres, 153-1317 nm for Resveratrol-loaded fibres) (Huang et al., 2006).  
Novel sustained ibuprofen delivery systems have also been developed in the form of triple 
component nanocomposites (Qian et al., 2013) and nanofibers (W. Huang et al., 2013).  Zein (a 
prolamine protein) was used to evenly distribute ibuprofen (the core) into N,N-
dimethylformamide fibres. Qian et al developed triple component nanocomposites 
(ibuprofen/PVA/ polyacrylonitrile (PAN)) with average diameter of 620±120 nm with 10.5% PVP 
content. Compared to double component nanocomposites (ibuprofen/PAN), the triple 
component structures significantly improved in vitro ibuprofen release kinetics, preventing the 
drug from being entrapped in the insoluble PAN molecules (Qian et al., 2013). 
BSA has been frequently used as a model protein to demonstrate the delivery of proteins using 
COES (Xu et al., 2013, Jiang et al., 2005; Raheja et al., 2013). Electrospun fibrous scaffolds have 
been developed in which two proteins have been incorporated to provide structural support as 
well as for the stimulation of tissue regeneration. BSA and myoglobin were integrated into PLGA-
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PF127 fibrous scaffolds (423±209 nm) with a loading efficiency of around 80% proving to be a 
useful dual protein delivery system for tissue engineering applications (Xu et al., 2013). BSA has 
also been incorporated into poly(l-lactide-co-ε-caprolactone) (PLLACL) NFs in conjunction with 
rhodamine B to develop novel dual drug release tissue engineering and drug delivery carriers 
(Su et al., 2012).  More recently, electrospun PLLA/gum tragacanth NFs exhibited promising 
capabilities as grafts for nerve tissue regeneration showing high cell differentiation as well as 
higher proliferation. The addition of gum tragacanth increased the hydrophilicity of PLLA 
scaffolds as well as NF diameter (226±73 nm) (Ranjbar-Mohammadi et al., 2016).  
The use of coaxial EHDA configuration has also extended to more complex routes of application, 
for example transdermal administration. PVP particles (100nm-3μm) were sprayed onto the tips 
of microneedles; providing a rapidly dissolving coating for burst release of drug in the dermis of 
the skin (Khan et al., 2014).  
Systems using more than 2 needles arranged concentrically have successfully produced multi-
layered structures, enabling the resulting products to have much more complex release kinetics. 
Biodegradable multi-layered fibres having been fabricated by Lui et al using triaxial (3 needle) 
electrospinning set up (Liu et al., 2013). PCL (intermediate layer) and gelatin (sheath and core) 
were electrospun and fibres of 25µm were generated, revealed by Field Emission Scanning 
electron microscopy (FESEM), showing the ability of preparing materials for application in 
biotechnology.  PCL was also used to produce 3-layered NFs exhibiting sustained release of 
probes from the core and a burst release from the sheath, highlighting the potential use of dual-
drug triaxial NF membranes for wound treatment, externally and internally (Han and Steckl, 
2013).  
An ongoing issue with ES is the rate of fiber production. To overcome this, research has diverted 
towards the use of multi-needle devices (Regele et al., 2002). Utilising a multi-needle 
electrospinning system is a cost effective, convenient, one-step method to fabricate specific 
structured nanofibres at a high production rate (Jiang et al., 2014). The use of several needles 
and syringes within the process allows the fabrication of fibrous mats such as tissues, 
electrospun from a multi-jet. This system is more complex than single needle or coaxial (2 
needle) spinning as repulsion may occur between similarly charged jets. Multi-needle systems 
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require well thought out configuration of needles in order to optimise electrospinning 
productivity. Needles can be configured in various ways for example circular, triangular or 
hexagonal as demonstrated by Yang el al (Yang et al., 2010). Preliminary simulations studies 
showed that using outer needles in a hexagonal shape assisted in the creation of a uniform 
electric field near the tips of the nozzles; yielding finer PEO fibres (as small as 200 nm).  
A novel approach for ES was developed by Yarin et al; utilising a needleless system with a 
magnetic suspension and magnetic field to force the suspension through a polymer solution, 
resulting in fibers which ranged from 200-800 nm in size. Perturbation of the polymer layer by 
the ferromagnetic suspension led to a 12-fold enhancement of the production rate of the ES 
process (Yarin and Zussman, 2004). Bocanegra et al also developed a needleless system which 
used orifices rather than nozzle capillaries to achieve a steady jet for atomization of liquids 
(Bocanegra et al., 2005). The system (consisting of up to 37 pores) was found to increase the 
stability and reliability of the EHDA process. The orifices were arranged in a planar hexagonal 
pattern with each delivering a cone-jet in the multi-spray system that behaved independently 
from adjacent jets. The multi-pore system was electrically stable, regardless of pore number or 
orifice diameter.  
Jet-bending (from electrostatic interactions with neighbouring jets) has been demonstrated 
using a flute-like horizontal device for the high throughput production of PCL MPs (Zhang et al., 
2015). The novel device utilised a multi-pore design instead of needle capillaries where 
modifying pore configuration and processing parameters yielded uniform MPs. The spatial 
location of these multiple pores found to have adverse effects on the stability of the jets with 
electrostatic forces between adjacent jets causing the jets to bend, generating particles with 
irregular morphologies. By manipulating the spatial locations, these inconsistences in 
morphology can be overcome.  
Another recent development has moved away from concentric nozzles, and focused more on 
aligned or converging nozzles (also termed co-jetting). Here, atomised materials do not 
encapsulate one another, but rather form composites as segmented compartments. These have 
been useful for the preparation of several Janus particle systems, which are able to combine 
functional properties through precursor spraying (for further processing) (Mou et al., 2013), as 
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well as altering the shape and segment loading volume which has great potential in targeted 
drug delivery (Rahmani et al., 2015).  
2.4.3.4 Utilising EHDA for Ocular Drug Delivery 
Only in recent years has the potential of using EHDA for ocular application been recognised, with 
researchers producing fibrous structures for not only drug delivery but corneal tissue 
engineering. Lancina et al developed electrospun dendrimer nanofibers as a matrix to delivery 
anti-glaucoma drug brimonidine tartrate topically to the cornea (Lancina et al., 2017). Whilst IOP 
responses were similar between this developed system and pure drug solution, in a single dose 
test the dendrimer fibers demonstrated much improved efficacy over 3 weeks. This, along with 
the fibers exhibiting no toxicity or ocular irritation, indicates these electrospun fibers have great 
potential as drug vehicle for topical ocular drug delivery.  
Antibiotic-eluting sutures for post-surgery treatment have been fabricated by a research team 
in the USA (Kashiwabuchi et al., 2017). Kashiwabuchi et al used a wet electrospinning process to 
develop levofloxacin sutures, which were 45.11 ± 7.7 µm in diameter and successfully inhibited 
the growth of Staphylococcus epidermis, an ocular infecting bacteria. The PLLA-PEG absorbable 
sutures were histologically equivalent to commercial available nylon used for the same 
application. Using ES in this manner yielded strong, absorbable sutures capable for delivery of 
not only antibiotics but also other ocular actives. Antibiotics acyclovir, ciprofloxacin and 
cyanocobalamin have also been loaded into PVP and PCL fibers yielding 2 sets of electrospun 
fibers which possessed half-lives of up to 6 days (Baskakova et al., 2016). This is greater than 
those of a pure drug solution using the same in vivo model, highlighting the potential for 
generation of intravitreal implants.  PCL has also been used for an implantable scaffold, 
developed as a delivery system for cells and drugs to the eye (Irani et al., 2015). PCL fibers with 
pressed, nanostructured porous silicone MPs displayed successful attachment to human lens 
epithelial cells (SRAOVG4) and proliferated the growth of these cells. To assess drug release, 
insulin was seeded onto the pressed porous composites and the insulin was released 
continuously over 6 days, with an initial burst release followed by subsequent slower release. 
Whilst these composites did not cause neovascularisation, they did trigger a mild foreign body 
response. The ability to support attachment and growth of ocular epithelial cells highlights the 
potential of this composite as a novel implantable device for treatment.  
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PCL has also been used as a matrix to deliver antibiotic ofloxacin for the treatment of ocular 
infections (Karatas et al., 2016). The yielded fibers released ofloxacin via burst release and 
microbiological activity was tested against P. aeruginosa, S. epidermis and S. aureus results 
showed the fibers released sufficient ofloxacin to successfully inhibit the growth of the tested 
bacteria.  
The potential of using ES for ocular inserts has been scrutinised and compared to the technique 
of solvent casting (Bhattarai et al., 2017). The electrospun PLA/PVA fibers were found to be 
much thinner (1% PVA = 50 µm, 5% PVA = 62.5 µm) than brittle solvent cast polymer inserts 
(>200 µm) and were capable of releasing drug in a sustained manner.  
With biocompatibility being a crucial prerequisite when developing novel ocular delivery 
systems, full in vitro and in vivo testing is essential. Da Silva et al demonstrated the 
biocompatibility of PCL NFs using M10-M1 and ARPE-19 cell cultures (in vitro) and rats (in vivo) 
using Optical Coherence Topography and Histology (Da Silva et al., 2015). They found the fibers 
proliferated in the in vitro cells and formed organised monolayers. The NFs also displayed great 
potential in the in vivo characterisation test by not producing an inflammatory reaction and the 
retinal cells did not express pro-inflammatory cytokines. This display of cellular biocompatibility 
highlights the potential of PCL as a carrier or matrix in ocular drug delivery.  
In addition, PLGA has been electrospun to produce rapidly biodegrading membranes for 
cultural limbal stem cell transplantation (Sefat et al., 2013). These fibrous membranes were 
capable of supporting rLEC for at least 2-3 weeks, with subsequent breakdown due to uptake of 
water. What is noteworthy here is following 12 months of storage, the polymeric membrane 
was still able to support growth of limbal epithelial cells, highlighting the use of electrospun 
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2.5 Conclusion 
In this chapter I have reviewed the use of contact lenses as drug delivery devices and a number 
of methods of drug loading for said devices. A thorough review into EHDA and its current uses 
has allowed me to decipher the fundamental principles of the process and summarise the 
successful applications of this engineering process. By researching glaucoma and criticising 
methods currently used to treat and manage ocular conditions, I have chosen to select and take 
forward EHDA and contacts lenses with the aim to combine two well-known avenues to develop 
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Chapter 3 Materials and Methods 
This chapter will outline all the materials used in this research project alongside detailed 
descriptions of the methods and characterisation techniques utilised throughout the project.  
3.1 Materials 
3.1.1 Polyvinylpyrrolidone  
Polyvinylpyrrolidone (PVP) (Figure 3.1) is a versatile, biocompatible, non-ionic polymer 
commonly used in the pharmaceutical industry often as a tablet binder or filler. Its hydrophilic 
nature enables PVP to form complexes with proton donors resulting in rapid dissolution as well 
as enhanced drug/API solubility in aqueous environments.  Formation of complexes with proton 
donors can also contribute to uniform distribution of other excipients (e.g. APIs) enabling 
controlled release of APIs. PVP was sourced from Ashland (Worcestershire, UK) and was used at 
a molecular weight of 4.4x104 g/mol.   
 
3.1.2 Poly (N-isopropylacrylamide)  
Poly (N-isopropylacrylamide) (PNIPAM) (Figure 3.2) is a biocompatible, thermo-responsive 
polymer synthesised from N-isopropylacrylamide (Lima, Morales and Cabral, 2016). This 
polymer undergoes a reversible Lower Critical Solution Temperature (LCST) transition above 
32°C in water. At this critical temperature, the 3D hydrogel expels at least 90% of its volume 
transitioning into a dehydrated state from a solute state. Due to this transition occurring at a 
Figure 3.1 Structure of PVP 
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temperature close to physiological conditions, there are many advantages in using PNIPAM in 
the healthcare remit; especially as a drug carrier matrix and in bioengineering.  PNIPAM was 
sourced from Sigma Aldrich (Dorset, UK) and 2-4x104 g/mol molecular weight was used.  
 
3.1.3 Chitosan 
Chitosan is a bioadhesive cationic polysaccharide (Figure 3.3) derived from the alkaline 
deacetylation of chitin, a naturally occurring polysaccharide. It is a widely used polymer due to 
its biocompatibility, biodegradability and non-toxicity (Muxika et al., 2017). Chitosan has been 
found to have multiple uses including as a haemostatic agent, a mucoadhesive agent and a 
permeation enhancer. The cationic nature of chitosan promotes molecular pull towards 
negatively charged mucosal membranes (e.g. corneal surfaces) due to electrostatic attraction. 
The amino groups can also protonate easily at low pH, a characteristic that can be exploited in 
targeted drug delivery (Shastri, 2017). Chitosan was sourced from Sigma Aldrich (Dorset, UK) 
and used at a concentration 5 x104 g/mol – 1.0x 105 g/mol.  
Figure 3.2 Structure of PNIPAM 
Figure 3.3 Structure of Chitosan 
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3.1.4 Surfactants 
Surfactants are compounds that are able to lower the surface tension between solid-liquid 
interfaces or liquid-liquid interfaces. They are naturally present in low concentrations in the lipid 
bilayer in epithelial cells. At these low concentrations, the surfactants can modify the physical 
properties of the cell membrane. However, upon saturation, membrane solubilisation occurs 
because of micelle formation, removing phospholipids from the cell membrane. All surfactants 
used in this research were sourced from Sigma Aldrich (Dorset, UK) 
Brij® 78 is a biodegradable, non-ionic surfactant (Figure 3.4) used as an absorption promoter in 
ocular DD (Kapoor et al., 2009). It possesses good thermal and chemical stability and supposedly 
enhances drug permeation transcellularly as opposed to via the paracellular pathway like 
calcium chelators.   
 
BAC is a quaternary ammonium compound (Figure 3.5) typically used as an antimicrobial agent 
and preservative in many pharmaceutical and personal care products. BAC is a cationic 
surfactant that acts as a permeation enhancer by breaking down anatomical and physiological 
barriers of the corneal epithelial layer, creating an increase in intercellular space by opening 
tight junctions between cells (Saettone et al., 1996).   
Figure 3.5 Structure of BAC 
Figure 3.4 Structure of Brij® 78 
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3.1.5 Ethylenediaminetetraacetic acid 
Ethylenediaminetetraacetic acid (EDTA) (Figure 3.6) is a calcium chelating agent which is used 
to loosen tight junctions between corneal epithelial cells. Chelating agents are typically used to 
inhibit unwanted side effects of specific heavy metals or drugs. Chelating agents work by binding 
to metal ions or minerals such as calcium (Ca2+) and remove them from the bloodstream for 
excretion via kidneys (Kaur and Smitha, 2002). A reduction in Ca2+ in the corneal epithelium 
causes not only disturbance of adherent junctions but also actin filaments. Depletion of Ca2+ also 
activates protein kinases; integral in the formation and barrier properties of tight junctions. 
3.1.6 Borneol 
Borneol (Figure 3.7) is a naturally occurring compound derived from the resin of the 
Dryobalanops aromatica, also known as Borneo Camphor (Yi et al., 2016). It is commonly used 
in Chinese herbal formulations but has also been found to have potential in the pharmaceutical 
industry in ocular formulations such as topical eye drops (Huang et al., 2015; Yang et al., 2009; 
Wu Chun-Jie et al., 2006). Although poorly water soluble, the long term clinical safety of the 




Figure 3.6 Structure of EDTA 
Figure 3.7 Structure of 
Borneol 
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3.1.7 Timolol Maleate 
Timolol Maleate (TM) (tert-butyl (2-hydroxy-3-{[4-(morpholin-4-yl-)-1, 2, 4-thiadiazole-3-
yl)oxy}propan-2-ol) (Figure 3.8) is a non-selective beta-adrenergic blocking agent which 
competes with adrenergic neurotransmitters to block the action of the sympathetic nervous 






In a clinical setting, TM is used to treat hypertension, angina pectoris (Vedoya and Schena, 1974), 
myocardial infarction (Anderson, Jones and Evanko, 2003) and most commonly glaucoma. 
Although the mechanism of action for the treatment of glaucoma is not yet established, the 
leading theory is associated with the production of AH.  TM is thought to block beta- receptors 
found on the ciliary body, reducing the amount of AH produced and secreted. There is also 
research that suggests timolol binds to receptors on the blood vessels that nourish the ciliary 
body, resulting in vasoconstriction, hence reducing the volume of fluid and its flow out of the 
vessels that later produces AH (Stamper, Lieberman and Drake, 2009). The blockage of beta-
adrenergic receptors decreases cardiac activity (slows heart rate, in both healthy and heart-
disease patients) and can also increase airway resistance from the parasympathetic system. TM 
was approved by the FDA for ocular use in 1978 and has since been used widely for the 
treatment of glaucoma (Jung and Chauhan, 2013). It is typically administered topically as eye 
drops, although commercial in situ gels have also been approved. Timolol maleate eye drops 
usually contain 0.25%w/v timolol and are administered twice daily, approximately 12 hours 
apart with one drop in each affected eye.  TM is a hydrophilic drug and the products and 
formulations it is incorporated into are hydrophilic to aid penetration through the cornea once 
topically applied.  
Figure 3.8 Structure of Timolol Maleate 
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3.2 Methods 
3.2.1 Solution Characterisation 
3.2.1.1 Viscosity  
Viscosity is defined as a fluid’s thickness or a fluid’s resistance to flow. This liquid property is 
primarily quantified using a viscometer. A sine-wave vibra viscometer (A&D SC-10) was used to 
determine the viscosity (mPa.s) of the polymeric solutions used during all studies, as seen in 
Figure 3.9. The mechanism for measuring viscosity here involves identifying the driving electric 
current required to resonate two gold-plated sensors maintained at a constant frequency of 30 
Hz.  The difference in the viscous drag between the pair of plates and the sample is detected as 
the driving current, with the viscosity being measured by exploiting the proportional relationship 
between the driving current and viscous resistance.  The sample container was filled with 10 ml 
of the formulation and the gold-plated sensor plates were submerged into the container. The 
experiments were carried out in triplicate at room temperature (23°C±0.5°C) 
 
Figure 3.9 Digital Image of an A&D SV-10 sine-wave vibra viscometer 
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3.2.1.2 Surface Tension 
The ST of formulations were measured using the du Noüy ring method (du Noüy, 1925), (Figure 
3.10). The force required to remove or withdraw a platinum ring from one phase (often the 
surface of a liquid) into another phase (air/gas) is measured. The ring is lowered onto the surface 
of the liquid and upon external forces, the ring is lifted away from the liquid surface. This force 
required is what is ultimately used to calculate the liquids’ surface tension based on the 
following equation:   
𝜎 =  
𝐹
𝐿.cos 𝜃
                                      (3.1) 
Where σ is surface tension (N/m), F is the force (Newtons) and L is the wetting length of the ring 
(sum of the inner and outer circumference) (meters), θ is the contact angle between the liquid 
and the ring. ST experiments were conducted using a torsion balance by White Elec Inst Co Ltd. 
Experiments were carried out in triplicate at ambient temperatures (23°C±0.5°C).  
Figure 3.10 Digital Image of a While Elec Ltd Torsion balance 
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3.2.1.3 Electro-conductivity  
The ability of a solution to transmit an electrical current is analysed using a conductive meter. 
The conductive meter consists of a probe that holds 4 electrodes (the probe is as seen in Figure 
3.11). An alternating current is initiated by the probe once inserted into the liquid sample and 
its current is passed between the four electrodes. The distance between the probes’ electrodes 
alongside the potential between the electrodes is used to calculate the conductivity of the liquid 
using Ohm’s Law:  
𝐼 =  
𝑉
𝑅
      (3.2) 
Where 𝐼 is the current (in Amperes), V is the voltage (in volts) and R is the resistance (in Ohms).  
The electro-conductivity of formulations were quantified using a Mettler Toledo LE73 
Conductivity Meter. The probe was submersed in 20 ml of formulation at room temperature. 
The experiments were carried out in triplicate and an average was taken.   
 
Figure 3.11 Digital Image of a Mettler Toledo Electrical 
Conductivity Meter 
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3.2.2 Electrohydrodynamic atomization  
The basic EHDA set-up consists of 5 key components: a syringe holding the formulation, a syringe 
infusion pump, a conductive stainless steel needle, a voltage supply and a collection plate 
(Figure 3.12).  
The infusion pump allows the flow rate of the formulation to be regulated through the system 
whilst the voltage supply can control the applied voltage to the system. The formulation is 
infused through silicone tubing to the needle. Introduction of the voltage to the system 
overcomes the surface tension of the liquid at needle exit, resulting in solvent evaporation and 
ultimately the production of particles or fibers.  Section 2.4.2 outlines the EHDA process in more 











Figure 3.12 Digital Image of the EHDA system 
Chapter 3 Materials and Methods 
101 | P a g e  
 
3.2.3 Scanning Electron Microscopy  
Scanning Electron Microscopy (SEM) (Figure 3.13) is a microscopic technique that utilises an 
electron beam rather than the conventional light beam to create an image of a samples surface.  
The electron beam scans the sample surface in a raster pattern, producing signals displayed as 
3D images. The electrons are produced at the top of the SEM column and the electron gun emits 
the electrons, accelerating them in a powerful electromagnetic field. The electrons pass through 
a series of condenser lenses and apertures, focusing the electron beam onto the samples’ 
surface. Upon interaction with the surface, the electrons either reflect back off the sample 
(backscatter detection) or they transfer some of their energy to atoms in the sample. The latter 
is known as secondary electron detection. In practise, the sample may have to be gold or carbon 
coated to make the sample conductive. The sample is then loaded onto aluminium stubs with 
copper tape which are mounted on to a stage in the main chamber. SEM is a popular microscopic 
technique due to the ability to achieve high resolution (1 nm) 3D images and highly detailed 










Figure 3.13 Digital Image of a Zeiss Evo HD-15 Scanning 
Electron Microscope 
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3.2.4 Differential Scanning Calorimetry 
DSC is a thermal analytical method used to measure the energy changes within a sample as it is 
heated. The study of thermal transitions of materials can establish the thermal stability of the 
sample in question. In practise, DSC measures the heat flow to the sample and an inert reference 
as they are both subjected to the same temperature and heated at the same rate, ensuring there 
is no temperature difference between the sample and reference. During application of heat the 
sample can undergo changes, for example, chemical reactions such as hydrolysis or physical 
changes like melting. These changes either emit heat (exothermic) or require heat to occur 
(endothermic). In order to maintain the equal temperatures between the sample and the 
reference, the heat flow is adjusted; it is this difference in heat flow which is analysed in DSC. 
Any adjustments in heat flow are established and observed as peaks and troughs in a 




Figure 3.14 Digital Image of a Perkin Elmer Jade differential scanning calorimeter 
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3.2.5 Thermogravimetric Analysis 
Thermogravimetric Analysis (TGA) is a thermal analytical technique which observes the physical 
changes in mass of a sample as the sample is subjected to a controlled heating programme. TGA 
can be used to analyse the thermal stability and oxidative stability of materials along with 
analysing the decomposition kinetics of samples. In practise, the sample is heated in a controlled 
manner in an inert atmosphere (commonly nitrogen) and the changes in mass are measured as 
a function of temperature. During heating, the changes in mass can result due to a number of 
reasons. Weight loss can be a result of decomposition (chemical bonds breaking), evaporation 
of volatile solvents or desorption. Weight gain can be an outcome of oxidation or absorption.  
These mass changes are represented by peaks and troughs in TGA thermograms as a function of 











 Figure 3.15 Digital Image of a Perkin Elmer Pyris 1 
thermogravimetric analyser 
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3.2.6 Goniometry 
Goniometry is the observation of liquid droplet morphology when in contact with a solid surface. 
The quantitative analysis of this wetting of a solid is known as the contact angle (CA), θ.  A 
droplet of liquid is introduced to a sample on a microscope slide via a precision syringe (Figure 
3.16a). A camera is used to continually monitor the liquid drop and sample over time. Computer 
software is used to help analyse drop morphology and is used for quantitative analysis. The CA 
is defined as the angle produced by the liquid drop at the intersection of the 3 phases; liquid 
(drop), solid (sample) and gas (atmosphere). The contact between these three phases can be 
defined by the Young equation: 
𝛾𝑆𝐺 =  𝛾𝑆𝐿 +  𝛾𝐿𝐺 cos 𝜃      (3.3) 
    Where:   γSG is the solid-gas interfacial energy 
     γSL is the solid-liquid intefacial energy 
     γLG is the liquid-gas interfacial energy  
     θ is the equilibrium contact angle 
 
Based on the contact angle, there are 3 degrees of wetting ability. If θ < 90°, the liquid “wets” 
the sample. If θ = 0° indicates complete spreading of the liquid droplet whilst θ>90°, the surface 






Figure 3.16 a) Annotated Digital Image of a Thetalite TL100 goniometer, b) a schematic diagram of the three degrees 
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3.2.7 Fourier Transform Infrared Spectroscopy 
FTIR spectroscopy is most commonly used to identify unknown samples or confirm structures of 
molecules or compounds based on the samples’ characteristic absorption of infrared (IR) 
radiation.  When an IR beam passes through a sample, some energy is absorbed and some is 
transmitted. The absorbed radiation by selective molecules causes changes in dipole moment 
of the sample molecules. Due to this, the vibrational energy level of the sample transitions to an 
excited state. This transfer from ground state is depicted as an absorption peak on a 
“fingerprint” of the sample and the intensity of these peaks correlates with the change of dipole 
moment (Gaffney and Marley, 2012). The wavelength region of 4000-400 cm-1 is used for FTIR 
as most organics absorb within this range. Attenuated Total Reflection (ATR) is a side branch of 
FTIR which utilises an optically dense crystal and internal IR beam which reflects upon contact 
with the sample (Figure 3.17). The IR beam is concentrated onto the highly refractive crystal and 
the internal reflectance causes an evanescent wave. This wave passes not only through the 
crystal but through the sample too. If the energy is absorbed within the range (4000-400cm-1), 
the wave attenuates and this altered energy is transferred to the IR beam. It continues to pass 
through the optical dense crystal and to a detector, creating a fingerprint spectrum unique to 
that sample (Minnes et al., 2017). It is useful with samples that produce strong and intense 
transmission peaks. ATR is advantageous over FTIR due to its ease of operation and ability to 
analyse samples in their natural state (liquid, solid). High resolution fingerprints are also yielded. 
Appendix A shows characteristic infrared absorption wavenumbers for common functional 
groups (Berthomieu and Hienerwadel, 2009).  
Sample Slot 
Compression Tip/Diamond 
Figure 3.17 Digital Image of a ATR-FTIR spectrophotometer 
fitted with Bruker Alpha Opus 27 FT-IR 
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3.2.8 Drug Release and Drug Permeability  
To overcome the challenges met with using animal models to assess drug release and drug 
permeability in the ocular pharmaceutical remit, in vitro release testing (using cellulose acetate 
as a dialysis membrane) and ex vivo permeability testing (using freshly excised ocular tissue) is 
vital and extremely useful in drug delivery device development as they are able to 
predict/forecast in vivo behaviour.  
3.2.8.1 In Vitro Testing 
3.2.8.1.1 In Vitro Drug Release 
In vitro testing refers to experiments carried out in a controlled environment or atmosphere 
mimicking physiological conditions. In vitro drug release testing involves quantifying or 
measuring the release of drug from a matrix or carrier in an environment simulating 
physiological conditions. Whilst these studies are typically carried out at physiological conditions 
(temperature: 37°C, pH: 7.1-7.4), customised or personalised dosage forms may require 
elevated or dropped temperatures and/or pH.  
In vitro Elution Testing is used to assess the release of drug from an eluting device that is subject 
to a continuously stirred medium. The sample is introduced to system in the donor compartment 
which is separated from the receptor compartment by a dialysis membrane (e.g. cellulose 
acetate). At pre-determined time points, the medium in the receptor compartment is sampled 
and quantified to produce a release profile as a function of time. The conditions at which this 
type of testing is carried out is solely dependent on the application of the device/product being 
tested.  The cumulative drug release data obtained from such studies can be scrutinized to 
produce release profiles as a function of time which can then be used to determine release 
kinetics and the mechanism of drug release (e.g. Fickian Diffusion).   
3.2.8.1.2 Release Kinetic Modelling 
Drug release following zero-order kinetics demonstrates a release independent to the drug 
concentration (Equation 3.4) whilst first-order kinetics indicate the release of drug is 
concentration dependent (Equation 3.5).  
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                                                              𝐶𝑡 = 𝐶0 +  𝑘0𝑡                                  (3.4) 
Where Ct is the amount of drug released at time t, C0 is the initial amount of drug in solution and 
k0 is the zero-order rate constant. In order to determine if the release of TM was zero order, the 
cumulative percentage release of TM was plotted against time.  
      log 𝐶 = log 𝐶0 −  𝐾𝑡 2.303⁄                                                (3.5) 
Where C0 is the initial concentration of drug and K is the first order release constant and 2.303 
is a constant.  Here, log percentage drug remaining was plotted as a function of time.  
Hixson-Cromwell cube root law describes the release of drug due to change in particle surface 
area and diameter (Hixson and Cromwell, 1931), where the cube root of the percentage of drug 
remaining in the matrix is plotted versus time, according to Equation 3.6: 




3 = 𝑘𝑡     (3.6) 
The Higuchi model describes drug dissolution from various types of modified release from 
polymeric matrices. The model was originally intended for planar systems but evolved to extend 
to different geometries and porous matrices. The Higuchi model has been generalised to yield 
the simplified Higuchi Model (Siepmann and Peppas, 2011) and was used here. (Equation 3.7): 
                                                                     𝑀𝑡 = 𝑘𝐻√𝑡                                                                  (3.7) 
where Mt is the quantity of cumulative drug released (µg) at time t, and kH is the Higuchi 
constant. This model is based on several hypotheses: i) initial drug concentration in the matrix 
is much higher than drug solubility; ii) drug diffusion is only in one plane; iii) drug particles are 
much smaller than the system matrix; iv) the matrix swelling and dissolution is negligible; v) 
drug diffusivity is constant; vi) perfect sink conditions in release environment are reached. The 
cumulative drug release of TM from all 3 samples was plotted as function of square root of 
time. 
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The Korsmeyer-Peppas model was devised to explain the type of diffusive mechanism from 
polymeric matrix. The Korsmeyer-Peppas model is helpful when there are multiple possible 
release mechanisms. Equation 3.8 shows the Korsmeyer-Peppas model;  
            
𝑀𝑡
𝑀∞
=  𝑘 𝑡𝑛                  (3.8) 
Where Mt/M∞ is the proportion of drug released at time, t; k is the release rate constant and n 
is the release exponent, the factor that determines the mechanism of drug release.  Equation 
3.9 shows how to derive the release exponent.  
                    
                                                      log (
𝑀𝑡
𝑀∞
× 100) = 𝑛 log 𝑡 +  log 𝑘                                             (3.9) 
 
For spherical/cylindrical matrices, various n values depict specific release mechanisms; n≤0.45 
corresponds to quasi-Fickian drug transport: n=0.5 shows Fickian diffusion (molecular diffusion 
of drug due to a chemical potential gradient), while 0.45<n<0.89 relates a Non- Fickian 
diffusion mechanis; n=0.89 relates to the case II transport, with n>0.89 corresponds to the 
super case II transport (Riger and Peppas, 1987) (drug transport mechanism associated with 
stresses and state transition in hydrophilic glassy polymers which swell in water and other 
biological fluids) (Korsmeyer et al., 1983).  Log cumulative release (%) was plotted as a function 
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3.2.8.2 Ex Vivo Testing  
Quantifying the rate of drug permeation through a biological membrane is vital as its impact is 
key in the absorption and distribution of the released drug.  The most common model used for 
ex vivo permeation studies is Vertical Franz Diffusion Cells (Figure 3.18). The donor 
compartment and receptor compartment are separated by freshly excised animal tissue, as 
opposed to a synthetic membrane in in vitro studies. Samples are removed from the sampling 
port and the cumulative amount of API is measured over time. From these results, the apparent 
permeability coefficient (Papp) can be derived and compared to known established values in 
literature.  Papp (or flux) is the rate of drug permeated or accumulated in the receptor 



















Dialysis Membrane / 
Biological membrane  
Figure 3.18 A typical Franz Cell prepared for an ex vivo permeability study 
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3.2.9 Bovine Corneal Opacity and Permeability Testing 
The Bovine Corneal Opacity and Permeability (BCOP) test is an in vitro test utilised as an 
alternate ocular irritation assay (Gautheron et al. 1992). Damage to freshly excised bovine 
cornea due to exposure to test sample can be defined using the BCOP test. The corneal opacity 
aspect of the test can detect protein denaturation or stromal swelling; the cornea is a 
transparent structure hence any opacity is indicative of damage. An increase in corneal 
permeability shows the cellular structure of the cornea has been compromised; losing the 
protective barrier function.  The bovine cornea is freshly excised from the eye and is treated 
with phosphate buffer saline (PBS) before the sample is introduced (Figure 3.19a). Corneal 
Permeability is assessed by analysing the penetration/permeation of sodium fluorescein dye 
following introduction of sample (Figure 3.19c).  Visual observation was used to analyse the 
extent of damage for corneal opacity; a cloudy appearance reveals some damage has occurred 











Figure 3.19 Digital Image showing a) incubation of freshly excised bovine eyes, b) Digital image of 
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Chapter 4 Finding a suitable polymeric 
matrix for on-demand electrically atomised 
coatings 
4.1 Introduction 
This chapter scrutinises the properties of various atomised polymeric contact lens coatings with 
the aim of finding the most suitable matrix for TM encapsulation and release.  
4.2 Background 
With glaucoma being the 2nd leading cause of visual impairment globally (after cataracts) (World 
Health Organisation., 2015), it is vital to understand the aetiology and pathophysiology of the 
ocular condition for appropriate and successful treatment. Currently there is no ultimate cure 
for glaucoma due to the fact the definitive cause for the condition has not yet been identified. 
Hence, research in this field is still very much active and is thriving. Many of the approaches to 
treatment of glaucoma involve the use of eye drops, requiring multiple dosing throughout the 
day. For example Timoptol® (0.25 % or 0.5 %w/v TM) eye drops are to be administered twice a 
day; one drop in each affected eye (MHRA., 2015) whilst Trusopt® (20 mg/ml dorzolamide) eye 
drops are administered 3 times a day (morning, afternoon and night) (MHRA., 2017).  
Regardless of the ease of formulating and developing liquid formulations like eye drops, there 
are some limitations with such dosage forms. The short residence time in the eye due to 
drainage mechanisms such as nasolacrimal drainage and tear dilution leads to poor drug 
bioavailability; with only 5% of the active reaching the target site (Schopf et al., 2015).  
As a result of these confines, many researchers have explored the developments of new drug 
delivery devices. The most extensive device to emerge from this shift in research are CLs (ElShaer 
et al., 2014). While being typically used for vision correction, the uses of these lenses have now 
extended to cosmetics, pharmaceutics and theranostics (Peng, Kim and Chauhan, 2010; Thomas, 
Lähdesmäki and Parviz, 2012; Kaczmarek et al., 2014; Tashakori-Sabzevar and Mohajeri, 2015). 
Even though the first concept of using CLs as drug delivery devices was first proposed half a 
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century ago, it was only in the last two decades that the full potential of drug-eluting lenses was 
considered. Since the 1990s, the delivery of many classes of actives using CLs have been assessed 
including antibiotics (Hui, Sheardown and Jones, 2012), NSAIDs (Andrade-Vivero et al., 2007) 
and antiglaucoma drugs (Hollo and Katsanos, 2015; Bengani and Chauhan, 2013).   
To eradicate the need for frequent dosing and to improve drug bioavailability, EHDA was used 
here to produce drug-loaded coatings for commercial lenses which would provide controlled 
and sustained release of TM. Polymers PVP and PNIPAM were used as matrices with TM as the 
active to develop the novel coatings. Following thorough research in this field, to date, this 
application of EHDA has not yet been exploited thereby introducing a novel, on-demand 
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4.3 Materials and Methods 
4.3.1 Materials 
PVP (4.4x104 g/mol) was sourced from Ashland, UK. PNIPAM (2-4x104 g/mol), methanol, TM 
(>98%), acetone, sodium hydroxide, and rhodamine B dye were all obtained from Sigma Aldrich, 
Dorset, UK. PureVision® Balafilcon A silicone hydrogel contact lenses were supplied by Bausch 
and Lomb, New York, USA. All reagents used were of analytical grade.  
4.3.2 Methods 
4.3.2.1 Timolol Maleate Calibration Curve 
A stock solution (SS1) was prepared by weighing 10 mg of TM on an analytical balance and 
dissolving this in 100 ml of freshly prepared phosphate buffer saline (PBS) at pH 7.4. 10 ml was 
taken from SS1 and made up to 100 ml to make a second stock solution (SS2). 
Both stock solutions were used to achieve a range of TM concentrations from 0 µg/ml to 50 
µg/ml (Table 4.1). UV spectroscopy was used to firstly determine the wavelength of maximum 
absorbance (in scanning mode) and then consequently to read the absorbance of the range of 
TM solutions (in fixed mode). A calibration curve of TM was plotted using these absorbance 
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Table 4.1 The volumes required from stock solutions to make up a range of TM concentrations and the 
corresponding absorbance readings 






 50 5 0.94 
 45 4.5 0.857 
 40 4 0.766 
 35 3.5 0.678 
 30 3 0.583 
 25 2.5 0.491 
 20 2 0.396 
 15 1.5 0.295 
Using SS2    
 10 SS2 0.202 
 5 5 0.119 
 2 2 0.072 
 1 1 0.03 
 
4.3.2.2 Solution Preparation 
20 ml solutions containing 5 %w/v of each polymer and composite of both PVP and PNIPAM at 
a 1:1 ratio were prepared using methanol as the vehicle. Each solution also contained TM at a 
concentration of 5 %w/w of the polymer. All excipients were added to 20 ml of methanol and 
were prepared by magnetic stirring for 10 minutes at ambient temperatures. Table 4.2 shows 
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              Table 4.2 Formulation Composition 
 
4.3.2.3 Characterisation of Polymeric Solutions 
Each formulation was characterised based on three physical liquid properties; viscosity, surface 
tension and electro-conductivity. These experiments were carried out as specified in Section 
3.2.1. 
4.3.2.4 EHDA Set-Up 
Figure 3.12 shows the set-up of a single needle electrospraying system. A BD Plastipak™ Luer 
syringe containing 5 ml of solution was mounted on to a Pump11 Elite syringe infusion pump 
(Harvard Apparatus, USA) which was used to precisely control the flow of solution through the 
EHDA system. The syringe was connected to a BD Microlance™ 3 needle (21G, 1 ½ inch) which 
in turn was inserted into silicone tubing. The formulation was infused through the tube to a 
stainless steel conductive coaxial needle device, where only the outer needle was used.  The 
coaxial device was also coupled to a high power voltage supply from Glassman High Voltage 
Supply, UK.  A collector plate was placed 12 cm under the needle exit; this was the working 
distance (determined via exploratory experiments).  All atomization processes were carried out 
at ambient temperatures; 23 °C±0.5 °C.   
4.3.2.5 Optimisation of EHDA process 
Firstly, the EHDA process was optimised for each formulation as each possessed varying physical 
liquid properties. Each formulation was atomised at flow rates in increasing increments of 1 
µl/min from 0 µl/min up to 20 µl/min. At each flow rate, the voltage required to produce a stable 
jet, an unstable jet and to achieve dripping mode were recorded. These values were utilised to 




(%w/w of polymer ) 
F1 PVP 5 5 
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construct jetting mode maps enabling the optimum flow rate and voltage ranges to be identified 
for each formulation.  A flow rate of 15 µl/min was used for atomising F1, 10 µl/min for F2 and 
10 µl/min for F3. A voltage between 13 kV and 20 kV sufficed for establishing a stable jet.  
4.3.2.6 EHDA Coating Application 
The resulting atomised coatings were initially collected on glass microscope slides for 
preliminary analysis, with subsequent characterisation carried out on coated commercial 
contact lenses. PureVision® Balafilcon A lenses were dried in a desiccator on a novel lens holder 
(to maintain lens shape) for 30 minutes and were weighed before and following the coating 
process to determine the weight of the coating sample. Controlled deposition of coating was 
achieved by using a modified lens holder (which held 4 lenses) with an additional mask arm 
which enabled deposition onto peripheral regions keeping central regions clear for vision.   
4.3.2.7 Coating Characterisation 
4.3.2.7.1 Imaging and Size Distribution 
Exploratory analysis of morphology and size of the nanostructures that made up the atomised 
coatings were conducted using SEM. Coated microscope slides were gold coated (S150B, 
Edwards, Crawley, UK) and mounted onto aluminium stubs before being analysed using a Zeiss 
Evo HD-15 microscope. High resolution images at both x5k and x50k magnification were 
obtained using a working distance between 9.5 mm and 10.5 mm, respectively, with a voltage 
between 10kV and 18kV.  
Smart Tiff software was used in conjunction with SEM to gather data on average diameter size 
and size distribution information of the atomised structures. These samples were further 
analysed on CLs to ensure the lenses (i.e. the surface the coatings were collected on) did not 
affect the resulting atomised structures. Digital images were also taken of an uncoated lens and 
a coated lenses using a Samsung NX200 mirrorless digital camera. An Evos Fluorescence 
microscope was utilised to exhibit probe encapsulation within the atomised polymer 
nanostructures at x40 magnification.  
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4.3.2.7.2 Drug Encapsulation 
Atomised coatings were collected, weighed and dissolved in methanol and left for 1 week.   
Equation 4.1 was used to calculate encapsulation efficiency (EE):  
𝐸𝐸 =  
𝐷𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 − 𝑓𝑟𝑒𝑒 𝑑𝑟𝑢𝑔
𝐷𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
  
Calculating the amount of drug that is present within the atomised coatings aids the analysis of 
subsequent in vitro and ex vivo testing.  
4.3.2.7.3 DSC 
DSC studies were carried out using a Jade Differential Scanning Calorimeter, (PerkinElmer, US) 
(Figure 3.14). Indium, with a known melting point, Tm, of 156.6 °C was used as a standard to 
calibrate the temperature scale of the calorimeter. 2-4 mg of coating samples were sealed in 
aluminium pans and heated at a rate of 20 °C/min under a flow of nitrogen gas.  
4.3.2.7.4 TGA 
Pyris 1 TGA Thermogravimetric analyser (PerkinElmer, USA) was used to carry out TGA analysis 
(Figure 3.15). Similar to DSC, this thermoanalytical technique was carried out under a flow of 
nitrogen gas along with air. Sealed pans containing 8-10 mg of sample were heated from 20 °C 
to 700 °C in increasing increments of 20 °C/min.  
4.3.2.7.5 Goniometry 
The wetting ability of the coatings was quantitatively analysed using Thetalite TL100 goniometer 
and OneAttention software (Biolin Scientific, Sweden) (Figure 3.16). Distilled water droplets (10 
µl) were used and each sample was ran 5 times in Sessile Drop Mode and an average was taken.  
4.3.2.7.6 Spectroscopy 
Any interactions between the polymers and TM was studied using ATR-FTIR. Spectras were 
obtained using FTIR Platinum-ATR spectrophotometer fitted with Bruker Alpha Opus 27 FT-IR 
(Figure 3.17). Raw materials and atomised coatings were scanned over the range of 400-4000 
cm-1 at an average of 10 scans with 4 cm-1 resolution.  
(4.1) 
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4.3.2.7.7 In vitro Release and Kinetics 
4.3.2.7.7.1 In Vitro Drug Release 
A lens holder was designed and developed to carry the coated lenses and to maximise surface 
contact between the lens and the synthetic dialysis membrane. The cellophane membrane 
separated the donor compartment from the receptor compartment, which contained PBS at pH 
7.4 (which acted as the release medium). The coated lens were fixed into the holder and exposed 
to vials filled with 10 ml PBS at 37 °C. At fixed time intervals, the holder was removed and placed 
into fresh vials of PBS. This in vitro drug release method was adapted from Mehta et al (Mehta 
et al., 2015). Drug release into the medium was quantified using UV spectroscopy (λ=295nm).  
4.3.2.7.7.2 In Vitro Probe Release 
Probe release was demonstrated using a similar set-up to the process described above. Contact 
lenses were coated with polymeric nanostructures containing rhodamine B, 5 %w/w of the 
polymer as opposed to TM. Five lenses were coated and exposed to PBS at 37 °C. Each lens was 
removed at specific predetermined time points: 0 minutes, 10 minutes, 1 hour, 6 hours and 24 
hours. Fluorescence microscopy was used to determined dye intensity (DI) on the lens and UV 
spectroscopy to determine DI in the receptor medium (PBS) at λ=560 nm.  Experiments were 
carried out in triplicate for all 3 formulations.  
4.3.2.7.7.3 Release Kinetic Modelling 
The mechanism of TM release from the polymeric coatings was determined by utilising in vitro 
data and applying it to various kinetic models; as outlined in Section 3.2.8.1.2.  
4.3.2.7.8 Ocular Irritancy Testing 
Any damage the atomised coating could cause to the eye was evaluated using BCOP assay. This 
test can assess ocular tolerability by investigating corneal integrity. Six samples were tested; 
normal saline (as a negative control), acetone (mild positive control), sodium hydroxide (positive 
control), F1, F2 and F3. Freshly excised bovine eyes (source from ABP Food Groups Abattoir) 
were primarily checked for epithelial detachment and/or corneal damage and were then 
incubated at 37 °C in a water bath for 10 minutes.  A drop of saline was applied to the corneal 
surface before incubating for a further 5 minutes. 100 µl of sample (control or coating dissolved 
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in PBS) was introduced to the corneal surface and left for 30 seconds before the bovine eyes 
were washed with normal saline (10 ml) and left to incubate for a further 10 minutes. The degree 
of corneal damage was visually gauged by extent of opacification and was further assessed using 
a staining method; using sodium fluorescein dye (2% w/v) under a cobalt blue light (465-490 
nm). 
4.3.2.7.9 Ex Vivo Testing 
TM release from the atomised coatings and permeation through freshly excised bovine cornea 
was studied using vertical diffusion cells. Figure 4.1 shows the process of ex vivo analysis; from 
excising the cornea to fixing it between the donor and receptor compartment. Freshly excised 
bovine eyes were checked for any corneal damage before dissection to obtain the cornea with 
a 2 mm sclera border to preserve corneal structure. The cornea-sclera tissue was washed with 
PBS and mounted in between glass donor compartment (surface area =1.77 cm2) and receptor 
compartment; corneal endothelium facing the latter. The receptor was filled with 12 ml PBS and 
contained a mini magnetic stirrer to ensure constant stirring. The temperature of the cells was 
maintained at 37 °C via a heating block. At pre-determined times, 400 µl of receptor medium 
was removed from the receptor compartment and replaced with fresh PBS. Cumulative drug 
permeation was analysed using UV spectroscopy (λ=295 nm). The cumulative amount of TM 
permeating through the cornea was plotted as function of time and the linear slope of the 
resulting plot was used to calculate the steady state flux.  
 
Figure 4.1 Preparation of bovine cornea for ex vivo drug permeation study 
using vertical Franz Cells 
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4.3.2.7.10 Statistical Analysis 
All experiments (unless stated otherwise) were carried out in triplicate. Statistical analysis (one 
–way analysis of variance, ANOVA) was performed. Differences in results between formulations 
were considered significant at a level of p<0.05. 
4.4 Results and Discussion  
The two polymers investigated in this study were PVP and PNIPAM. PVP was selected for its 
biocompatibility and hydrophilic nature, allowing for rapid dissolution in an aqueous 
environment.  The hydroxyl groups on the polymer backbone enables the PVP to form 
complexes with materials capable of donating protons. The hydrogen bonds result in not only 
rapid dissolution of the polymeric matrix but also increased API solubility in an aqueous 
environment. Mehta et al 2015 used PVP to demonstrate the rapid dissolution of electrically 
atomised multifunctional particles and fibers loaded with probe and antibacterial API (Mehta et 
al., 2015). The polymeric matrix dissolved within two minutes when exposed to PBS, pH 7.4; 
releasing 100% of the active and probe. Wang et al found as a result of the incorporation of PVP 
in 3D film patches produced using EHDA printing, the release of antibacterial tetracycline 
hydrochloride was expedited (Wang et al., 2017). Based on these observations, PVP was chosen 
to achieve rapid drug release.  
PNIPAM is a polymer which has exceptional potential in the pharmaceutical industry with 
respect to controlled and self-regulating drug delivery. It is one of the most extensively 
researched stimuli-responsive polymers. Above 32°C, PNIPAM undergoes a reversible phase 
transition, transforming from a swollen state to a dehydrated state. At physiological 
temperatures (37°C) PNIPAM loses up to 90% of its original weight due to expelling of its 
contents i.e. any material the polymeric matrix is holding. This property can and has been 
exploited in temperature-modulated drug release in the human body. PNIPAM has been used 
as a microgel in the form of microbeads (Chen et al., 2013; Jia et al., 2014), particles (Hanga and 
Holdich, 2014; Inoue et al., 2018; Tempesti et al., 2018; Chen et al., 2018; Luckanagul et al., 
2018), 2D films (Weng et al., 2017; Weng et al., 2016) and 3D structures (Iwata, Miyashita and 
Iwase, 2017; Lee et al., 2017; Dosh et al., 2017; Ma et al., 2016).  
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Using PNIPAM for temperature controlled drug delivery using EHDA was first proposed by a 
research group from Newarke, USA. Rockwood et al developed fibrous PNIPAM mats which 
were stable with no compromise of PNIPAM structure during the engineering process 
(Rockwood et al., 2008). The LCST of PNIPAM was exploited by Schoolaert et al who produced 
continuous, bead-free PNIPAM NFs from water (Schoolaert et al., 2017). Waterborne ES of 
PNIPAM yielded structurally strong fibers which were stable in water at temperatures above 
32°C in an ecological manner. These research groups yielded positive findings using EHDA 
however, to date there is no research published using PNIPAM alongside PVP in ocular drug 
delivery as electrospun dual-polymer matrices for contact lenses.  
4.4.1 Timolol Maleate Calibration Curve  
To obtain a calibration curve for TM, various concentrations of TM solutions with PBS were 
made. The most concentrated solution (50 µg/ml) was first analysed by the spectrophotometer 
in scanning mode, giving a wavelength of maximum absorbance (λmax) of 295 nm, as found in 
literature (Mohammedi, Shyale and Shanta Kumar, 2011). All following solutions were measured 
in fixed UV mode, at a wavelength 295nm. The absorbance values were plotted against 
concentration resulting in the calibration curve shown in Figure 4.2. A coefficient (R2) of 0.9975 
was determined indicating strong linearity.  
Figure 4.2 Calibration Curve of Timolol Maleate 
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4.4.2 Solution Characterisation 
4.4.2.1 Viscosity 
It is imperative to determine the viscosity of the formulations being atomised as it allows the 
prediction or differentiation between electrospraying and electrospinning (Bock, Dargaville and 
Woodruff, 2012).  Figure 4.3 shows the average readings for all 3 formulations as well as the 
solvent, methanol. It is clear to see the addition of polymer to the solvent increases the viscosity 
of the resulting solution. The addition of PVP to methanol increased the viscosity from 0.6 mPa.s 
to 1.4 mPa.s; a 2.33 fold increase. The incorporation of PNIPAM to methanol saw an increase to 
3.09 mPa.s; over 5 times as viscous as that of methanol alone. Dissolving both PVP and PNIPAM 








A hypothesis can be made on this observation of increased viscosity with formulations that 
contain PNIPAM: upon EHD processing, these formulations will produce fibers. Utilising a high 
molecular weight of PNIPAM means there is the presence of more polymeric chains, causing 
them to entangle and become more disordered in solution. Consequently, the mobility of the 
polymeric chains is reduced/limited, increasing the viscosity (Ganan-Calvo, Davila and Barrero, 
1997; Jayasinghe and Edirisinghe, 2002). Due to the increased viscosity, the liquid at the exit of 
the stainless steel needle will not break up into droplets, but instead will stretch. This results in 
Figure 4.3 Average Viscosity of Pure Methanol, F1, F2 and F3 
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rapid whipping of the unstable elongated liquid stream in the synapse between the needle and 
the collection plate which in turn causes evaporation of the volatile solvent. The remaining 
excipients in the formulation form continuous fibrous structures. Lower solution viscosities are 
ideal for the formation of a stable Taylor cone jet, which will result in small, uniform particles 
(Jayasinghe and Edirisinghe, 2002).  
4.4.2.2 Surface Tension 
Atomization during EHD processing is principally due to the ST of the liquid being overcome by 
the applied electrical field. The ST essentially “competes” with the electrical forces in the 
atomising process. As a result, the electrical potential needs to overcome the ST in order for 
atomization to occur. The ST of all 3 formulations were very similar with an average reading of 
22.91, 23.53 and 20.88 mN/m for F1, F2 and F3, respectively (Figure 4.4). These values are close 
to that of pure methanol, showing the addition of a polymer (PVP, PNIPAM or Composite) did 
not appear to have an effect on ST.  
This is expected due to methanol making up a large majority of the formulations with the 
polymer not making a drastic difference. Tang and Gomez found a stable cone jet is most likely 
not going to take effect if the ST of the liquid is too high due to the fact that it would exceed the 
electrical field when the voltage is applied thus not allowing the liquid to atomise (Tang and 
Gomez, 1995). Solutions with ST higher than 50-2 N/m will not be able to be atomised, so to 
Figure 4.4 Average Surface Tension of Pure Methanol, F1, F2 and F3 
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overcome this, organic solvents with low ST such as methanol are often used in the EHDA 
process (Smith, 1986).  
4.4.2.3 Electro-conductivity 
The formulations subjected to EHD processing must be conductive due to the principle driving 
force for EHDA being the electrical field (Larriba-Andaluz and de la Mora, 2010). Previous 
research has found materials or solutions with an EC below 10-11 Sm-1 were unable to carry 
sufficient charge, leading to an unstable jet and therefore yielding poly-dispersed atomised 
nanostructures (Smith, 1986; Smeets, Clasen and Van der Mooter, 2017).  Figure 4.5 
demonstrates the differences in electrical conductivity between pure methanol and the three 
formulations.  Upon introduction of polymer to methanol, the EC of the resulting solution greatly 
increased; with F3 having the highest EC reading (199.20 µS/cm). This considerable increase in 
EC places all three formulations within the ideal range for EC: between 10 µSm-1 and 100,000 








4.4.3 Optimising the EHD Process 
The manner in which the liquid formulation exits the stainless steel needle and how the liquid 
breaks up will determine the EHD spraying mode. Every EHD system starts in “Dripping Mode.” 
Here, the liquid breaks up into fragments giving rise to poly-dispersed atomised structures. Upon 
Figure 4.5 Average electrical conductivity of Pure Methanol, F1, F2 and F3 
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application of electrostatic forces, the liquid will start to stabilise as it is infused through the 
needle. At the optimum voltage, a stable cone forms at the needle exit, known as the Taylor 
Cone. This EHD mode is known as “Jetting Mode”.  
The mono-dispersed atomised droplets undergo rapid drying to form nanostructures such as 
particles, fibers or beaded fibers. To obtain a Taylor Cone, it was vital to optimise the system. 
There are two main approaches to this; i) modify the liquid physical properties or ii) alter the 
process parameters. In this research, a simplistic polymeric matrix was imperative to establish a 
suitable carrier hence the latter approach was taken. Due to the vast combinations of liquid 
physical properties the formulations in this study had (Figures 4.3 – 4.5), the optimised process 
parameters required to produce a stable jet must be identified in order to yield near uniform 
particle/fiber production.  
Generating jetting mode maps enables the EHDA process to be optimised for specific 
formulations. The resulting maps (achieved by looking at the relationship between flow rate and 
applied voltage) presents an operating window within which a stable Taylor Cone jet is 
produced. Figure 4.6 shows the maps produced for F1, F2, and F3. Each solution was subject to 
flow rates ranging from 0 to 20 µl/min (in 1 µl/min increments) to determine the optimum 
voltage for each flow rate. Voltages between 13 kV and 20 kV were found to produce a stable 
jet yielding atomised structures within the nanometre range in the form of particles and beaded 
structures. The working distance is also a critical process parameter to optimise; too short a 
distance between the needle exit and the collection plate and the solvent (methanol) does not 
have enough spatial span to evaporate before reaching the collection plate. Too long a distance 
can result in losing the atomised structures to the external surrounding environment. By 
performing exploratory experiments that involved altering the working distance alongside the 
jetting map studies, an ideal deposition distance for particle engineering was determined. This 
was found to be 12 cm.  Figure 4.7 illustrates the flow of liquid in various modes alongside the 
stable cone jet formed at the needle exit when atomising F1, F2 and F3 and the optimised 
process parameters deciphered using the jetting maps.  
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Figure 4.6 Jetting Maps to determine the relationship between flow rate and applied 
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4.4.4 Coating Characterisation 
4.4.4.1 Imaging 
Figure 4.8 presents digital images of dehydrated lenses: an uncoated lens (Figure 4.8a) and an 
example of a coated lens (Figure 4.8b). The atomised coatings can be identified by observing the 
fine white “mist” on the outer surface of the lens. A mask arm used in the atomization process 
successfully permitted the lenses to only be coated on the peripheral regions; allowing the 
central region to be vacant for vision.  
 
 
Figure 4.7 Flow of liquid under an electrical field using a single conductive needle under a) no flow, b) dripping 
mode. Stable cone jet formation when spraying c) F1, d) F2, e) F3. 
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4.4.4.1.1 Morphology 
Determining the morphology of nanostructures and, more significantly, controlling 
nanomaterial morphology is critical when exploiting the functional characteristics in emerging 
pharmaceutical technologies. EHDA has previously demonstrated its ability to produce atomised 
structures with an array of morphologies including (but not limited to) spherical structures 
(Huanbutta et al., 2016; Yuan et al., 2015), rods (Deotare and Kameoka, 2015), porous structures 
(Ekemen et al., 2013; Khajavi and Abbasipour, 2012; Kim and Lee, 2014), hollow structures 
(Chang, Stride and Edirisinghe, 2010; B. Wang et al., 2016; Rasekh et al., 2015), core-shell 
structures (Liao, Chew and Leong, 2006; Yan et al., 2014), triple-layered structures (Labbaf et al., 
2013; Kim and Kim, 2011), red-blood cell shaped (Doshi et al., 2009) and strawberry-like 
structures (Z. Ma et al., 2011). Table 4.3 shows the presence and morphology of the resulting 
particles after the EHD processing of all three formulations using SEM. Small (nanoscale), 
uniform structures (with respect to size and morphology) would be ideal here to ensure even 
distribution of drug and to aid reproducibility of the engineering process for this application.  
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Using the jetting maps, a flow rate from dripping mode, unstable mode and stable mode was 
used primarily to demonstrate the difference in morphology as a resulting of the EHDA mode. 
At low flow rate for all three formulations, dripping mode was established. This resulted in 
extreme differences in particle/fiber morphology (Table 4.3). Large globules varying in 
morphology and size can be observed at a flow rate of 5 µl/min, highlighting a stable cone jet 
was not formed at this flow rate; resulting in wet samples. Table 4.3 shows spherical, uniform 
(with respect to shape size) particles were produced using F1 at a flow rate of 15 µL/min. The 
particle coatings (F1) produced with lower flow rates (10 µl/min) more poly-dispersed; which 
could eventually lead to uneven drug distribution and ultimately uncontrollable drug release 
(Nguyen, Clasen and Van den Mooter, 2016).  Increasing the flow rate to a value within the stable 
zone of the jetting profiles saw a change in the morphology of the structures; coatings consisting 
of more uniform nanostructures were engineered. Another thing to note was the addition of 
fibrous structures when atomising F2 and F3; yielding beaded fibers. This was an early 
hypothesis proved correct due to the increased viscosity of the solutions containing PNIPAM. 
The increase in viscosity of the polymeric solutions upon incorporation of PNIPAM caused the 
stable cone jet to elongate rather than break-up into particles. The elongation of the viscoelastic 
solution at the nozzle tip results in fibrous structures being fabricated (Zhang, Jayasinghe and 
Edirisinghe, 2006).   
The appearance of the deposited particles and fibers show that the TM-loaded structures were 
essentially dry before hitting the collection plate; the methanol had successfully evaporated. 
Nevertheless, for the electrosprayed particles using F2 and F3 also showed collapsed/porous 
particles, indicating the evaporation rate of the solvent from the particles may have been too 
fast (Ahmad et al., 2008).   
4.4.4.1.2 Size and Size Distribution 
The need for particles and structures on a nano scale has grown significantly in pharmaceuticals.  
This evolution enables the generation of particles which can be utilised for various routes of 
administration. Due to their size, the carrying capacity of the particles increases when within the 
nanometre range due to increased surface area to volume ratio hence more drug can be 
delivered.  
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To obtain particle/fiber size distribution, SmartTiff software was used in conjunction with SEM. 
Figure 4.9 depicts the histograms following analysis of SEM images for all 3 formulations.  All 3 
formulations demonstrated positively skewed data, with more than 52% of the atomised 
structures having a diameter under 200 nm.  
 
The average diameter for each formulation was 183 nm, 262 nm and 458 nm for F1, F2 and F3, 
respectively.  70% of the sampled particles from F1 had diameters under 200 nm with 24% 
between 201 and 400 nm. 67% of F2 atomised nanostructures were below 200 nm in diameter 
with 25% of the beaded fibers having a diameter between 201 and 400 nm. Over 45% of the 
beaded fibers produced by electrically atomising F3 were thicker than 201 nm. The increase in 
diameter could be attributed to the use/incorporation of PNIPAM into the formulation. As seen 
in Table 4.3, formulations containing PNIPAM yielded fibers fused to particles. As mentioned 
earlier, fibrous and spherical structures were produced simultaneously, resulting in beaded 
fibers due to the transition between electrospraying and electrospinning, hence the diameters 
of the atomised structures seem larger. Regardless, less than 2% of the structures were larger 
than 1 µm.  
Figure 4.9 Size Distribution of Atomised Coatings 
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PVP has previously been electrospun to produce indomethacin-loaded fibers for wound 
dressings (Rasekh et al., 2014). Fibers with mean diameters of 2.58±0.3 µm were produced; 
much thicker than the beaded fibers produced with F3. As these structures are particles fused 
with fibers, the fibers are therefore much thinner. PVP has also been used to engineer coatings 
to develop smart microneedles (Khan et al., 2014). Particles (100 nm-3 µm) and fibers ranging 
between 400 nm and 1 µm were produced; a similar range to those yielded with F1, F2 and F3. 
Rockwood et al used a PNIPAM-acetone solution which led to the production of fibers (600 nm-
1.7 µm in diameter) with “intermittent beads” (Rockwood et al., 2008). Here, 6 %w/v polymer 
concentration was used, a concentration similar to the one used in this study (5 %w/v); however 
when F2 was electrospun, much thinner beaded fibers were produced. Rockwood et al also 
found similar morphologies when electrospinning PNIPAM-tetrahydrofuran solutions; however 
these fibers were much thicker (13.5 µm).   
By using low polymer concentrations in this study (5 %w/v), alongside a combination of 
polymers, much thinner fibers than previous studies have yielded have been produced (Garg 
and Bowlin, 2011); resulting in atomised coatings with larger surface area and therefore higher 
drug carrying capacity.  
The preliminary studies of jet mapping and morphological analysis allowed the selection of an 
appropriate flow rate and voltage, using a flow rate of 15 µl/min, 10 µl/min and 10 µl/min for 
F1, F2 and F3, respectively.  
4.4.4.1.3 Probe encapsulation 
The ability of these electrically atomised coatings to encapsulate actives was demonstrated by 
replacing TM with model dye rhodamine B in all the formulations at the same concentration (5 
%w/w of the polymer). The solutions were atomised, collected on microscope slides and were 
subjected to fluorescence microscopic analysis. Figure 4.10 shows the entrapment of the probe 
within the polymeric matrix.  
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Figure 4.10a shows the encapsulation of rhodamine B in a PVP matrix. The excitation of the C=O 
bond in the PVP structure (Figure 3.1) emitted a long wavelength (green) whereas the 
conjugated double bonds within the ring structure in rhodamine B induced red-shift in 
absorption when exposed to RFP. The fluorescent images show structures with yellow cores and 
slightly darker shell; demonstrating probe encapsulation within the PVP matrix. PNIPAM does 
not fluoresce so when overlaid with rhodamine B under RFP, a speckled effect can be observed 
(Figure 4.10b) showing the probe within the particles. Figure 4.10c shows images of composite 
particles. Yellow structures can be seen due to the presence of PVP in the formulation. These 
results coincide with Khan et al findings when using PVP as the polymer matrix for NP coatings 
of solid microneedles for insertion in the skin (Khan et al., 2014).  
 
4.4.4.2 Drug Encapsulation 
Table 4.4 displays information regarding the drug EE percentages of each formulation. F3 
showed the highest EE with almost all of the drug (99.7%) being loaded into the atomised 
coating. The least efficient EE was exhibited with F1 (64.63%).   




These values were used to calculate the total amount of drug present in the samples used in in 






Figure 4.10 Fluorescence Microscopic Images confirming probe encapsulation in a) PVP coatings, b) 
PNIPAM coatings and c) Composite coatings 
a) b) c) 
100 µm 100 µm 100 µm 
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4.4.4.3 Thermal Analysis  
4.4.4.3.1 Differential Scanning Calorimetry  
When using novel techniques within the pharmaceutical industry, it is imperative to ensure that 
the processing parameters do not affect the physical form of the active or materials used. DSC 
was utilised to analyse the thermal transitions of the raw materials within the electrically 
atomised particles to ensure the solvent (methanol) and the electrospraying process has not 
altered the crystallinity of the polymers and subsequently the properties of the resulting 
particles. Figure 4.11 presents the DSC thermograms for all 3 formulations, including raw 
materials and pure drug.  
 
Pure TM is a crystalline drug with a defined melting point (Tm) of 218 °C as seen in Figure 4.11. 
Figure 4.11 shows characteristic endothermic peaks at 131 °C and 138 °C for PVP and PNIPAM 
Figure 4.11 DSC thermograms of raw materials and atomised coatings 
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respectively, corresponding to their melting point. The 3 formulations (polymer + drug) had 
similar broad endothermic peaks (60 °C-165 °C) with peaks at 115 °C, 113 °C and 120 °C for PVP, 
PNIPAM and the composite formulation respectively.  
The thermograms comprise of one peak for each formulation, demonstrating that the original 
structures of the raw materials were not compromised, highlighting the materials formed 
polymer-drug complexes and are acting as one system rather than individual components.  The 
resulting DSC scan for F3 particles show a lack of phase characteristic peaks of both PVP and 
PNIPAM as well as TM, except a broad peak with a maximum of 120 °C, (a higher melting point 
than PVP and PNIPAM alone), suggesting a single, more stable system. The absence of the sharp 
endothermic peak indicative of pure TM Tm in the thermograms of F1-F3 illustrates the drug is 
no longer present in crystalline form but now distributed in amorphous form within the 
polymeric matrix.  
4.4.4.3.2 Thermogravimetric Analysis 
TGA is a vital thermal characteristic to determine the degradation properties of samples. To 
investigate the thermal behaviour of raw materials and the resultant coatings, they were 
subjected to TGA. Figure 4.12a and b shows the TGA profile for raw materials and atomised 
samples. The trace for raw TM depicts a sharp weight loss (75.14%) between 201 °C and 370 °C 
that is shown as a significant decrease between this range. This decline is characteristic of drug 
degradation (Joshi et al., 2009). 
Two major weight loss events can be observed with the TGA profiles for both raw polymers. The 
first weight loss reduction is seen between 40 °C and 140 °C and between 40 °C and 168 °C for 
PVP (11.19% loss) and PNIPAM (3.8% loss) respectively; corresponding to initial moisture loss of 
the surface-associated water within the polymer. The second weight loss event is characteristic 
of polymeric thermal degradation. Within the temperature interval 390 °C and 525 °C, a weight 
loss of 83.32% can be seen with the PVP TGA trace, where the PVP thermally degraded by release 
of pyrrolidone side group followed by decomposition of polyenic chains. These results coincide 
with Peniche’s work (Peniche et al., 1993). Thermal degradation of PNIPAM can be observed at 
342 °C-470 °C; a weight loss of 93.18%, which correlates to the degradation of PNIPAM found in 
literature (Bauri et al., 2013).  
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Figure 4.12b shows the TGA thermogram of the atomised coatings. The profile for all three 
samples are similar; all three formulations exhibited 2 major weight loss events between 20°C 
and 120°C and between 370°C and 485°C. The first weight loss occurrence corresponds to the 
dispelling of water and the second drastic weight loss is due to polymer degradation. F3 coatings 
degraded at a lower temperature compared to sole polymer-drug samples, which could be a 
result of the arrangement of polymeric chains during the atomization process.  As with DSC, the 
presence of just two weight loss events for the coatings suggests the polymers and the drug are 
acting as one system rather than independent components. 
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4.4.4.4 Contact Angle 
CA is a quantitative measurement of the wetting of a solid by a liquid (usually water). Introducing 
a droplet of distilled water and analysing the droplet spreading kinetics can also provide data on 
the hydrophilicity of the material. Angles smaller than 90° indicate high wettability (hydrophilic) 
whilst angles larger than 90° indicate poor wettability and therefore are more hydrophobic. The 
wettability of the surface of the electrically atomised samples were characterised and analysed 
over time (Figure 4.13).  
Upon dropping the water droplet, the highest static CA was observed with beaded fibers 
produced by atomising F2 and F3 (130.1° and 126.27°, respectively). At 0 seconds, the CA for 
TM-loaded PVP particles, an average CA of 83.02° was recorded using a trigger-sensor camera 
(Figure 4.13d). This difference in initial CA between particles and fibers could be due to the 
surface roughness of the structures.  
 
The “featureless” surface of PVP particles (as confirmed through SEM) and high surface area of 
particles results in less air entrapment between the solid and liquid phases, ultimately resulting 
Figure 4.13 Contact Angle Analysis. Digital images taken during contact angle 
measurements over time for a) F1 samples, b) F2 samples, c) F3 samples at i) 0 s, ii) 30 s, 
iii) 10 mins, iv) 30 mins d) Contact Angle analysis over time for F1, F2 and F3. 
a i) a ii) a iii) a iv) 
b i) b ii) b iii) b iv) 
c i) 
c ii) 
c iii) c iv) 
d) 
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in a low static CA as soon as the water droplet comes into contact with the sample (W. Ma et 
al., 2017). The water droplet applied to F2 samples completely disintegrated within 10 seconds 
indicating rapid penetration of water through the sample, dissolution of sample and/or the 
increase of degree of wettability with time (Figure 4.13b). This can be corroborated by the 
hydrophilic nature of PNIPAM (Ashraf et al., 2016). The CA for F1 and F3 samples were 
unmeasurable after 10 minutes and 30 minutes, respectively due to complete spreading of 
water after these time points. The polarity of PVP makes the polymer highly hydrophilic; 
indicating a low CA at 0 seconds. However, the density of the samples can cause particles to 
agglomerate, trapping air between the particles. This may prevent the water droplet penetrating 
and spreading. The dissolution of PVP and PNIPAM over time allows the water to penetrate the 
inter-particle pores and spread; with the droplet spreading completely within 10 minutes of 
application (Kim, Kim and Kim, 2013). The combination of particles and fibers with F3 samples 
increases the surface area and surface roughness of the sample; which in turn can contribute to 
the time it took for the CA to reduce from an average of 126° at 0 seconds to 0° after 1800 
seconds, enabling the coating to be remain on the lens for longer; prolonging drug retention.  
4.4.4.5 FTIR Spectroscopy Analysis 
EHDA technologies have become more and more favoured due to the fact that the processing 
conditions do not seem to affect the structure of the materials being handled (Xie et al., 2015). 
FTIR is able to identify the presence of functional groups of materials. Following EHD processing, 
the resulting engineered products can be subjected to FTIR analysis to ensure the structure of 
the active and other additives have not been compromised.  Here, FTIR was performed on raw 
materials (as obtained in powder form) and atomised structures (beaded fibers and particles). 
The fingerprint of PVP and PNIPAM can be observed using FTIR; as seen in Figure 4.14 based on 
structural groups present.  
With respect to PVP, peaks at 3469 cm-1 and 1664 cm-1 correspond to O-H stretching vibrations 
and C=O and N-C stretching vibration, respectively. Multiple peaks at 2948 cm-1, 2918 cm-1 and 
2875 cm-1 are present due to CH-CH2 stretch vibrations. Evidence of C-H deformation of cyclic 
CH2 groups can be seen at 1492 cm-1, 1459 cm-1, 1419 cm-1 and 1371 cm-1. Amide III bond (C-N 
stretching vibration), amide V (CH2 rocking vibrations) and amide IV bond are present at 1282 
cm-1, 732 cm-1 and 648 cm-1 respectively. Characteristic absorption peaks on the PNIPAM spectra 
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included amide II bond at 1550 cm-1, C=O stretching and CH3 asymmetric stretching vibrations 
at  1650 cm-1 and 2970 cm-1 , respectively.  
 
The stability of TM in the presence of PVP and PNIPAM (separately and as composite) and 
following EHDA process can be assessed by analysing the drug-polymer interactions in the 
resulting spectra from FTIR spectroscopy. A broad band in the spectrum for TM corresponds to 
O-H/N-H stretching vibrations whilst peaks at 2968 cm-1, 2891 cm-1 and 2854 cm-1 are present 
due to aliphatic C-H stretching vibration. The acid carbonyl group of maleic acid and the N-H 
bending vibrations show peaks at 1707 cm-1 and 1496 cm-1. Bands at 1229 cm-1 and 954 cm-1 are 
due to O-H bending and hydroxyl C-O stretching vibrations, respectively. Similar peaks in the 
spectra for the atomised formulations indicate the chemical structure of TM was not 
compromised and was unaffected by the EHDA process.  
Figure 4.14 FTIR Spectra for raw materials and atomised structures 
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4.4.4.6 In Vitro Studies 
4.4.4.6.1 Drug Release Studies 
Drug release from polymeric matrices is a critical study to conduct with respect to establishing 
product behaviour during the numerous stages of drug product development.  Establishing the 
drug release behaviour can provide extensive information on the dosage form alongside release 
mechanisms and kinetics.  Nano-particulate structures and nanofibrous systems are considered 
to be complex dosage forms, hence monitoring and deciphering drug release from these systems 
is of great importance. In vitro drug release testing involves quantifying or measuring the release 
of drug from a matrix or carrier in an environment simulating physiological conditions. Figure 
4.15 shows cumulative release (%) of TM from polymeric coatings in PBS at physiological 
conditions (pH=7.4, 37 °C). The release study showed after 1 minute, 25.1%, 12.4% and 11% of 
TM was released from F1, F2 and F3 samples, respectively. 
After 30 minutes, over 50% of TM was released from all 3 samples. Readings taken at 24 hours, 
drug release was found to be 89.8% for F2 whereas for F1 and F3, only 63.2% and 68.2% of TM 
was released, respectively.  
Figure 4.15 In Vitro cumulative TM release (%) from various polymeric coatings 
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There is a noticeable general trend for all three formulations as similar release profiles can be 
observed. There is an initial burst release, followed by a sustained, controlled release phase that 
slowed but still increased with time eventually saturating at 24 hours. The rapidly dissolving 
nature of PVP could explain the initial burst release seen with F1 and F3. The morphology 
(combination of particles and fibers) of the atomised structures using F2 and F3 could account 
for the initial burst release observed, as particles tend to release drug more quickly due to higher 
total surface area. PVP has been used previously in ophthalmic formulations. For example, PVP 
was utilised as a rapidly dissolving matrix for the delivery of rifampicin (Braha et al., 2009) and 
in the manufacture of ocular films for delivery of anti-inflammatory drug diclofenac sodium 
which displayed controlled drug release. More than 50% of drug was released within 1 hour and 
the remaining drug was released within 4 hours (Jafariazar et al., 2015). Controlled release of 
drug using PNIPAM has been previously shown where PNIPAM was used as a nano-vesicular 
carrier for anticancer drug 5-fluorouracil (Li et al., 2015).  Increasing the temperature to 
physiological temperature saw a more controlled sustained release with 35% of drug being 
released within 24 hours.  The combination of a fast dissolving polymer (PVP) and a more 
sustained dissolving polymer (PNIPAM) here along with the novel technology of EHDA can be 
used to develop a polymeric device with controlled and prolonged release, as shown by these in 
vitro studies.  
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4.4.4.6.2 Probe Release Studies 
To demonstrate the drug leaving the lens at a sustained rate as well as the coating remaining on 
the lens, lenses were coated with atomised probe-loaded polymeric coatings and exposed to 
PBS. Table 4.5 shows the dye intensity on the lens using fluorescence microscopy and Figure 




For PVP coated lenses, there is 100% DI on lens at 0 minutes and 0 DI in PBS. As time increased, 
the DI on lenses decreased (down to 8.7%) (Figure 4.16a) and the DI in PBS increased (up to 
0.034). An initial burst release in the first 10 minutes (100% to 43% DI on Lens) was observed 
which gradually saturated after 6 hours (9.79% DI on lens). The data collated from UV 
spectroscopy reflected what was found with fluorescence microscopy: an initial burst release of 
probe into PBS from 0 to 0.0064 within the first 10 mins of exposure which then gradually 
increased to 0.034 after 24 hours.  For the PNIPAM coated lens, a similar release profile was 
observed as with PVP: initial burst release followed by sustained release. Table 4.6 shows 
fluorescence images of each contact lens after removal from PBS and Figure 4.16b shows the 
Table 4.5 Fluorescence images of probe-loaded coatings over 24 hours when exposed to PBS medium 
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release profiles of rhodamine B from the lens and into PBS.  DI on the lens decreased rapidly 
within 10 minutes (65.5% of probe was released) and the profile of release into PBS showed a 
sudden initial increase (from 0 to 0.01) within 10 minutes with subsequent gradual increase after 
1 hour (0.016) to 24 hours (0.047). With respect to the composite lenses an initial burst release 
with subsequent sustained release was observed with approximately 50% of the dye being 
released into the media and 50% remaining on the lens (Figure 4.16c). After 6 hours, 71% of the 
dye had been released from the polymeric sample and following the 24 hour mark, 89% of the 
dye had been released into the PBS. The sustained release of rhodamine B was exhibited from 
10 mins (0.07667; absorbance in PBS) to 24 hours (0.0426).  The results for all three formulations 
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Figure 4.16 In vitro Probe detection from lens into PBS medium from a) F1 coatings, b) F2 
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4.4.4.6.3 Drug Release Kinetic Modelling 
To determine the mechanism by which TM was released from the atomised polymeric coatings, 
data from the in vitro release studies was fitted to various kinetic models to obtain graphical 
plots. The linearity of graphs was demonstrated by the regression co-efficient, R2; the higher the 
R2 value, the more linear the graph and subsequently, the better the correlation between the 
variables. Drug release following zero-order kinetics demonstrates a release independent to the 
drug concentration whilst first-order kinetics indicate the release of drug is concentration 
dependent .  
In order to determine if the release of TM was zero order, the cumulative percentage release of 
TM was plotted against time (Figure 4.17).  For analysis of first order kinetics, log cumulative 




Figure 4.17 Timolol Maleate Release from atomised coatings according to zero-order model 
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Figure 4.19 Timolol Maleate Release from atomised coatings according to the Hixson-Cromwell model 
Figure 4.18 Timolol Maleate Release from atomised coatings according to first-order model 
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Hixson-Cromwell cube root law describes the release of drug due to change in particle surface 
area and diameter (Hixson and Cromwell, 1931), where the cube root of percentage of drug 
remaining in the matrix is plotted versus time (figure 4.19). 
The Higuchi model describes drug dissolution from various types of modified release from 
polymeric matrices. The model was originally intended for planar systems but evolved to extend 
to different geometries and porous matrices. It has been generalised to yield the simplified 
Higuchi Model (Siepmann and Peppas, 2011).   It is based on several hypotheses: i) initial drug 
concentration in the matrix is much higher than drug solubility; ii) drug diffusion is only in one 
plane; iii) drug particles are much smaller than the system matrix; iv) the matrix swelling and 
dissolution is negligible; v) drug diffusivity is constant; vi) perfect sink conditions in release 
environment are reached. The cumulative drug release of TM from all three samples was plotted 
as function of square root of time (Figure 4.20).  
 
All three formulations showed a poor fit for zero order and first order release kinetics, confirmed 
by low R2 values (Table 4.7), showing drug concentration had no effect on the release of TM 
from the atomised coating.  
Figure 4.20 Timolol Maleate Release from atomised coatings according to the Higuchi model 
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Table 4.6 Kinetic Models for timolol maleate release expressed by regression coefficient, R2 
 
Results from the Hixson Cromwell model indicate the release of TM was not limited by 
dissolution but by the transport of drug through the polymeric matrix. Adequate linearity (as 
classified by Siepmann and Peppas) across all 3 TM loaded polymeric samples were observed 
with the Higuchi Model (Figure 4.20 and Table 4.6); suggesting TM release was a diffusive 
mechanism, in particular it is likely to be quasi-Fickian Diffusion. This is mirrored in the 
coefficient of determination (R2) of 0.5073, 0.6227 and 0.5021 for F1, F2 and F3 atomised 
formulations, respectively.  
The Korsmeyer-Peppas model was devised to explain the type of diffusive mechanism from 
polymeric matrices. It is a logical kinetic model to use when there could be multiple possible 
release mechanisms. For spherical matrices, various n values depict specific release mechanisms 
stated in section 3.2.8.1.2.  Log cumulative release (%) was plotted as a function of log t with 
only the first 60% was fitted to the Korsmeyer-Peppas model. The resulting parameters collated 
from the model given in Table 4.7. For F1, F2 and F3, the n values were 0.1588, 0.1964 and 
0.4921, respectively, which, like the Higuchi model, indicated quasi-Fickian transport dominated 
the release of TM from polymeric nano-structures into PBS. Therefore the release mechanism 
of TM here was diffusion dominated (Riger and Peppas, 1987; Korsmeyer et al., 1983).  
 
Table 4.7 Korsmeyer-Peppas model parameters for timolol maleate release 
 
Formulation Zero-order First-order Hixson-
Cromwell 
Higuchi 
F1 0.1826 0.2092 0.0596 0.4973 
F2 0.3376 0.2217 0.1377 0.6227 
F3 0.2355 0.1604 0.0912 0.5021 
Formulation R2 n k 
F1 0.8107 0.1588 0.502 
F2 0.7967 0.4921 0.2443 
F3 0.6932 0.1964 0.3903 
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4.4.4.7 Ocular Irritancy Testing 
The BCOP test is an organotypic assay utilised to assess the irritancy of test materials based on 
how corneal opacity and permeability is affected. An undamaged cornea is a clear structure, 
which acts as a protective barrier enabling the cornea to remain impermeable to a large array 
of materials including sodium fluorescein dye. Hence, any damage to the corneal cells following 
treatment with test substances can be associated with said substances (Abdelkader et al., 2015; 
Wilson, Ahearne and Hopkinson, 2015). 
Figures 4.21a-c illustrates the response of bovine cornea opacity to TM-loaded nano-structures 
alongside controls. Visual observation (i.e. human eye) of the cornea confirms normal saline, the 
concurrent negative control, shows no damage to the cornea. There is also no change in the 
opacity of the cornea. In contrast, NaOH (the positive control), unmistakable opacification can 
be detected; indicating the most severe damage to the cornea. Application of NaOH to the 
cornea results in interactions with corneal cell membranes. Subsequently, fatty acids in these 
cells undergo saponification, compromising not only the tight junctions between the corneal 
epithelial cells but the whole epithelium layer; increasing the permeability of the cornea to the 
fluorescein dye (Reim, Schrage and Becker, 2001). Clear visual evidence under a cobalt blue filter 
(465-490nm) indicates that the fluorescein dye has permeated through the corneal layers in 
NaOH-treated cornea as seen in Figure 4.21h).   
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The mild positive control (acetone) exhibited a faint cloudy region, suggesting acetone to be a 
mild irritant to the eye. Acetone causes partial injury to epithelial cells because of lipid solvent 
interaction properties that can irritate mucosal membranes, ultimately resulting in eye irritation 
(demonstrated under a cobalt light filter as slight fluorescence) (Figure 4.21i). The bovine cornea 
Figure 4.21 BCOP results of freshly excised bovine cornea. Digital images of treated cornea: a) 
negative control, b) positive control, c) mildly positive control, d) F1, e) F2, and f) F3. Fluorescence 
images under cobalt blue filter: g) negative control, h) positive control, i) mildly positive control, 
j) F1, k) F2 and l) F3 
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treated with normal saline exhibited no fluorescence, showing the dye had not permeated the 
cornea, highlighting the integrity of the cornea was not compromised. Staining of F1, F2 and F3 
treated bovine cornea also showed no fluorescence, indicating there was no damage to the 
cornea and therefore these are biocompatible formulations for ocular drug delivery (Figures 
4.21j-l).  
4.4.4.8 Ex Vivo Testing 
Ex vivo permeation studies can provide an insight to how the electrically atomised formulations 
release drug and how the active permeates through the corneal tissue. TM permeation was 
measured using freshly excised bovine corneas. By calculating the cumulative amount of TM 
that permeated through the cornea and using the dimensions of the vertical Franz cells used in 
this study, various parameters (steady state flux (Jss), apparent permeation coefficient (Papp)) can 
be derived. Table 4.8 shows the Jss and Papp values for all three atomised formulations.  
Table 4.8 Summary of parameters derived from ex-vivo release studies 
 
Statistical analysis (one way ANOVA) was conducted to report the statistical significance 
between the three formulations. The results showed a significant difference in ex vivo 
permeation between all three formulations (p<0.05) with regards to the amount of TM 
permeating through the excised cornea. The permeation rate of TM from F3 formulation was 
the highest (Jss=4.431 µg/cm2/h; Papp = 0.9334 cm/h) and was the lowest F1 (Jss=0.86977 
µg/cm2/h; Papp = 0.2827 cm/h). This difference is due to the combination of rapidly dissolving 
polymer (PVP) and thermosensitive, slowly dissolving polymer (PNIPAM) allowing the facilitation 
of TM corneal drug delivery. Based on a study by Moosa the in vivo effect on TM release from 
  F1 F2 F3 
  Lens 1 Lens 2 Lens 3 Lens 1 Lens 2 Lens 3 Lens 1 Lens 2 Lens 3 
Sample Weight (mg) 1.3 1.3 1.4 3.9 2.8 4.1 1.3 1.3 2.3 
% Permeated / Surface 
area (%/cm²) after 24 hrs 
60.6 54.4 65.4 43.7 42.3 51.7 92.9 80.1 97.34 
Steady State Flux 
(µg/cm²/min) 
0.015 0.015 0.021 0.019 0.020 0.021 0.058 0.039 0.074 
Apparent Permeability 
Coefficient (cm²/min) 
0.0047 0.0048 0.0069 0.005 0.0053 0.0054 0.012 0.008 0.016 
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ocular inserts, marketed eye drops demonstrated Papp of 1.7x10-4 cm/min and Jss = 0.00052 
mg/cm2/min in rabbit eyes. The values are contrastingly higher that those derived in this study 
suggesting atomised (coated) lenses could lead to a reduction in frequent dosing and medicated 
applications. This reduction, in turn, has the potential to minimise the risk of ocular toxicity 
because of lowered systemic drug absorption (Moosa et al., 2014). Furthermore, such systems 
provide greater potential for patient compliance; a challenge which current methods of 
treatment (e.g. eye drops) are met with.  
4.5 Conclusion  
This chapter looked at the potential of 3 different polymeric coatings for the effective loading, 
release and permeation of antiglaucoma drug TM. These coatings were engineered using EHD 
processing for the outer surface of soft contact lenses and were found to consist of particles or 
beaded fibers in the nanometre range. Probe encapsulation was demonstrated using 
fluorescence microscopy, FTIR analysis confirmed the structures of the raw materials, and drug 
was not compromised during EHD processing. In vitro release studies and kinetic modelling 
studies revealed that TM was released from the polymeric coatings in a biphasic manner via 
quasi-Fickian diffusion. BCOP testing confirmed the ocular tolerability of all three atomised 
coatings and ex vivo permeation studies indicated significant differences between the 3 
polymeric matrices with respect to TM penetration through bovine cornea.    
Following these experiments, I chose to focus on improving TM permeation through the cornea. 
Whilst ex vivo studies did show some promising results, long lag times were identified, indicating 
delayed drug action. In vitro studies suggested an initial burst release of TM followed by 
sustained release for 24 hours which is not mirrored in the ex vivo studies. While all three 
formulations assessed here had the potential to be further modified, F3 was selected due to the 
combination of PVP and PNIPAM as the polymeric matrix. This formulation presented a biphasic 
release profile with only approximately 68% of loaded TM being released after 24 hours. 
Therefore, attempting to improve TM permeation through the use of permeation enhancers felt 
like the natural progression of this current research.  
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Chapter 5 Improving timolol maleate 
permeation through the cornea  
5.1 Introduction 
This chapter looks at modifying the most suitable formulation identified in chapter 4- composite 
polymer loaded with 5% timolol maleate. The results shown in this chapter of work demonstrate 
the in vitro and ex vivo effect of incorporating 4 different permeation enhancers on i) the 
resulting electrically atomised coatings with respect to size, shape and stability , ii) the release 
of TM from the coatings and iii) the permeation of TM through the cornea.  
Initially, the reason behind selecting and utilising PNIPAM was its unique thermoresponsive 
behaviour. In chapter 4, the results suggested the introduction of PNIPAM to PVP solution 
yielded beaded fibers when electrohydrodynamically processed which in turn found to 
contribute to a biphasic release profile of TM via a burst release from the PVP and more 
sustained release from PNIPAM fibers. Due to this, the reasoning behind continuing to use 
PNIPAM was its ability to provide sustained TM release as opposed to its thermoresponsive 
nature.  
5.2 Background 
The eye, whilst being an easily accessible organ, poses great challenges with respect to topical 
ocular drug delivery (Taskar, Tatke and Majumdar, 2017). More explicitly, the corneal structure 
is one of the most important barriers with ocular drug delivery. Its composition (ranging in 
degrees of hydrophilicity) can limit the topical delivery of ocular therapeutic actives (Kong and 
Mi, 2016).  
Whilst the structure of the cornea is the most imperative anatomical barrier to drug delivery, 
there are an array of factors that can affect drug permeation through this tissue. These factors 
can be categorised into 3 groups: physiochemical factors (Mun et al., 2014), physiological factors 
and formulation factors (Malhotra and Majumdar, 2001), all of which have been summarised in 
Table 2.1.  The approach taken in the work in this thesis was formulation based. From a 
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formulation point of view, these factors are arguably the most crucial due to patient safety. 
There have been many attempts to improve drug penetration but each are not without their 
downfalls. Increasing the concentration of the drug in question can increase the bioavailability 
of the active and consequently improve treatment; however, the maximum safety concentration 
threshold must not be breached. There is also the possibility of increasing drug particle size or 
using suspensions (for poorly soluble drugs) to increase residence time and provide sustained 
drug release. However, there is a maximum particle size which can be utilised (10µm) before 
they will be detected as foreign matter; initiating reflex tear production (Aldrich et al., 2013). 
Another approach taken to improve bioavailability by increasing residence time is increasing the 
viscosity of the formulation in question. This has been extremely successful and has led to 
commercialisation of many products such as Timoptic-XE®, a gel-forming solution. However, an 
increase in viscosity can lead to blurred vision, causing inconvenience to the patient and limiting 
the time at which the treatment can be used (i.e. at night).  Other successful approaches include 
altering the pH and tonicity of the formulations, resulting in higher drug bioavailability and 
consequently extended drug delivery (Gupta, Samanta and Raichur, 2010; Reddy and Ahmed, 
2013; Suresh and Abhishek, 2016).   
The biggest hurdle research & development and formulation scientists experience in ODD is the 
poor bioavailability of ocular drugs. One approach to overcome this is to modify the formulation 
by incorporating permeation enhancers (PEs) (Kim et al., 2016). There are 5 main classes of PEs. 
Calcium chelators like EDTA work by weakening the tight junctions between epithelial cells in 
the corneal epithelium, enhancing the paracellular movement of active through the cornea 
(Kaur and Smitha, 2002; Morrison and Khutoryanskiy, 2014).   
Unlike calcium chelators, surfactants enhance drug permeation via transcellular methods. 
Surfactants are molecules which lower the surface tension between 2 phases.  It has been 
implied that surfactants interfere with the lipid bilayer of epithelial layers; forming micelles 
causing the phospholipids to be removed from the membrane (Abdelkader, Alani and Alany, 
2014). Both non-ionic and cationic surfactants have been used to increase the permeability of 
various ocular drugs (Sahoo, Biswas and Guha, 2014) such as prednisolone, dexamethasone, 
atenolol and timolol. Non-ionic surfactants such as Brij®98 and Brij® 78 have been exploited as 
PEs showing promising results in ocular drug delivery, highlighting the safety and efficacy of 
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these surface active agents (Saettone et al., 1996). One of the most common surfactants used 
in ophthalmic formulations is BAC, a cationic surfactant, usually incorporated in ocular solutions 
at very low concentrations to act as preservative (de los Angeles Ramos-Cadena and Spaeth, 
2016; Fukuda and Sasaki, 2015). The effects of this preservative have proven to be more 
effective in enhancing corneal permeation than other commonly used preservatives such as 
chlorobutanol and organomercurials. Borneol is a naturally occurring essential oil of 
Cinnamonum camphora. Although it does not fit into a defined category of PEs, it has shown 
potential in promoting corneal permeation of ocular drugs TM (Wu et al., 2006), dexamethasone 
(Yang et al., 2009), indomethacin (Yang et al., 2009) and ofloxacin (Yang et al., 2009).   
The limitations of conventional methods to increasing BA can easily be overcome using 
implantable devices (i.e. CLs). By optimising formulations and combining EHDA with the use of 
CLs, it is possible to extend drug retention time whilst reducing the need of frequent 
administration. The utilization of nanocoatings engineered using EHDA can increase drug loading 
capacity due to increased surface area-to-volume ratio and hence reduce the need for multiple 
doses as with eye drops.  
Here, four PEs were incorporated into composite-TM solution from chapter 4 which were 
subsequently electrohydrodynamically processed to engineer atomised contact lens coatings 
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5.3 Materials and Methods  
5.3.1 Materials 
PVP (4.4x104 g/mol) was sourced from Ashland (Worcestershire, UK). PNIPAM (2-4x104 g/mol), 
ethanol, TM (>98%), acetone, sodium hydroxide, rhodamine B, BAC, EDTA, borneol and Brij®78 
were all obtained from Sigma Aldrich (Dorset, UK). PureVision® Balafilcon A silicone hydrogel 
contact lenses were supplied by Bausch and Lomb (New York, USA). All reagents used were of 
analytical grade.  
5.3.2 Methods 
5.3.2.1 Solution Preparation 
A base solution was prepared by dissolving PVP and PNIPAM in ethanol, yielding a 5%w/v 
polymeric solution. This base solution was used to prepare 8 different formulations, containing 
different drug concentrations and PE concentrations. Table 5.1 shows the composition of each 
formulation.  All solid excipients were weighed using an analytical balance and were mixed using 
a magnetic stirrer for 30 minutes to ensure solution homogeneity.  
5.3.2.2 Solution Characterisation  
Each formulation was characterised based on three physical liquid properties: viscosity, surface 
tension and electro-conductivity. The measurements were carried out as stated in Section 3.2.1, 
in triplicate, with an average reading taken.    
5.3.2.3 EHDA Set-up and Optimisation 
The system set-up was similar to that specified in Section 4.3.2.4.  Briefly, polymeric solutions 
were drawn into 5 mL syringes that were attached to a syringe infusion pump. This pump 
enabled the flow of the polymer-drug-PE solution to be controlled throughout the atomization 
process. The solution was infused through silicone tubing to a single stainless steel conductive 
coaxial needle device (where only the outer needle was used) at various flow rates.  This set-up 
was connected to a high power voltage supply. All atomization processes were carried out in 
ambient conditions (23°C).  
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Due to incorporation of new excipients to the composite formulation, new jetting mode maps 
need to be generated to determine the optimum process parameters for each formulation. Each 
formulation was processed at flow rates in increasing increments of 1 µl/min from 0 µl/min up 
to 20 µl/min. At each flow rate, the voltage that was required to produce various spraying modes 
(stable, unstable, dripping) were logged, providing data to generate jetting mode maps. Table 
5.1 shows the specific flow rates used and voltages applied to each formulation produce 
atomised coatings upon production of a stable jet.  
Table 5.1 Formulation Composition and Optimum Process parameters for each formulation. Each formulation 
contained PVP and PNIPAM at 1:1 ratio to achieve 5 %w/v solution 
Formulation TM 
Concentration 















5 -- -- 10 13.6 
F1 5 BAC 0.01 8 14.5 
F2 5 EDTA 0.5 10 15.6 
F3 5 Borneol 0.1 8 13.2 
F4 5 Brij® 78 1 15 14.7 
F5 15 BAC 0.01 8 14.8 
F6 15 EDTA 0.5 10 15.3 
F7 15 Borneol 0.1 8 14.1 
F8 15 Brij® 78 1 15 15.3 
 
5.3.2.4 Coating Engineering 
As with the experiments in chapter 4, microscope slides were used as a preliminary collection 
device for pilot characterisation studies. Thereafter, in vitro and ex vivo characterisation were 
conducted on coated commercial contact lenses. The lenses were dried in a desiccator on a 
novel lens holder (which helped maintain typical lens shape) for 30 minutes and were weighed 
before and after the coating process to ascertain the weight of the coating sample. Controlled 
deposition was again achieved using a modified lens holder and a mask arm producing 
peripherally coated lenses.  
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5.3.2.5 Characterisation of TM-Loaded Coatings 
5.3.2.5.1 Imaging  
Morphological and structure size analysis was carried out as stated in Section 4.3.2.7.1. Coatings 
on both microscope slides and dehydrated contacted lenses were analysed using SEM whilst 
fluorescence microscopy was used to demonstrate active encapsulation within the atomised 
coatings.  
5.3.2.5.2 Drug Encapsulation Efficiency and Coating Composition 
To determine TM encapsulation efficiency; weighed coating samples were dissolved in ethanol 
for 1 week. UV spectroscopy (λ=295 nm) was used to determine the amount of drug loaded into 
the weighed sample. Equation 4.1 was used to calculate encapsulation efficiency.  The 
encapsulation efficiency was then used to decipher the coating composition.  
5.3.2.5.3 Thermal Behaviour  
The stability and thermal behaviour (i.e. melting point) were assessed using TGA and DSC, 
respectively. Both studies were carried out as stated in Section 4.3.2.7.3 (DSC) and 4.3.2.7.4 
(TGA).  Both raw materials and atomised coatings were analysed under the flow of nitrogen gas 
at a heating rate of 20 °C/min.  
5.3.2.5.4 Goniometry  
Contact angle hysteresis was determined using contacts lenses with the atomised coatings, as 
specified in Section 4.3.2.7.5.  10 µl of distilled water was introduced to the samples and each 
sample was measured in sessile mode at pre-determined time points. Readings were taken in 
triplicate and an average was derived.  
5.3.2.5.5 FTIR 
Any potential interactions between the raw excipients during and following 
electrohydrodynamic processing was assessed using FTIR.  Both raw materials and atomised 
coatings were analysed over the range 400-4000 cm-1 using FTIR Platinum-ATR fitted with Bruker 
Alpha Opus 27 FT-IT at an average of 10 scans at a resolution of 4 cm-1.  
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5.3.2.5.6 In vitro Release and Kinetics 
Drug release and probe release was evaluated as stated in Section 4.3.2.7.7. Briefly, weighed 
contact lenses were introduced to the donor compartment; which had been specially designed 
to maximise surface contact between the lens and the synthetic dialysis membrane (which 
separated the donor compartment and the receptor compartment). Upon fixing the lenses in 
the holder, the entire device was submerged into the “receptor compartment”; a vial containing 
10 ml PBS at pH 7.4. At predetermined time points, 1 ml of release medium was retracted and 
replaced with fresh 1ml PBS.  Probe release from the coatings into the release medium was as 
described in Section 4.3.2.7.7.2. Both drug release and probe release studies were conducted 
in triplicate at 37 °C.  In vitro drug release data was collated and plotted in various kinetic models 
to assess the release kinetics to ascertain the mechanism of TM release from the various 
polymeric coatings.  
5.3.2.5.7 Biological Evaluation of Atomised Coatings 
To ensure the formulations and ultimately the engineered coatings are biocompatible and 
display ocular tolerability, a BCOP test was performed as stated in Section 4.3.2.7.8.  
5.3.2.5.8 Ex Vivo Testing  
The release and permeation of TM from the atomised coatings was studied ex vivo using freshly 
excised bovine cornea as the membrane between the donor and receptor compartments when 
using Vertical Diffusion Cells. The method that was followed here is described in Section 
4.3.2.7.9.  
5.3.2.5.9 Statistical Analysis 
ANOVA test was carried to compare the release of drug from polymer coatings containing 
different PEs. Derived p values less than 0.5 were considered statistically significant.  
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5.4 Results and Discussion 
The effects of incorporating PEs into polymeric solutions containing TM was analysed here. In 
chapter 4, methanol was utilised as vehicle for the solutions. However, the solubility of the 
additional excipients used in this work was higher in ethanol; hence, this was the choice of 
solvent.  
5.4.1 Solution Characterisation  
The physical properties of liquids can greatly influence the structures that arise following EHD 
processing, especially in terms of morphology and size. Hence the viscosity, surface tension and 
electrical conductive nature of each formulation was investigated.  
Table 5.2 shows the average viscosity, ST and EC readings of all 9 formulations alongside the 
vehicle ethanol.  Compared to the vehicle, all the formulations show an increase in viscosity. The 
incorporation of PVP and PNIPAM to ethanol, (Composite-TM) showed an increase in viscosity; 
from 1.15 mPa.s to 4.01 mPa.s. This increase in viscosity may have an impact on the resulting 
atomized structures; leading to the production of fibrous coatings rather than particulate 
coatings (Barrero et al., 1999; Bock, Dargaville and Woodruff, 2012; Haider, Haider and Kang, 
2015). This will be confirmed with subsequent morphological analysis using SEM. Upon addition 
of PEs there is no significant difference between the average viscosity readings (p= 0.687). 
With respect to ST the incorporation of PEs lowered the overall surface tension of the 
formulations. Formulations that contained BAC and Brij® 78 found to have lower surface tension 
than Composite-TM; demonstrating these PEs also acted as surface active agents. BAC is found 
in over 70% of ocular formulations and is most commonly added as a preservative (Tu, 2014); 
however its cationic nature enables it to serve as a surfactant, lowering the formulations’ surface 
tension. Brij® 78 is a non-ionic surfactant that has previously been researched in ocular DD 
(Montenegro, Bucolo and Puglisi, 2003), however, there have been no recent developments 
involving the use of this surface active agent.  
Whilst mainly viewed as a chelating agent, EDTA can also be seen as an anionic surfactant. This 
conclusion can be drawn by observing the reduction in surface tension of formulations 
containing EDTA compared to PE-free formulations. Regardless of the small reduction; this will 
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aid the EHD process as the applied voltage can more easily overcome the surface tension on the 
liquid.  







Ethanol 1.15±0.0058 21.6±0.917 1.78±0.01 
Composite-TM 4.01±0.061 21.24±0.21 199.20±0.02 
BAC 4.25±0.60 19.03±0.097 195.02±0.42 
EDTA 4.01±0.18 18.54±0.095 177.54.63±0.83 
Borneol 3.93±0.086 21.05±1.35 221.94±0.19 
Brij® 78 4.25±0.21 17.82±0.53 218.37±0.13 
 
With respect to electro-conductivity, a large increase can be seen from 1.78 µS/cm to 199.20 
µS/cm upon dissolving both polymers in ethanol.  Upon introduction of PEs, there was no real 
difference in the average electrical conductivity readings. Due to these readings being within the 
ideal range for electro-conductivity for EHD processing (10-4 and 10-8 S/m), a stable jetting mode 
can be achieved with all 9 formulations.  
5.4.2 EHDA Optimisation 
Due to the varying physical liquid properties of the formulations used in this study, the flow rates 
and strength of electric field required to achieve various EHD jetting modes (dripping, unstable 
and stable) needs to be scrutinised to ensure the optimum process conditions are used during 
EHD processing. Figure 5.1 shows the resulting jetting mode-maps that were generated.  Due to 
the endless process parameter combinations, one parameter was kept constant for all 9 
formulations from chapter 4. The working distance was kept at 12 cm. Maintaining this distance 
between the needle exit and collection plate ensured comparisons between the formulations 
would not be biased towards working distance. 
The regions coloured lilac demonstrates the optimum window where any combination of 
applied voltage and flow rate will result in a stable cone forming at the needle exit. The dripping 
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mode (highlighted in peach) demonstrates at those specific combinations, the electrical field 
applied is not sufficient to overcome the surface tension of the liquid at that particular flow rate.  
The build up to achieving a stable jet often results in unstable jetting, as seen in Figure 5.1 in 
blue. As a result of the positions of all three regions; flow rates and voltages utilised in this study 
were selected from the optimum working window. Selecting any other process parameters 
would result in polydisperse, non-uniform atomised structures which in turn could affect the 
release profile and kinetics of loaded therapeutic actives.   Figure 5.2 shows the formation of 
the stable cone jet at the nozzle exit upon processing each formulation.  
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a) b) c) d) 
e) f) g) h) 
Figure 5.2 Stable Jet Formation when electrohydrodynamically processing each formulation at optimum process 
parameters. a) F1, b) F2, c) F3, d) F4, e) F5, f) F6, g) F7, h) F8 
3mm 3mm 3mm 3mm 
3mm 3mm 3mm 3mm 
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5.4.3 Coating Characterisation 
5.4.3.1 Imaging and Size Distribution 
Figure 5.3 shows the images derived from SEM analysis which were used to determine the 
morphology of the atomised structures that made up the contact lens coating. Figure 5.4 shows 
the fiber size distribution for each formulation.  Atomising the PE-free formulation seemed to 
yield beaded fibers similar to that found in chapter 4. The production of beaded fibers here could 
be as a result of insufficient synapse distance between the needle exit and the collection plate, 
hence there is insufficient space for the viscous formulation to “stretch” at the nozzle, causing 
inadequate solution evaporation to produce smooth fibers. The production of beaded fibers 
could also be due to the materials used. Electrohydrodynamic processing of low molecular 
weight PVP has previously reported to produce smooth, spherical particles (Mehta et al., 2015; 
Figure 5.3 Scanning Electron Micrographs of atomised coatings at x50k magnification of a) 
Permeation free formulation, b) F1, c) F2, d) F3, e) F4, f) F5, g) F6, h) F7, i) F8 
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H. Khan et al., 2014). This could account for the “beads” of the resulting structures. The 
incorporation of PNIPAM increased the viscosity of the formulations; leading to the production 
of fibers upon atomization.  
Electrically atomising F1 also produced visibly beaded fibers with some fibers as thin as 33 nm. 
BAC-containing fibers loaded with higher concentration of TM showed much smoother fibers 
than those with low drug concentration (5 %w/w with respect to the polymer). The increase in 
drug concentration distinctly had an effect on the morphology of the electrospun fibers, 
however, the average diameter increased to 90 nm as result of this increase in drug loading. F5 
fibers demonstrated a positively skewed size distribution; with more than 65% of the NFs having 
a diameter less than 100 nm. Unlike PE-free NFs, F1 and F5, the incorporation of the remaining 
3 PEs produced smooth fibers. SEM images revealed electrospun F2 fibers to have smooth 
surfaces with an average diameter of 55 nm with positively skewed data; almost half of NFs had 
a diameter between 1 and 50 nm. Electrospun F6 fibers demonstrated a non-uniform size 
distribution indicating high drug loading in the presence of EDTA does not achieve a narrow size 
distribution. F6 fibers had the largest average fiber diameter at 142±35 nm. This and the non-
uniform size distribution could be attributed to the formation of a suspension when EDTA was 
incorporated into the formulation. As EDTA is insoluble in ethanol, a suspension was formed. As 
a result, EDTA would exist as its original particle size and therefore would not be completely 
homogenously dispersed throughout the matrix, even when electrohydrodynamically 
processed; hence possibly increasing the diameter of the resulting fibers.  
Both F3 and F7 produced smooth-surfaced NFs with bell-shaped distribution; with drug loading 
not altering fiber diameter yielding fibers 74nm and 74nm respectively. These fibers are much 
thinner than those reported by Li et al when using just PVP as polymeric matrix. The borneol-
PVP electrospun nanocomposites produced possessed smooth surfaces with an average fiber 
size of 610±120 nm (Li et al., 2012). Beaded NFs were produced when electrospinning F4 and 
F8, showing insufficient working distance as with F1 NFs. A negatively skewed distribution was 
observed with fibers engineered using F8 with 61% of fibers being above 100 nm in dimeter as 
opposed to 75% of F4 fibers being under 100 nm. This increase in diameter is associated with 
the incorporation of higher drug concentration encapsulated within the fibers.   
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PVP has been previously been electrospun to produce fibers with an average diameter of 305 
nm (Huang et al., 2016); almost double that what has been fabricated here. Research involving 
the processing TM-loaded composite formulations for ocular delivery using EHDA is very scarce. 
However, TM has been electrospun into PVA and PCL fibers producing NF patches with fibers 
ranging between 200 nm and 400 nm (Gagandeep et al., 2014). PVP has been previously 
reported to produce contact lens coatings yielding both nanoparticles (50 nm-130 nm) and NFs 
(130-250 nm) (Mehta et al., 2015). The PE-loaded NFs produced here are reportedly much 
thinner than those previously stated in literature using single needle electrospinning (Huang et 
al., 2003; Braghirolli, Steffens and Pranke, 2014; Haider et al., 2015).  
 
 
Figure 5.4 Fiber Diameter Distribution of formulations containing a) BAC, b) EDTA, c) borneol and d) Brij® 
78. Pink is formulations containing 5% TM and blue is formulations containing 15% TM  
x ̅= 65±7nm 
x ̅= 90±5nm 
x ̅= 56±8nm 
x ̅= 142±35nm 
x ̅= 74±4nm 
x ̅= 74±3nm 
x ̅= 80±12nm 
x ̅= 118±32nm 
a) b) 
c) d) 
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5.4.3.2 Drug Encapsulation Efficiency and Coating Composition 
 Table 5.3 shows the theoretical compositions of the fibers produced. These calculations were 
based on the initial concentrations of materials and the TM encapsulation characteristics of the 
electrospun fibers are shown in Table 5.3. The highest encapsulation efficiency was found with 
F7 with almost all of the loaded TM (99.7%) being encapsulated within the matrix and the lowest 
with F4 (51.75%).  For both drug loadings (5 %w/w and 15 %w/w), it seems the highest 
encapsulation was achieved with formulations containing borneol. The drug encapsulation 
efficiency was used to calculate how much of the weighted sample would be drug. Following 
this, the proportion of sample that is made up by polymer and permeation enhancer can be then 
interpreted as each concentration is known i.e. polymeric concentration is 5 %w/v.  
Table 5.3 Fiber Composition and Drug Encapsulation Efficiency of each electrically atomised coating.  
 
5.4.3.3 Thermal Analysis  
5.4.3.3.1 DSC Analysis 
Figure 5.5 presents the DSC thermograms of all 8 formulations; including raw composite and 
pure drug. Due to electrospinning emerging as an imminent method of fiber production, it is 
important to demonstrate the process parameters do not affect the physical stability of the 
actives used as well as the resulting electrospun fibers. Pure TM is a crystalline drug with a 
defined Tm of 218 °C (Figure 5.5). The absence of this sharp endothermic peak in the 
thermograms of F1-F8 indicates the drug is no longer present in crystalline form but now in 
Formulation Theoretical Fiber Composition  








F1 95.05 4.75 0.2 92.21 
F2 86.96 4.35 8.69 60.92 
F3 93.45 4.67 1.88 93.11 
F4 80 4 16 51.75 
F5 86.81 13.02 0.17 70.74 
F6 80 12 8 57.01 
F7 85.47 12.82 1.71 99.7 
F8 74.1 11.1 14.8 82.45 
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amorphous form within the polymeric matrix.  The Tm of each sample is expressed by a broad 
endothermic peak in each thermograms. Whilst the thermograms for electrospun fibers 
exhibited similar endothermic peaks to raw composite (131 °C), they all showed a lower melting 
point (114-125 °C), demonstrating the TM was evenly distributed throughout the fibers resulting 
in an increased dispersion of drug within the polymeric matrix. The presence of just a single, 
broad peak in each thermograms confirm the structure of the physical structures of raw 
polymer, drug and PE were not compromised during the EHD processing. This indicates the 
materials assembled into polymer-drug-PE complexes; acting as one “system” as opposed to 
individual excipients.  
PVP and PNIPAM are predominantly amorphous polymers which experience a phase transition 
upon temperature changes at specific thresholds. During the transition, the polymer morphs 
from amorphous state to a partial rubber state-partial glassy state (Khan, Asmatulu and Eltabey, 
2013; Pawar et al., 2015). The threshold at which this occurs is known as the Glass Transition 
Temperature (Tg). Whilst incorporation of solid materials (e.g. permeation enhancers) can 
significantly affect the Tg, our study shows there is insignificant effect of PE incorporation on Tg 
of the raw composite (depicted between approximately 55-65 °C) in the thermograms for raw 
composite and all 8 formulations.  The lack of change in Tg may also be as a result of weak 
interactions (i.e. covalent bonds) between TM and the polymeric chains (W. S. Khan et al., 2013). 
The reported Tm of each PE used is as follows: BAC: 34-37 °C, EDTA: 237 °C, borneol: 208 °C, Brij® 
78: 44-46 °C. In the case of no interaction between TM and polymer and PE, these Tm would be 
exposed as sharp endothermic peaks in the thermograms of each formulation at the respective 
temperatures. The absence of these peaks (and presence of solitary peaks) confirms the 
formation of drug-polymer-PE complexes to form stable systems in turn producing stable NFs. 
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5.4.3.3.2 TGA Analysis 
Figure 5.6 shows the TGA thermograms for pure TM, PE-free NFs and all 8 electrically atomised 
formulations. The thermogram for pure TM shows a single sharp endothermic weight loss event 
between 201 °C and 370 °C characteristic of drug degradation; also seen by Joshi et al (Joshi et 
al., 2009). Formulations F1-F8 exhibited a 2-step degradation profile; with initial weight loss (6-
8%) due to moisture loss of surface-embedded water or even residual solvent within the 
polymeric matrix of the NFs. The second, more conspicuous decrease in weight loss is indicative 
of polymer degradation of PVP and PNIPAM. For all 8 formulations, the second weight loss event 
occurs between 300 °C and 540 °C (92-94%). The incorporation of PEs into the polymer-TM 
system causes this dominant weight loss to occur over a larger temperature range compared to 
PE-free fibers. Whilst this shift in degradation temperature may show encapsulation of drug and  
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PE (Nazari et al., 2017), it also implies formulations containing PEs are more stable and that 
polymer degradation was delayed by the incorporation of PE (Sundaray et al., 2008). One thing 
to note with these thermograms is there are no prominent physical or chemical changes at or 
over the narrow temperature of biological ocular temperature.  
5.4.3.4 Goniometry  
The wettability the electrospun coatings was characterised and analysed over time using CA 
analysis (Figure 5.7). CA is a critical measure as the interaction between the fibrous coatings and 
the lens material can determine detachment and release of coating and drug, respectively. 
Upon application of water droplet, F2 demonstrated the highest static angle (79.91°) whilst F1 
has the lowest (66.6°). This drastic difference in CA at 0 seconds compared to formulation 
without any permeation enhancers (CA=126.27°) shows the addition of PE (which all act as 
surfactants) lowered the surface tension of the formulations and in turn of the electrospun NFs 
(Stephansen et al., 2016).  This consequently increases the wettability of the samples; indicating 
the samples have become more hydrophilic. This difference in CA could also be due to the 
change in morphology of the NFs of the formulations compared to the beaded-fibers of the 
formulation not containing PE. The presence of spherical structures with fibrous structures 
increases the amount of air entrapped between the solid and liquid droplet, in turn pinning the 
motion of the water droplet as it advances, causing an increase in CA. The combination of 
particles and fibers in Composite-TM samples (without PE) both increases surface area and 
surface roughness which can contribute to the increased time period required for the water 
droplet to completely disappear. Whilst the CA of electrospun NFs devoid of PE was still 
quantifiable for 1800 seconds (30 mins), the CA of all 8 formulations containing PEs were 
unmeasurable after 30 seconds as a result of complete spreading of water droplet within this 
time. The complete spreading of water within 20 seconds demonstrates the hydrophilicity of the 
fibrous coatings, highlighting an affinity to the hydrophilic soft contact lenses aiding the 
attachment of the electrospun coating to the lens.  
 
Chapter 5 Improving timolol maleate permeation through the cornea 
182 | P a g e  
 
One thing to note is the concentration of drug (5 %w/w or 15 %w/w with respect to the polymer) 
did not affect the initial CA or the CA profile. As seen in Figure 5.7 those containing the same PE 
displayed almost identical CA profiles over time.  
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t=0s t=10 t=20s t=30s t=60s t=0s t=10s t=20s t=30s t=60s 
Figure 5.7 Contact angle analysis over time for formulations containing a) BAC b) EDTA c) Borneol d) Brij® 78 at two 
different drug loadings; 5 %w/w and 15%w/w.   Digital Images of liquid droplet over time of formulations containing 
(e) 5%w/w TM and (f) 15%w/w 
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5.4.3.5 FTIR 
Figure 5.8 shows the spectroscopic spectra derived from FTIR analysis of all 8 formulations and 
raw materials. FTIR was used here to show the stability of TM when processed in conjunction 
with polymer and PE. FTIR analysis is advantageous when trying to show compatibility between 
different excipients in a sample. Secondary interactions such as hydrogen bonding and Van der 
Waals (induced dipoles) often increase the stability of structures; interactions which can be 
detected by shifts in wavelength (cm-1) in FTIR spectra. 
Pure TM shows characteristic peaks at 2968 cm-1 (aliphatic C-H stretching), 3063 cm-1 (aromatic 
C-H stretching), 1718 cm-1 (C=O), 1229 cm-1 (O-H bending), 954 cm-1 (C-O stretching vibrations). 
These peaks are less prominent in the spectra for all 8 formulations; with some peaks shifting 
very slightly. These changes in the peaks confirms formation of hydrogen bonds with polymer 
and/or PE. Characteristic peak at 1651 cm-1 in all spectra for 8 formulations correspond C=O 
stretching vibrations in PVP. Multiple peaks at 2948 cm-1, 2918 cm-1 and 2875 cm-1 are present 
due to CH-CH2 stretch vibration. Evidence of C-H deformation of cyclic CH2 groups can be seen 
at 1492 cm-1, 1459 cm-1, 1419 cm-1 and 1371 cm-1. Amide III bond (C-N stretching vibration), 
amide V (CH2 rocking vibrations) and amide IV bond are present at 1282 cm-1, 732 cm-1 and 648 
cm-1 respectively. Characteristic absorption peaks on the PNIPAM spectra included amide II bond 
at 1550 cm-1, C=O stretching and CH3 asymmetric stretching vibrations at  1650 cm-1 and 2970 
cm-1, respectively; all highlighted in Figure 5.8 
In Figure 5.8a, a clear peak at 2927 cm-1 is present in the FTIR fingerprint of BAC (indicative of C-
H3 bending vibrations). However, this peak is less prominent in the spectra for F1 and F5; 
highlighting interaction between components within the sample. With samples containing 
EDTA, the distinctive peaks have shifted as a result of O-H groups being capable of forming 
hydrogen bonds with composite polymer and drug. A similar case is seen with F3 and F7 with 
the incorporation of borneol (Figure 5.8c). With respect to pure borneol, sharp peaks at 1054 
cm-1, 1456 cm-1 and 2950 cm-1 are observed; peaks which are absent in the fingerprint of F3 and 
F7. The presence of C=O bonds in PVP molecules and O-H group in borneol molecules enables 
them to act as proton receptor and proton donors, respectively, forming hydrogen bonds (Li et 
al., 2012). Brij® 78 is also able to form hydrogen bonds with the composite polymer and drug 
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with characteristic peaks at 2890 cm-1, 1108 cm-1, 1341 cm-1 and 1471 cm-1 (for pure Brij® 78) 
being omitted from the spectra for F4 and F8 (Figure 5.8d).  
FTIR analysis was also carried out to observe any changes as a result of initial drug concentration. 
With all four PEs, the concentration of drug did not seem to have any effect on the FTIR 




















































































































Figure 5.8 FTIR spectra for raw materials and electrospun fibers (a) NFs containing BAC, (b) NFs containing EDTA, (c) NFs 
containing Borneol, (d) NFs containing Brij® 78 
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5.4.3.6 In Vitro Release and Kinetics 
5.4.3.6.1 In Vitro Drug Release 
Understanding the release profile of TM from these electrospun coatings was crucial to see how 
the drug delivery device (i.e. the lens) would allow the fibrous coating to detach and allow for 
subsequent drug release.  Figure 5.9 shows the in vitro cumulative TM release from electrospun 
composite fibers. PE-free NFs presented a biphasic release profile; initial burst release (47% 
released within 10 minutes) followed by slow, sustained release; 68.24% after 24 hours. F1-F7 
fibers exhibited triphasic release profile; initial burst release followed by gradual release and 
subsequent sustained release. The initial burst release is most likely to be due to the rapid 
release of surface-associated TM and PVP dissolution (Mehta et al., 2015). Subsequent gradual 
release is seemingly a result of breaking of PNIPAM polymer chains (dissolution of PNIPAM). The 
third phase of drug release (occurring at 300 mins) was caused by polymer erosion, releasing 
the drug in a more sustained fashion, with 20-32% of TM being released in the last 18 hours, 
depending on the PE used. The thermal transition of polymer from rubbery state to glassy state 
may account of this sustained release of TM. Some of the drug may be entrapped within the 
crystalline regions of the polymer and is therefore isolated from the release medium in the 
donor compartment. Only upon polymer degradation can the trapped drug be released resulting 
in gradual sustained release, forming the 3rd release phase (Natu, de Souza and Gil, 2011). The 
incorporation of PE may provide an extra barrier for drug molecule diffusion and these PE 
molecules may fill interfibrous voids, retarding drug diffusion through the matrix. This in turn 
slows the initial high burst release seen in the release from PE-free NFs. One exception to this 
was F8. As opposed to a triphasic release profile, F8 displayed a biphasic system with slow initial 
release with sustained release after 6 hours.  
Whilst the addition of PEs slowed down the initial release and modified the release profile from 
biphasic to triphasic, the total amount of drug released after 24 hours increased for all 8 
formulations (Table 5.4). For example, F7 NFs released 86.71% after 1440 minutes; 18.47% more 
than PE-free NFs. Due to this increase in TM release from the atomised coatings with in vitro 
testing, it can be hypothesised drug bioavailability may be enhanced, a theory which will be 
scrutinised with subsequent ex vivo testing.   
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Table 5.4 The percentage difference of timolol maleate release between permeation enhancer-free coatings and 






Whilst F1-F8 released similar percentage of TM after 24 hours, the release profiles for 
formulations containing different PE were contrastingly different; highlighting the fact that fiber 
composition has evidently influenced the release of TM.  F1 and F5 released 72% and 75%, 
respectively, after 6 hours as opposed to F2 and F6, which only released 56% and 57% of loaded 
TM, respectively. This drastic difference (∼20 %) in release could also be as a result of the 
morphology of BAC-loaded NFs. The beaded fibers can cause uneven distribution of drug 
molecules throughout the polymeric fibers; resulting in burst release from the beads upon 
dissolution hence releasing drug much faster than those with smooth fibers.  NFs containing 
high TM concentration and borneol as PE released the most drug after 24 hours (86.72%±3.09%) 
whilst F8 NFs released the least amount after 24 hours (77.33%±8.1%).  A noticeable difference 
is the slow initial release of F6 compared to burst release of other formulations. After 10 
minutes, 4.9% of the loaded drug had been released from F6 NFs whilst F5 fibers had released 
31.1% TM. This may be attributed to the fiber size: F6 NFs had an average size of 117 nm, with 
a majority of NFs being above 100 nm. As a result of this decreased surface area, dissolution rate 
of the NFs is slower than that of thinner fibers as with F5, hence, the drug is released much 
slower.  There was a statistical significance (p<0.05) difference in the release of TM from 
polymeric matrix containing different PEs as demonstrated by one way ANOVA; p=0.0345 and 
p=0.0358 for 5 %w/w TM-loaded NFs and 15 %w/w TM-loaded NFs respectively.   
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Figure 5.10 shows in vitro release between the 2 drug loadings; 5 %w/w and 15 %w/w. It is clear 
to see that the initial drug concentrations had no effect on the cumulative release of TM after 
24 hours with ANOVA statistical analysis showing there was no significant difference between 
these results (p=0.08). 
a) 
b) 
Figure 5.9 In Vitro cumulative timolol maleate release from electrospun fibers containing a) 5 %w/w 
timolol maleate and b) 15 %w/w timolol maleate 
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It was extremely challenging to compare these results to existing research as the materials and 
fiber compositions used here as well as the method and application have not yet been explored. 
However, Gangandeep et al developed electrospun PCL nanofibers and PVA nanofibers loaded 
with TM both of which were found to exhibit a 2 phase release profile, releasing 74% and 86% 
of timolol, respectively after 24 hours (Gagandeep et al., 2014).  This is similar to what was found 
here with PVP and PNIPAM nanofibers.   
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5.4.3.6.2 In Vitro Probe Release 
Figure 5.11 exhibits the probe release data both from the electrospun coatings on contact lenses 
and into release medium (PBS, pH 7.4, 37 °C) in order to show the affinity of the coatings to the 
dehydrated contact lenses whilst mimicking drug release, respectively. Probe-encapsulated NFs 
were produced with the same composition as in Table 5.1, with rhodamine B replacing TM as 
the active. The release of dye was depicted as DI on the lens (using fluorescence microscopic 
images) and DI of PBS (UV-Spectroscopy; absorbance as a function of time).  
a) b) 
c) d) 
Figure 5.11 In vitro cumulative probe release from electrospun coatings containing a) BAC b) EDTA c) Borneol d) Brij® 78 at 
two different drug loadings; 5 %w/w and 15%w/w 
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The fact the two profiles (DI on lens and DI of PBS) mirror each other for all 8 formulations show 
the atomised coatings do not detach from the contact lens upon exposure to the release 
medium, ensuring sustained release of the therapeutic active (in this case model probe) over 
time.  
5.4.3.6.3 Release Kinetics 
The data from in vitro TM release was applied to various release kinetic models to ascertain the 
prominent release mechanism of TM from the electrospun fibers. 
The data was fitted to zero-order (Figure 5.12), first-order (Figure 5.13), Higuchi (Figure 5.14) 
and Korsmeyer-Peppas (Figure 5.15) models; with the derived regression values and relevant 
component values being recorded in Table 5.5.  
 
Table 5.5 Regression Coefficients and release components derived from four different kinetic models 
Formulation Zero Order First Order Higuchi Korsmeyer-Peppas 
    R2 n 
F1 0.6257 0.8135 0.88 0.9858 0.329 
F2 0.7352 0.6394 0.9614 0.9948 0.339 
F3 0.5858 0.7428 0.8696 0.9896 0.502 
F4 0.6727 0.7592 0.9207 0.9802 0.509 
F5 0.4816 0.7301 0.8357 0.9739 0.2367 
F6 0.7526 0.7274 0.9537 0.9318 0.4445 
F7 0.5537 0.8308 0.9561 0.9550 0.5 
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The low R2 values derived from zero-order and first order models indicated poor linearity and 
therefore a poor fit for this type of release kinetics. Relatively high (>0.9300) R2 values for all 8 
formulations from Higuchi model analysis suggests TM was released via quasi-Fickian diffusion; 
a mechanism which involves partial diffusion through swollen matrix whilst water fills pores in 
the matrix. This derivation was further confirmed by the results from applying release data (first 
60%) to Korsmeyer-Peppas model. F1, F2, F5 and F8 showed characteristics for quasi-Fickian 
release with n values less than 0.45, whilst the remaining formulations released TM via Fickian 
diffusion.  
Applying the in vitro release data to these 4 kinetic models signify the release of TM from these 
atomised coatings was primarily diffusion-based. However, the lack of linearity of the plots 
achieved indicates these models may not represent the release mechanisms accurately with 
respect to this drug delivery system developed here.  
5.4.3.7 Biological Evaluation of Electrospun Fibrous Coatings 
The main purpose of the cornea is to protect the eye and therefore it must remain impenetrable 
to any foreign bodies or materials that may compromise the structure and/or function of the 
cornea, (Abdelkader et al., 2015; Wilson, Ahearne and Hopkinson, 2015). Any damage that 
affects the corneal structure (and subsequently cornea permeability) can be detected with 
fluorescent dyes under a filtered fluorescent light source. Whilst in chapter 4 it was found the 
combination of PVP and PNIPAM with TM did not inflict any damage to the cornea, it is vital to 
repeat this study with these new formulated coatings as the PEs have been incorporated at their 
maximum safety concentration. Whilst the mode of action of these PEs involves interaction with 
tight junctions between corneal epithelial cells, the structure of the cells themselves should not 
be compromised. Hence it is crucial to eliminate the possibility of ocular intolerability with 
respect to this of these formulation-modified atomised coatings.    
Figure 5.16 depicts the reaction of bovine corneal opacity to formulations F5-F8. Figure 5.16a-c 
demonstrates the effects of saline (negative control), acetone (mild positive control) and NaOH 
(positive control). Visual examination of the cornea treated with saline showed no damage 
(absence of cloudy region) whilst those treated with acetone showed a light, clouded region at 
the site of sample application (Figures 5.16b and e).  As mentioned earlier in chapter 4, acetone 
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interacts with the lipids in the layers of the cornea; causing damage to the corneal epithelial 
cells. This in turn can aggravate the ocular mucosal membrane; irritating the eye.  With respect 
to NaOH, severe opacification and strong fluorescence can be observed (Figure 5.16c, 5.16f). 
Upon application of NaOH to the cornea surface, saponification of the fatty acids present in 
corneal cell membranes is triggered. Subsequently, not only are intracellular tight junctions 
comprised, but the entire corneal epithelial layer is. As a result of this deterioration, the 
penetration of the dye through the cornea increases.  
BAC has previously found to be harmful to various cultured cells and animal corneas when used 
at clinical concentrations (Okahara et al., 2013) with EDTA also showing ocular intolerability in a 
study characterising ketorolac tromethamine eye drops (Ahuja et al., 2008). With respect to Brij® 
78, the ocular tolerability is a direct effect of the interaction between the hydrophobic regions 
of the non-ionic surfactant structure (the stearyl and ceyl chains) and the lipid bilayer of the cells 
(Kapoor, Howell and Chauhan, 2009). As a result of these incompatibilities, the loading of these 
PEs into ocular formulations needs to be assessed acutely to ensure there are no safety 
concerns.  
Despite all the PEs being used at their maximum safety concentrations, the BCOP analysis in the 
present study revealed no damage to the cornea when exposed to formulations F5 to F8; as 
portrayed in Figure 5.16g-n, with lack of fluorescence of sodium fluorescein dye under cobalt 
blue light.  The formulations with highest drug loading were tested here with the impression if 
these formulations indicated some biological interaction with the corneal issue, the lower drug 
loading formulations would be further tested. Due to no visual damage being detected and the 
lack of dye penetration indicates these TM-loaded-NFs are biocompatible formulations for 
contact lens coatings.   
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5.4.3.8 Ex Vivo Permeability Testing  
 
Figure 5.17 shows the permeation of TM through freshly excised bovine cornea following 
release from the electrospun PE-loaded coatings with Table 5.6 summarising the parameters 
derived from these ex vivo studies.  A lag time of 30 minutes was deciphered for all 8 
formulations, highlighted in Table 5.6. This temporal measurement is quantified here as the time 
taken for the TM to diffuse/move through the electrospun polymeric matrix of the coating and 
through the cornea before being released into the release medium in the receptor 
compartment.  This was a six fold decrease from the lag time calculated for PE-free coatings, 
highlighting the fact that the proposed reasoning for using PEs in this application was successful. 
Figure 5.16 BCOP test digital images with corresponding fluorescence images of freshly 
excised bovine cornea treated with (a,d) Negative control, (b,e ) Mild positive Control, (c,f) 
positive control (g,k) F5, (h,l) F6, (I,m) F7, (j,n) F8 
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The lag time of TM permeation was reduced; giving a more controlled and faster drug 
permeation.  
Table 5.6 Summary of parameters derived from ex-vivo studies 
 
The cumulative amount of TM permeated achieved with composite-TM was approximately 
53.39±3.95 µg/cm2 after 24 hours, the lowest of all 9 formulations. Regardless of specificity of 
PE, the incorporation of the additives increased the total amount of TM permeated through the 
cornea after 24 hours. Formulations containing EDTA (F2 and F6) showed to have the lowest 
amount of drug permeated per area after 24 hours. This could be attributed to these 
formulations existing as suspensions before EHD processing. EDTA is not soluble in ethanol and 
hence stayed particulate in F2 and F6. These EDTA particles may act as additional diffusional 
barriers; hindering the movement of TM through the polymeric matrix and the corneal 
membrane.  
A study carried out by Burgalassi et al found that BAC, EDTA and Brij® 78 all found to enhance 
the permeation of timolol by 3.06, 1.63 and 1.16 fold, respectively, with BAC being the most 
active enhancer (Burgalassi et al., 2001). Similar results were found in the present study; with 






Composite-TM 0.057±0.017 0.012±0.0038 180 
F1 0.07612±0.017 0.017±0.0039 30 
F2 0.098±0.010 0.037±0.0038 30 
F3 0.104±0.010 0.038±0.0087 30 
F4 0.101±0.0058 0.049±0.0027 30 
F5 0.057±0.0042 0.0084±0.0027 30 
F6 0.074±0.0044 0.00613±0.00037 30 
F7 0.098±0.0088 0.011±0.00095 30 
F8 0.059±0.0099 0.0048±0.00081 30 
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formulations containing BAC achieving highest amount of TM permeated through the cornea 
per area (5 %w/w drug loading: 97.6 µg/cm2 and 15 %w/w: 146.8 µg/cm2.  
The influence of borneol has been previously assessed on in vitro release and permeation of 
hydrophilic quinolone antibiotic ofloxacin. It was found the incorporation of the naturally 
occurring compound resulted in a 2.15 fold increase in the release of the antibiotic (Yang et al., 
2009). Borneol has also found to enhance the permeability of the blood-ocular barrier to dye 
Evan’s Blue (Yang et al., 2008); suggesting its use as a useful penetration enhancer in ophthalmic 
drug delivery. Its use in these electrically atomised coatings also mirror these results: the 
amount of TM permeating through the cornea is greatly increased compared to PE-free coatings.  
A permeability coefficient higher than 20x10-6 cm2/hr (as seen here with all 9 formulations) is 
indicative of high/good permeability. The evidence collated from in vitro probe release showing 
the atomised coatings does not detach from the lens shows there is increased contact time with 
the corneal surface in the pre-corneal region. This along with the hydrophilicity of timolol 
maleate and the excipients used (i.e. the permeation enhancers) aided the release and 
permeation of TM through the cornea at a much more sustained rate than without PE (Figure 
5.17).  These values are considerably lower than that of commercial eye drops (20.458 
µg/cm2/hr) (Shafie and Rady, 2012), showing these electrospun coatings on contact lenses 
delayed TM transport through the corneal membrane. This permits for less frequent dosing and 
hence reduces the risks of systemic absorption and ocular toxicity associated with high drug 
loading.   
As expected, the amount of TM released and permeated from F5-F8 was a lot higher than their 
lower drug loading counterparts. This, however, contradicts the results found with in vitro drug 
release studies. The drug loading did not affect the cumulative percentage release of TM, 
however there is an evident difference with ex vivo permeation studies. This could be a direct 
result of the fact that the cellophane dialysis membrane may not be an adequate membrane to 
mimic biological membrane. It is because of this in vitro drug release, probe release and ex vivo 
studies are vital to conduct in conjunction to get a more accurate conclusion.   
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Figure 5.17 Ex Vivo cumulative amount of timolol maleate permeated across freshly 
excised bovine cornea for initial drug loading of a) 5%w/w and b) 15%w/w 
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5.5 Conclusion 
This chapter was focussed on enhancing TM release from atomised contact lens coatings and 
TM permeation through the cornea. Morphological studies exhibited smooth nanofibers for the 
large majority with some formulations producing beaded-nanofibers. Thermal analysis 
confirmed the stability of nanofibers with DSC also showing the drug was molecularly distributed 
in an amorphous state throughout the polymeric matrix with all 8 formulations.  There were 
significant differences (p<0.05) in the TM-release profiles depending on the permeation 
enhancer used, with borneol presenting the most promising data for sustained release (20% 
more drug was released compared to permeation-enhancer-free fibers). TM release was based 
on quasi-Fickian or Fickian diffusion as shown by application of Higuchi and Korsmeyer-Peppas 
models whilst biological evaluation (using freshly excised bovine cornea) confirmed the 
biocompatibility of the formulations. Ex vivo permeation studies showed some improvement in 
the amount of TM through the cornea with F1-F8, showing the potential of modifying the 
polymeric solution from a formulation view point.  
As a result of these findings and thorough research in new developments with respect to PEs, 
F7 was taken forward to be further modified to achieve the ultimate aim of efficacious drug 
release and permeation from electrically atomised coatings for contact lenses. The high 
encapsulation efficiency of TM and stability of the engineered coatings using F7 is promising 
however ex vivo studies suggest further modification can fully optimise the formulation and 
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Chapter 6 Observing the effect of 
chitosan on in vitro timolol maleate 
release 
6.1 Introduction 
Whilst most of the formulations in Chapter 5 could be further modified to achieve efficacious 
local release of TM, F7 was selected as the formulation with the most potential for the EHD 
processing of contact lens coatings. F7 achieved over 99% encapsulation efficiency and released 
over 85% of the encapsulated TM via Fickian Diffusion during in vitro studies, the most out of all 
8 formulations studied. However, with ex vivo studies, F7 only attained a cumulative release of 
69 µg/cm2 after 24 hours. Hence, F7 was taken forward to be further optimised to match the 
total amount of drug that is usually achieved with commercial eye drops for treatment of 
glaucoma.  
6.2 Background 
Commercial TM eye drops (e.g. Timoptol®) are typically administered twice a day, one drop in 
each affected eye (MHRA., 2015).  This frequent dosing is needed due to an array of biological 
and physiological reasons. Firstly, the introduction of the eye drop to the eye instigates tear 
production, consequently leading to drug dilution. This production of tears also increases the 
volume of fluid in the precorneal region. Excess fluid (combination of eye drops and tears) will 
overflow and leak out of the eye. Some of this excess liquid may also drain into the nasolacrimal 
duct and then be taken away into the systemic blood flow (Agrahari et al., 2016; Djebli et al., 
2017; Forrester et al., 2015). As a result of these obstacles, drug BA is greatly reduced and hence 
frequent administration is required. 
The anatomical barrier of the eye (predominantly the cornea) also poses challenges with respect 
to obtaining sufficient drug BA in ODD. The varying degrees of hydrophilicity of the cornea (made 
up of 5 layers) can hinder the movement of drug molecules through this tissue, reducing the 
total dose permeating through the cornea, and consequently reaching the targeted tissue (Djebli 
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et al., 2017; Forrester et al., 2015; Kearns and Williams, 2009). As mentioned before, there have 
been various attempts to overcome this through the use of PEs as seen in chapter 5.  
More recently, because of material development and the exponential increase in research in 
this remit, certain polymers have found to possess permeation enhancing capabilities. Chitosan 
is a primary example of these “modern PEs” (Kumar, Vimal and Kumar, 2016).  This cationic 
polysaccharide has gained particular interest in pharmaceutics due to its mucoadhesiveness and 
non-toxicity (Mahaling and Katti, 2016; Muxika et al., 2017). Consequently, chitosan does not 
disrupt or compromise the corneal epithelium.  It is thought the cationic nature of chitosan 
interacts with the cell membranes, disrupting tight junction proteins and enhancing paracellular 
drug transport (Kumar et al., 2016).  
Chitosan has previously been utilised as a PE for an array of biological membranes including 
buccal tissue (Duttagupta, Jadhav and Kadam, 2015; Kontogiannidou et al., 2017), intestinal 
tissue (Chougule et al., 2014; Maher, Mrsny and Brayden, 2016; Ates, Kaynak and Sahin, 2016), 
and the nasal cavity (Krauland, Guggi and Bernkop-Schnurch, 2006; Benediktsdottir, Baldursson 
and Masson, 2014; Giuliani et al., 2018).  Chitosan has also been scrutinised in ocular drug 
delivery and has been found to act as a penetration enhancer, with drugs such as ofloxacin (Di 
Colo et al., 2004), triamcinolone acetonide (Raval, Khunt and Misra, 2018) and timolol maleate 
(Rodriguez et al., 2017). Most studies demonstrated enhanced ex vivo permeation of drug upon 
incorporation of chitosan or chitosan derivatives.  
Based on these findings, examining the potential chitosan may have to further improve the 
release and permeation of TM across the cornea when incorporated into electrically atomised 
coatings for contact lenses seemed the natural progression for this research. EHDA was still used 
as the method of coating engineering, with PVP and PNIPAM being used as the base composite 
polymeric matrix.  
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6.3 Materials and Methods 
6.3.1 Materials 
PVP (4.4x104 g/mol) was obtained from Ashland, Worcestershire, UK. PNIPAM (2-4x104 g/mol), 
low molecular weight chitosan (5.0x104 – 1.9x105 g/mol), ethanol, TM (>98%), acetone, sodium 
hydroxide, rhodamine B, and borneol were all purchased from Sigma Aldrich (Dorset, UK). 
PureVision® Balafilcon A silicone hydrogel contact lenses were supplied by Bausch and Lomb 
(New York, USA). All reagents used were of analytical grade. 
6.3.2 Methods 
6.3.2.1 Formulation Preparation 
A 5 %w/v polymeric solution was prepared by dissolving 2.5 %w/v PVP and 2.5 %w/v PNIPAM in 
ethanol.  This mixture was the base solution used to prepare a series of formulations (each 20 
ml) containing various concentrations of chitosan. Table 6.1 shows the composition of 
formulations. Each formulation also contained 15 %w/w TM (with respect to the 5 %w/v 
polymer concentration). All solid excipients were weighed using an analytical balance and were 
mixed using a magnetic stirrer for 30 minutes to ensure homogeneity. One thing to note here is 
chitosan is insoluble in ethanol, and therefore homogenous suspensions were formed.  
6.3.2.2 Formulation Characterisation  
Each formulation was characterised based on three physical liquid properties; viscosity, surface 
tension and electro-conductivity. The measurements were carried out as stated in Section 3.2.1, 
in triplicate, with an average reading taken.    
6.3.2.3 EHDA Set-Up and Optimisation  
The system set-up was similar to that specified in Section 4.3.2.4.  Briefly, polymeric 
formulations were drawn into 5 mL syringes which were attached to a syringe infusion pump. 
This pump enabled the flow of the formulation to be controlled throughout the atomization 
process. The liquid was infused through silicone tubing to a single stainless steel conductive 
coaxial needle device (where only the outer needle was used) at various flow rates.  This set-up 
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was connected to a high power voltage supply. All atomization processes were carried out in 
ambient conditions (23 °C). 
As with the formulations in chapter 5, jetting mode maps need to be created to ensure the most 
optimum process parameters are being used for the newly formulated suspensions.  Each 
formulation was processed at flow rates in increasing increments of 1 µl/min from 0 µl/min up 
to 20 µl/min. At each flow rate, the voltage that was required to produce various spraying modes 
(stable, unstable, dripping) were logged; providing data to generate jetting mode maps.  
Table 6.1 Formulation composition of each formulation. Each formulation contained 2.5 %w/v PVP, 2.5 %w/v 






6.3.2.4 Coating Engineering 
As mentioned previously in chapter 4 and 5, microscope slides were used as a preliminary 
collection device for initial pilot characterisation studies. Hereafter, in vitro and ex vivo 
characterisation were conducted on coated commercial contact lenses. To ensure the contact 
lens shape was maintained, the lenses were dried in a desiccator on a novel lens holder for 30 
minutes. The lenses were weighed before and after the coating process to ascertain the weight 
of the coating sample. Controlled deposition was again achieved using a modified lens holder 







Composite-TM 0 0 
F0 0.1 0 
F1 0.1 1 
F2 0.1 2 
F3 0.1 5 
F4 0 1 
F5 0 2 
F6 0 5 
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6.3.2.5 Characterisation of TM-Loaded Coatings 
6.3.2.5.1 Imaging  
Morphological and structure size analysis was carried out as stated in Section 4.3.2.7.1. Coatings 
on both microscope slides and dehydrated contacted lenses were analysed using SEM at 
magnification of x5k and x50k.  
6.3.2.5.2 Drug Encapsulation Efficiency and Coating Composition 
To determine TM encapsulation efficiency; weighed coating samples were dissolved in ethanol 
for 1 week. UV spectroscopy (λ=295 nm) was used to determine the amount of drug loaded into 
the weighed sample. Equation 4.1 was used to calculate encapsulation efficiency.   
6.3.2.5.3 Thermal Behaviour  
The stability and thermal behaviour (i.e. melting point) were assessed using TGA and DSC, 
respectively. Both studies were carried out as stated in Section 4.3.2.7.3 (DSC) and 4.3.2.7.4 
(TGA).  Both raw materials and atomised coatings were analysed under the flow of nitrogen gas 
at a heating rate of 10 °C/min.  
6.3.2.5.4 Goniometry  
Contact angle hysteresis was determined using contacts lenses with the atomised coatings, as 
specified in section 4.3.2.7.5.  10 µl of distilled water was introduced to the samples and each 
sample was measured in sessile mode at pre-determined time points. Readings were taken in 
triplicate and an average was derived.  
6.3.2.5.5 FTIR 
Any potential interactions between the raw excipients during and following 
electrohydrodynamic processing was assessed using FTIR.  Both raw materials and atomised 
coatings were analysed over the range 400-4000 cm-1 using FTIR Platinum-ATR fitted with Bruker 
Alpha Opus 27 FT-IT at an average of 10 scans at a resolution of 4 cm-1.  
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6.3.2.5.6 In vitro Release and Kinetics 
Drug release and probe release was evaluated as stated in Section 4.3.2.7.7. Briefly, weighed 
coated contact lenses were introduced to the donor compartment; which had been specially 
designed to maximise surface contact between the lens and the synthetic dialysis membrane 
(which separated the donor compartment and the receptor compartment). Upon fixing the 
lenses in the holder, the entire device was submerged into the “receptor compartment”; a vial 
containing 10 ml PBS at pH 7.4. At predetermined time points, 1 ml of release medium was 
retracted and replaced with fresh 1 ml PBS.  Probe release from the coatings into the release 
medium was as described in Section 4.3.2.7.7.2.  Both drug release and probe release studies 
were conducted in triplicate at 37 °C.  In vitro drug release data was collated and plotted in 
various kinetic models to assess the release kinetic models to ascertain the mechanism of TM 
release from the various polymeric coatings.  
6.3.2.5.7 Biological Evaluation of Atomised Coatings 
To ensure the formulations and ultimately the engineered coatings are biocompatible and do 
not compromise epithelial membrane integrity, a BCOP test was performed as stated in Section 
4.3.7.8.  
6.3.2.5.8 Statistical Analysis 
ANOVA test was carried to compare the release of TM from the atomised coatings. Derived p 
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6.4 Results and Discussion 
6.4.1 Solution Characterisation 
Whilst EHDA is a simple process to operate, there is some complexity to the process which is 
reflected in the various physical liquid properties which affect both size and morphology of the 
resulting atomised structures. Table 6.2 shows the average readings of viscosity, surface tension 
and electrical conductivity for all 8 formulations.   







Previous literature has reported the incorporation of chitosan in solution form yielded liquids 
with higher viscosities than the pure solvent (Sun and Li, 2011). However, these formulations 
have been produced by dissolving chitosan to yield homogenous solutions. In this thesis, 
chitosan was used as solid particles, formulating homogenously dispersed suspensions, 
therefore the effect on viscosity was negligible, as seen in Table 6.2. 
In order for a stable cone jet to form, the electrical field applied must be able to overcome the 
ST of the formulation being processed. The ST is the function of the solvent as it makes up the 
largest proportion of the solution/suspension. As with viscosity, the incorporation of chitosan 
did not have a considerable impact on the ST of the formulations. All values measured here are 
below 50 mNm-1 hence the electrical field would not be exceeded upon application of voltage 







Composite-TM 4.29±0.03 20.88±0.46 199.20±0.02 
F0 4.08±0.06 22.38±0.47 221.30±0.56 
F1 4.10±0.01 22.34±0.02 114.34±0.03 
F2 4.57±0.02 25.00±0.04 154.48±0.02 
F3 5.18±0.06 25.33±0.03 170.83±0.04 
F4 4.72±0.01 22.8±0.02 104.05±0.02 
F5 4.61±0.02 25.25±0.05 136.89±0.55 
F6 5.21±0.02 20.21±0.01 170.72±0.04 
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The electrical conductivity of the polymeric liquids are as a result of combination of solvent, 
polymer, additives or excipients which are present in their ionised form. Previously in this thesis, 
it was found incorporating borneol barely had an effect on electro-conductivity (due to being 
present in such small quantities) showing an average reading of 221.35 µScm-1 with PE-free 
solution showing a reading of 119.26 µScm-1. Incorporating chitosan in these formulations 
reduced the EC slightly. Despite the cationic nature of chitosan in solution, here the chitosan 
exists as solid particles and not in solution therefore not drastically altering the EC. All EC values 
here are within the ideal range for EHD processing (Kelly, 1990; Ganan-Calvo et al., 2016).  
6.4.2 EHD Process Optimisation  
The jetting maps produced in Figure 6.1 demonstrate the range of flow rates and corresponding 
applied voltages required to achieve various EHD modes. When the flow rate is too slow/fast 
and the voltage is not high/low enough (depending on the formulation in question) there are 2 
possible scenarios. Dripping mode can occur when the voltage applied is not strong enough to 
overcome the ST of the liquid to break up and form a stable cone jet, demonstrated in Figure 
6.1 as peach coloured regions. Unstable jetting occurs when the ST is competing with the 
electrical field, resulting in the liquid partially breaking up; yielding non-uniform structures with 
large size distributions (emphasised in blue in Figure 6.1). The lilac regions highlight the optimum 
window of operation where a stable jet is formed. All 6 formulations showed a wide range within 
which a stable jet could be formed. At 10 µl/min at 17.8 kV all 6 formulations formed a stable 
cone jet; so these process parameters were selected as the optimum EHD conditions. As with 
chapter 4 and 5, the synapse between the stainless steel needle exit and the collection plate 
was kept constant at 12 cm; ensuring no bias towards the working distance.   
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Figure 6.1 Jetting Maps to determine the relationship between flow rate and applied voltage a) F1, b) F2, c) F3, d) 
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6.4.3 Coating Characterisation 
6.4.3.1 Imaging and Size Distribution 
The morphological effect of utilising chitosan in this study can be observed in Figure 6.2. 
Atomising Composite-TM formulations presented beaded fibers as a result of an inadequate gap 
between the needle exit and the collection plate. This is could also be due to the combination 
of PVP and PNIPAM, polymers that usually yield particle and fibers when 
electrohydrodynamically processed separately (Figure 4.1). Addition of PE borneol yielded 
smooth-surfaced NFs with bell-shaped size distribution, an average of 74 nm in width; thinner 
than previously found when electrospinning borneol and PVP (Li et al., 2012). With respect to 
chitosan-loaded coatings it is clear to see there is a drastic morphological difference. Upon 
incorporating chitosan, the resulting atomised structures have now formed particles held 
together by scarce fibers. Figures 6.2c-e show the effect of chitosan concentration on the 
morphology of atomised coatings containing borneol with Figure 6.2f-h showing the effect of 
chitosan without borneol. It is clear to see the use of chitosan as solid particles has increased 
the over particle size and hence the particle size distribution. The chitosan particles may be 
trapped inside the composite matrix, hence increasing the overall size of the particles being 
produced. In the presence of borneol, there seems to be less particle/fiber aggregation; 
presumably due to the surface active agent properties of the PE. 
Increasing chitosan concentration also had an impact on the morphology of the structures that 
made up the coatings.  As concentration increased, the proportion of the final composition that 
is made up of PE decreases, reducing the fibrous network of the coatings. The smallest average 
diameter size was 114 nm achieved by electrospraying F1 with the highest being yielded by F6 
(919 nm). Whilst there is such a large difference in the size distributions between these 
formulations, all formulations yielded coatings consisting of structures less than 10 µm in 
diameter, the threshold for foreign body detection in the eye (Agrahari et al., 2016).  F1, F4 and 
F5 all demonstrated right skewed distribution (Figure 6.3), with more than 44% of all particles 
produced being under 100 nm. F2 and F6 showed negatively skewed data, highlighting at least 
45% of the structures were more than 200 nm in diameter for both formulations. F3 showed a 
multimodal distribution, with 75% of the structures being over 200 nm, 15% under 100 nm and 
9% between the range 100 nm and 200 nm.  
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Figure 6.3 Size Distribution for all 8 atomised coating samples 




2µm 2µm 2µm 
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6.4.3.2 Drug Encapsulation Efficiency and Coating Composition 
The EE for each formulation is displayed in Table 6.3. The highest encapsulation was exhibited 
by F1 (97.93%) with F6 showing the lowest EE at 88.38%. As the concentration of chitosan 
increases in the formulations containing borneol, the EE seems to reduce to 93.92% (2 %w/v 
chitosan) and 90.69% (5 %w/v chitosan). This pattern was also observed with borneol-free 
samples. Saroha et al found similar results with low concentrations of chitosan giving the 
maximum TM EE (75.34%) when using ionic gelation to develop NPs for improved ocular drug 
delivery (Saroha, Pandey and Kaushik., 2017). Regardless of these reductions in EE, all 
formulations are considered to have very high encapsulation.  
 













Composite-TM 89.96 13.04 -- -- 99.7 
F0 85.47 12.82 1.71 -- 99.7 
F1 72.99 10.95 1.46 14.60 97.93 
F2 63.70 9.55 1.27 25.48 93.92 
F3 46.08 6.91 0.93 46.08 90.69 
F4 74 11.2 -- 14.82 90.45 
F5 64.52 9.69 -- 25.80 88.80 
F6 46.51 6.98 -- 46.51 88.38 
 
6.4.3.3 DSC 
Figure 6.4 displays the DSC thermograms for F0-F6, with raw TM, raw chitosan and composite-
TM atomised coatings.  Pure drug showed a defined melting point of 218 °C and the lack of this 
prominent peak in the thermograms for all EHD processed coatings shows TM was now 
encapsulated in amorphous form in the polymeric matrix as opposed to in its original crystalline 
form, just as seen in chapter 4 and 5. The similar melting points for the broad endotherms of F1-
F6 labelled in Figure 6.4 (125 °C – 129 °C) are lower than the raw composite (131 °C); highlighting 
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TM was evenly distributed throughout the coatings.  Thermal glass transitions (Tg) can be 
detected in these thermograms between 59 °C and 77 °C as a result of the base polymer 
materials. Due to PVP and PNIPAM being amorphous materials, there is a temperature threshold 
at which they will transform from amorphous state to a part rubber part glass state (Khan, 
Asmatulu and Eltabey, 2013; Pawar et al., 2015).  Here, it was difficult to ascertain the exact Tg 
when incorporating chitosan.  
Figure 6.4 DSC Analysis of electrically atomised coatings with a) 
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Chitosan is semi-crystalline as a result of strong inter- and intra-molecular bonds and its 
amorphicity is due to the heterocyclic units (Figure 3.3).   
When heated to temperatures lower than its degradation temperature, changes in heat 
capacity/flow are too small to be distinguished (Wan et al., 2009). Additionally, this could also 
be due to water or moisture forming intermolecular hydrogen bonds and acting as a plasticizer 
in chitosan (Sarwar et al., 2015).  The weak Tg also suggests the initial atomised coatings were 
predominantly amorphous to begin with which is as predicted with PVP and PNIPAM making up 
a large proportion of these coatings.  
The inclusion of chitosan in the formulations also resulted in an extra exothermic event in each 
thermograms (F1-F6). Chitosan possesses few crystalline regions due to high degree of 
acetylation and therefore goes through thermal degradation without melting, highlighted by the 
absence of melting endotherm in Figure 6.4. The exothermic peaks between 263 °C and 267 °C 
(depending on chitosan concentration) are most likely due to the thermal decomposition of 
chitosan (Corazzari et al., 2015; Bizarria, d'Avila and Mei, 2014; Fei et al., 2016). The formation 
of two peaks here also further confirms chitosan being present as solid particles. As mentioned 
in previous discussions about DSC thermograms, single endotherms confirm the physical 
structures of raw materials were not compromised and were acting as one system. Here, the 
presence of the exotherm responsible for the crystallisation of chitosan indicates chitosan was 
acting independent to the EHD processed coating.  
6.4.3.4 TGA 
Figure 6.5 shows the resulting thermograms following TGA of raw TM, raw chitosan and 
atomised coatings. Pure TM again showed a sharp weight loss event between 20 °C and 370 °C; 
highlighting the temperature at which the drug thermally degraded (Abou-Sekkina et al., 2002; 
Joshi et al., 2009). Raw chitosan showed a total weight loss of 76%. The first weight loss event 
(starting at 57°C) is due to water desorption (Hong et al., 2007). The initiation of water loss here 
occurred at a low temperature; indicative of the water lost at this step was loosely bound 
moisture (Hong et al., 2007). 2nd weight loss event began at 254 °C, which has been previously 
found to be due to pyrolytic degradation (Corazzari et al., 2015).  
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All 8 atomised coatings demonstrated two weight loss events: initial water loss and subsequent 
thermal degradation. The temperature at which decomposition was initiated dropped slightly 
for formulations containing chitosan with degradation occurring over a wider temperature 
range (230 °C-520 °C) compared to chitosan-free formulation (300 °C -540 °C). This confirms TM 
and borneol have been encapsulated and the formulations are more thermally stable, showing 
both PE and chitosan slowed the degradation of the polymeric matrix (PVP and PNIPAM) 
(Sundaray et al., 2008; Nazari et al., 2017; Abou-Sekkina et al., 2002).  
Figure 6.5 TGA Analysis of raw timolol maleate, raw chitosan and electrically atomised 
coatings 
Chapter 6 Observing the effect of chitosan on in vitro timolol maleate release 
221 | P a g e  
 
Just as found in chapter 4 and 5, within the range of biological interest (35 °C -38 °C) there were 
no distinctive physical or chemical changes when heating the atomised coatings for TG analysis.  
6.4.3.5 Contact Angle Analysis 
Due to further modifying the solutions from a formulation point of view, the hydrophilicity of 
the resulting atomised coatings could be affected. Figure 6.6 shows digital images of the liquid 
droplet on the sample and how it dissipated over time. Figure 6.7 shows the CA analysis on the 
atomised coatings on the contact lenses. PE-free and chitosan-free coatings (Composite-TM) 
showed a high initial CA at 126.27°. Upon inclusion of borneol, the initial contact angle was found 
to be 71.5°, almost 2-fold reduction compared to the composite-TM samples. Here, the 
introduction of an excipient used primarily as a PE, was also found to double as a surface active 
agent; lowering the surface tension between the liquid droplet and fibrous coatings. Regardless 
of chitosan’s hydrophilic nature, the initial CA of the formulations containing both borneol and 
chitosan had increased to 96.70°, 91.21° and 91.36° for F1, F2 and F3, respectively. This increase 
in CA could be attributed to the incorporation of solid particles of chitosan; the particles may act 
as an additional barrier, which may fill voids and pores between the particles. Therefore, the 
water droplet has to penetrate through both the chitosan as well as the polymeric matrix of PVP 
and PNIPAM. 
Figure 6.6 Digital images taken during contact angle analysis over time for a) F1, b) F2, c) 
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Figure 6.7 Contact angle analysis over time for F1-F6 compared to composite-TM 
coatings and F0 coatings 
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The water droplet introduced to the composite-TM atomised coatings completely dissipated 
within 30 mins while the droplet placed on F0 samples completely spread within 20 seconds; 
highlighting the role of borneol as a surface active agent and helping to increase the 
hydrophilicity of the coatings. Incorporating chitosan into formulations containing borneol 
increased the time required for the water droplet to penetrate/dissolve through the coatings. 
The concentration of chitosan apparently affected CA over time; the higher the concentration, 
the longer it took for the water droplet to completely spread. This increased period of time could 
also be due to the increased density of the sample (as a result of the increased concentration). 
This increase in density can cause particle agglomeration and due to this air can become trapped 
between the particles; hindering water penetration and spreading.   
Formulations containing no PE but various concentrations of chitosan showed some interesting 
results. The absence of borneol showed an increase in the initial CA of F4, F5 and F6 to higher 
than that found with composite-TM samples. The higher the concentration of chitosan, the 
higher the initial CA. F4 and F5 took 7 minutes for the water droplet to spread whilst F6 took 8 
minutes on average. These timings are twice as longer than those with borneol and chitosan 
(3/4 minutes). This prolongation of water spreading may possibly aid the affinity of the coatings 
to the hydrophilic contact lenses, aiding the attachment of the coatings to the lens.  
6.4.3.6 FTIR Analysis 
It is vital to ensure the compatibility of the excipients used during EHDA. It is especially important 
here, as chitosan has not been used in solution. The use of chitosan in the form of solid particles 
may interfere with the resulting atomised coatings therefore FTIR analysis was used to ensure 
this was not the case.  The characteristic peaks of TM, PVP and PNIPAM studied in chapter 4 and 
5 have also been found here; (Figure 6.8) in the fingerprints of the raw materials.  Pure TM 
shows characteristic peaks at 2968 cm-1 (aliphatic C-H stretching), 3063 cm-1 (aromatic C-H 
stretching), 1718 cm-1 (C=O), 1229 cm-1 (O-H bending), 954 cm-1 (C-O stretching vibrations). The 
characteristic peak at 1651 cm-1 in all spectra for 6 formulations corresponds to C=O stretching 
vibrations in PVP whilst absorption peaks that are indicative of PNIPAM spectra included amide 
II bond at 1550 cm-1, C=O stretching and CH3 asymmetric stretching vibrations at  1650 cm-1 and 
2970 cm-1, respectively.  With respect to chitosan, the peak at 1636 cm-1 is due to N-H bending 
of NH2 group of the chitosan structure; whilst the peaks at 2890 cm-1 and 1028 cm-1 are as a 
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result of C=O amide group and C=O stretching vibrations. The stretching vibrations of the amino 
group gave rise to a peak at 1420 cm-1 and O-H stretching and amine N-H symmetric vibrations 
produced a peak at 3329 cm-1.   
These prominent peaks that are found with pure chitosan are also present in the fingerprints for 
all six formulations. No extreme shifts in the peaks can be detected showing the dissolved 
components had not interacted with the chitosan during the EHD process; i.e. no bonds seemed 
to form between the oligo saccharide and the polymers or drug.  
a) 
b) 
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One thing to note here is the increase in peak intensity that can be seen at 1710 cm-1, 2964 cm-
1, 1286 cm-1 and 3274 cm-1. This increase is indicative of mass increase as frequency of vibration 
is inversely proportional to mass. This could also be due to chitosan being present outside the 
atomised structures as opposed to being encapsulated (Merlini et al., 2014).   
6.4.3.7 In Vitro Release and Kinetics 
6.4.3.7.1 In Vitro Drug Release 
Figure 6.9 shows the in vitro release of TM from all six atomised coatings alongside PE free 
atomised coatings and chitosan-free coatings.  
The release from PE-free coatings demonstrated a biphasic profile as previously seen in chapter 
4, with 67% of encapsulated TM being released after 24 hours. Similar to what was concluded 
in chapter 5, F1-F6 demonstrated triphasic release profiles. However, in this case the initial 
release phase was a slow gradual release as opposed to an initial burst release. The maximum 
amount released after 10 minutes was only 9.8% by F1 and F5; contradicting what was found 
with PE free (47.5%) and chitosan free (14.15%).  This delay in drug release could be due to drug 
diffusion being hindered by the barrier of solid chitosan particles. As discussed with contact 
angle analysis, these particles fill the pores and voids in the coatings matrix, reducing the spatial 
environment available for the drug molecules to diffuse out. 
 Another reason for this delay in drug release could be attributed to the very high EE achieved 
for all six formulations. Almost all of the drug was trapped within the polymeric matrix (with 
hardly any surface associated drug), therefore this matrix must swell or dissolve before drug 
release can occur. Furthermore, chitosan also prevents the release medium (PBS) from entering 
the polymeric matrix at a rate that would otherwise by faster; causing the dissolution and/or 
swelling of the polymeric matrix to occur at a much slower rate. 
The two subsequent release phases are due to the polymer base of PVP and PNIPAM. The 2nd 
release phase is due to the eventual dissolution of PVP and breaking of PNIPAM chains whilst 
the 3rd phase is release due to polymer erosion. As seen in chapter 5 and now here, the DSC 
thermograms indicated a thermal transition of polymer from rubbery state to glassy state. This 
could provide an explanation for the sustained release of TM observed in phase 2 and phase 3.  
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Some of the drug may be trapped within the crystalline regions of the polymer, hence is isolated 
from the release medium in the donor compartment. Only upon polymer degradation can the 
trapped drug be released, resulting in gradual sustained release (forming the 3rd release phase) 
(Natu, de Souza and Gil, 2011). 
Fulĝencio et al developed mucoadhesive chitosan films loaded with TM and achieved 85% drug 
release over two weeks (Fulgencio et al., 2012). Whilst this release was successfully prolonged, 
the practicality of such a device is questionable. Whilst the research presented here is mainly a 
proof of concept, the use of contact lenses has already been proven successful in vision 
correction and cosmetics. Furthermore, over 89% of drug was delivered with 24 hours, a more 
a) 
b) 
Figure 6.9 In Vitro Cumulative TM release from electrically atomised coatings 
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convenient dosing period for the patient.  Agarwal et al used chitosan and nanocarrier niosomes 
to assess their combined ability to enhance TM release (Aggarwal and Kaur, 2005). Their study 
found that by coating the niosomes with chitosan, drug release was significantly prolonged from 
91% in 2 hours to 40.43% within 10 hours.  
The concentration of chitosan did significantly affect the total cumulative percentage released 
(p=0.0276), albeit only slightly. Formulations containing 1% chitosan (F1 and F4) released 89.7% 
and 90.78% TM with this decreasing to 88.16% and 78.05% for F3 and F6, respectively. Increasing 
the concentration of chitosan means there is a greater proportion of solid particles dispersed 
throughout the atomised matrix further delaying drug diffusion.  
6.4.3.7.2 In Vitro Probe Release 
Figure 6.10 shows the release of rhodamine B from the atomised coatings on the contact lenses 
and into PBS (pH 7.4; 37 °C). The atomised coatings were composed of the same materials as 
stated in table 6.1; however, rhodamine B replaced TM. The fluorescing of the contact lens at 
the sampled time points indicates the coatings did not detach from the lens upon introduction 
to the release medium whilst the probe release into PBS found to mirror the results found with 
in vitro drug release in Section 6.4.3.7.1 
 
Chapter 6 Observing the effect of chitosan on in vitro timolol maleate release 
228 | P a g e  
 
 
Figure 6.10 In Vitro Probe Release from atomised coatings into PBS from a) F1 
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6.4.3.7.3 Drug Release Kinetics 
The in vitro data collated in section 6.4.3.7.1 was fitted to various kinetic models: zero order 
(figure 6.11), first order (Figure 6.12), Hixson-Cromwell (Figure 6.13), Higuchi (Figure 6.14) and 
Korsmeyer-Peppas (Figure 6.15). Analysing the resulting plots, the mechanism of TM release can 
be found. Table 6.4 collates the regression coefficients for the first 4 models; with Table 6.5 
summarising the important parameters derived from the Korsmeyer-Peppas model.  
 
Figure 6.11 Release of Timolol Maleate from atomised coatings according to the zero order 
model for formulations a) containing borneol and b) free of borneol 
a) 
b) 
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Table 6.4 Kinetic Models for timolol maleate release expressed by regression coefficient, R2 
 
All 6 formulations demonstrated poor fit to the zero-order model with R2 values ranging from 
0.5869 to 0.8363. When fitted to first order release kinetic model, high R2 values (0.8178-0.9930) 
were calculated, indicating the rate of TM release was dependent on the initial drug 
concentration. Fitting the in vitro data to the Hixson-Cromwell model showed TM was not being 
released via dissolution (low R2 values). This, however, does not confirm drug release was via 
diffusion. Due to this, Higuchi and Korsmeyer-Peppas models were also utilised. If R2 values 
above 0.95 were derived from the Higuchi kinetic model, the drug release is considered to be 
diffusion based. High R2 values were obtained from F1 and F6 (0.9921 and 0.9707, respectively) 
suggesting TM was released from the atomised coatings via Fickian Diffusion; based on Fick’s 
Law of release being square root time dependent.  Formulations F2-F5 had R2 values ranging 
between 0.8807 and 0.9388; suggesting a non-Fickian diffusion mechanism. This is mirrored by 
the n values calculated from the Korsmeyer-Peppas model. F1 and F6 had n values of 0.5399 and 
0.5609, which again indicate Fickian diffusion. F2-F5 had values that suggested TM release with 
these coatings was because of both diffusion and swelling and the release was time dependent, 
which mirrored the results collated from the first order kinetic model.  
One thing to note here is as the concentration of chitosan increased, the more the release was 
based on swelling, as the release mechanism changed from Fickian Diffusion when using 1 %w/v 
chitosan (F1) to non-Fickian diffusion using 5 %w/v (F3).  
 
Formulation Zero Order First Order Hixson-
Cromwell 
Higuchi 
F1 0.8363 0.993 0.4272 0.9921 
F2 0.7023 0.9217 0.3938 0.9351 
F3 0.7138 0.9281 0.4130 0.9388 
F4 0.6820 0.9063 0.3847 0.9178 
F5 0.5869 0.8178 0.3250 0.8807 
F6 0.7637 0.9301 0.4070 0.9707 
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6.4.3.8 Biological Evaluation of Atomised Coatings 
Any formulation that is to be in contact with the eye must be biocompatible and not interfere 
with the integral epithelial cells of the cornea. If the cell membrane is compromised, the cornea 
can no longer work to protect the eye; allowing foreign bodies to enter the eye (Abdelkader et 
al., 2015; Wilson, Ahearne and Hopkinson, 2015).  BCOP testing allows samples to be tested to 
ensure the materials used do not interfere with corneal membrane proteins and cause any 
toxicity. Figure 6.16 shows how the cornea of freshly excised bovine cornea reacted when 
treated with F3, F8 and a range of controls.  
Saline posed as the negative control, showing no signs of toxicity (which can be visually observed 
with no change in opacity of the cornea) (Figure 6.16a, f). Contrasting this is the application of 
either acetone (mildly positive control) or NaOH (positive control). Treating the cornea with 
acetone showed a slight cloudy region which is more prominent under the blue cobalt 
Formulation R2 n Mechanism of Release 
F1 0.9474 0.5399 Fickian Diffusion 
F2 0.9926 0.6873 Non-Fickian Diffusion 
F3 0.9855 0.7274 Non-Fickian Diffusion 
F4 0.9248 0.7799 Non-Fickian Diffusion 
F5 0.9862 0.48 Non-Fickian Diffusion 
F6 0.9741 0.5609 Fickian Diffusion 
a) b) c) d) e) 
f) g) h) i) j) 
Figure 6.16 BCOP results of freshly excised bovine cornea. Digital Images of cornea treated with a) Saline, b) 
Acetone, c) NaOH, d) F3 and e) F8. Fluorescence images of cornea under cobalt blue filter treated with f) 
saline, g) acetone, h) NaOH, i) F4, j) F8 
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fluorescent light (Figure 6.16g and h). This permeation of fluorescein dye through the cornea 
indicated there was some ocular irritancy as a result of interaction with lipids in the epithelial 
membrane (Maurer et al., 2001). NaOH was utilised here to demonstrate the effect non-
compatible materials with the cornea. NaOH has the ability to initiate saponification of fatty 
acids present in corneal cells; disrupting the entirety of the epithelial layer (Reim, Schrage and 
Becker, 2001). This in turn increases the permeability of the cornea to foreign bodies. Figure 
6.16c and h shows the severe, evident damage done to the cornea which is visible even without 
the use of the blue cobalt filtered light.  
With respect to testing the formulations used in this study, the only changing variables was the 
presence of borneol and the concentrations of chitosan used. Therefore, only F3 (borneol and 5 
%w/v chitosan) and F8 (5 %w/v chitosan) were tested. If these formulations showed any ocular 
toxicity, all other formulations would be tested to identify if lower concentrations of chitosan 
displayed any signs of incompatibility. The staining of F3 and F6 treated bovine cornea showed 
no any visual opacification under natural light (Figure 6.16d and e)  and no indication of 
fluorescence under a fluorescent light (Figure 6.16i and j), highlighting these formulations were 
biocompatible and suitable for use in ocular drug delivery.  
6.5 Conclusion 
This chapter looked at the effect of chitosan on the release of TM from electrically atomised 
coatings. The incorporation of chitosan into polymeric formulations loaded with TM and borneol 
changed the morphological characteristics of the structures that made up the atomised coatings 
to particles (as opposed to the fibers produced with formulations without chitosan). Subject to 
chitosan concentration, a wide range of particle size distributions were derived for each 
formulation.  Thermal analysis confirmed TM was continually being encapsulated in amorphous 
form and that chitosan was present as solid particles, as confirmed by the occurrence of an 
exotherm at ~ 260 °C. The critical assessment of the effectiveness of chitosan (in vitro/ex vivo) 
found the oligo polysaccharide found to be successful as a PE, increasing TM release up to 23% 
more than composite-TM coatings and up to 11% from borneol-loaded coatings (F0). In 
conclusion, the incorporation of chitosan as a PE showed promising results. The results indicate 
the engineered coatings have the ability to achieve sustained release over 24 hours, overcoming 
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the need for frequent administration and prolonging drug retention; drawbacks usually met 
using conventional dosage forms like eye drops.  
 The novelty of combining an on-demand engineering process like EHDA for drug delivery and 
an already established ocular drug delivery device has not yet been explored and the results 
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Chapter 7 Conclusions and Future 
Perspectives 
7.1 General Conclusion 
The aim of this research was to demonstrate the applicability of using EHDA to engineer coatings 
for ocular contact lenses. The thesis is split into three sections: the first was finding a suitable 
polymeric matrix to function as a biodegradable, stable drug carrier (Chapter 4). The following 
two chapters focussed on optimising the base formulation selected in chapter 4 to improve TM 
release and enhance TM permeation through the cornea.  
Explicit details on specific aims and objectives are stated in section 1.2 and 1.3.   
Chapter 4 looks at the effects of using two different polymers on the encapsulation, release and 
permeation of TM within and from EHD processed coatings respectively. PVP, a rapidly 
dissolving polymer, and PNIPAM (thermo-responsive polymer) were separately analysed and 
also in conjunction; creating a composite formulation. Firstly, the EHDA process was optimised 
to deduce the specific optimum processing window for each formulation that was developed. 
Once the process parameters were selected the resulting coatings were characterised using 
various techniques. The atomised coatings were found to be made up of particles (PVP) or 
beaded fibers (PNIPAM, composite); both within the nanometre range. Particles as small as 50 
nm were observed using PVP-TM solutions, yielding an average diameter of 183 nm. 
Formulations containing PNIPAM yielded beaded fibers as a result of increased formulation 
viscosity. All 3 formulations assessed here demonstrated adequate EE (>64%) and higher 
stability with no material incompatibility. Thermal behaviour analysis showed TM was 
encapsulated and homogenously dispersed within the polymeric matrix in amorphous 
formulation. In vitro release studies showed TM release to follow a biphasic release profile with 
an initial burst release followed by subsequent sustained release.  Ex vivo studies using bovine 
cornea indicated significant differences (p<0.05) between the 3 different polymeric matrices 
used with respect to TM penetration.  
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From these results, it was found using PVP and PNIPAM in conjunction provided excellent EE 
(99.7%) with great potential to be further modified to achieve controlled drug delivery.  
Chapter 5 focussed on using this composite polymeric matrix as a base formulation to try and 
improve TM permeation due to the weak ex vivo results found in chapter 4. Here, four different 
PEs were incorporated. The EHDA process was optimised again due to the inclusion of new 
additives. As in chapter 4, the coatings were subjected to various characterisation with all 
coatings demonstrating similar results. The inclusion of PEs still yielded structures within the 
nanometre range, however smooth-surfaced fibers were found with a majority of formulations 
with some exhibiting beaded NFs. Thermal analysis confirmed TM was still in amorphous form 
and FTIR analysis established the structure of all excipients used were not compromised and 
hence functioned as they should. Significant differences were found with in vitro release and ex 
vivo studies depending on the PE used. The use of different PEs found to improve cumulative 
TM release by at least 9.08%. Release kinetics hinted at release of TM was via quasi-Fickian or 
Fickian diffusion from the atomised coatings. Ex vivo permeation studies showed some 
improvement in TM permeation through bovine cornea, with lag times reducing from 180 
minutes with PE-free coatings to 30 minutes with PE-loaded coatings.  
The work in chapter 6 detailed using chitosan as a modern PE to further increase TM permeation; 
with an aim for 100% permeation through the cornea. Using various concentrations of chitosan 
significantly affected the size of the atomised structures. Chitosan was introduced to the base 
formulations in the form of solid particles, increasing the diameter of the resulting atomised 
structures. Incorporation of chitosan also enhanced in vitro drug release up to 23% more than 
composite TM coatings.  
7.2 Future Perspective 
Using EHDA and contact lenses in conjunction in this research proposes a novel formulation and 
ODD device to enhance TM release for the treatment of glaucoma. This evidence of proof-of-
concept highlights the potential of EHDA. There is great potential in using this approach in 
clinical practise However, extensive further work is required to compliment this data and to 
further highlight the potential of these coated lenses as viable DD devices. 
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7.2.1 Material 
 Only two polymers were assessed in this research; PVP and PNIPAM. There are an array 
of polymers that have previously been utilised in ODD. Characterising a more diverse 
range of polymers such as pHEMA, PLGA, PAA and PLA may demonstrate more positive 
results compared to PVP and PNIPAM. pHEMA is a conventional contact lens material 
whilst PLGA has previously been used in HGs and as NPs for ocular application. PLGA has 
also been processed using EHDA with extremely promising results. PAA is capable of 
forming hydrogen bonds between its carboxyl groups and sialic-carboxylic group of 
mucin glycoproteins. This in turn increases formulation viscosity in situ, increasing 
residence time.  
 It is also possible to load multiple drugs into these atomised structures, providing multi-
functional DD devices. For example, to prevent any infections alongside treating 
glaucoma, antibiotics can be incorporated with the anti-glaucoma active; providing a bi-
functional application 
 In this research, only four PEs were chosen in Chapter 5 and a modern PE in Chapter 6. 
There are an array of PEs which may show more promising results than those assessed 
here. The PEs were also used at their maximum safety concentrations, different 
concentrations may alter drug release and permeation.  
 
7.2.2 Process 
 For all atomization experiments across all three chapters in this thesis, the working 
distance was kept constant at 12 cm. There is some evidence to suggest this distance 
between the collection plate and then needle exit can affect the morphology and size of 
the atomised structures. This is another aspect which can be studied.  
 The evolution of EHDA as evaluated in Chapter 2 has led to the development of various 
atomization/experimental set-ups, yielding various structures. Coaxial EHDA using 
multiple concentrically arranged needles can produce multi-layered structures to 
provide sustained and/or controlled drug release. These layers can also house multiple 
actives, developing multi-functional DD devices.  
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 EHD jet printing or 3D printing can also provide another avenue in this application. The 
method can be utilised to print bespoke lenses with respect to not only therapy but size 
and comfort for the patient.  
7.2.3 Characterisation 
 The atomised coatings here were characterised by in vitro techniques and ex vivo 
methods. Studying in vivo behaviour of these coatings would be advantageous. 
Introducing these TM-loaded coatings to in vivo IOP models such as glaucomatous 
beagle dogs or New Zealand white rabbits with glaucoma can confirm the effectiveness 
of the coatings with respect to drug release, permeation and IOP reduction. 
 With respect to the kinetic models used in this study, there are evident limitations. The 
models used here are weak and are suggestive as opposed to being definitive. The 
linearity of the kinetic plots derived throughout this work is questionable. They require 
refining/optimisation to correctly reflect the release mechanisms in this drug delivery 
system; something that relates to the mathematical approach to the model itself.  
7.3 Final Comments 
To the best of my knowledge, this work is the first of its kind; utilising an already successful 
device and combining it with an engineering process that has shown great potential in the drug 
delivery remit.  The work presented here has potentially opened avenues to be further 
investigated in a field that I have become very passionate about which I hope to continue to 
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